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MeCP2 was identified by its ability to bind DNA in a methylation-specific manner. 
Yet, how it interprets the DNA methylome remains unclear. Several mechanisms 
have been proposed, including a role in transcriptional repression. MeCP2 is highly 
abundant in the brain, and loss-of-function mutations result in a neurological disorder 
called Rett syndrome (RTT). Strikingly, RTT-causing missense mutations are almost 
all located in either the methyl-CpG-binding domain (MBD) or a region that has 
been shown to bind the NCoR/SMRT co-repressor complex (NID). This suggests 
that the MBD and the NID are the key functional domains in MeCP2, and that the 
role of MeCP2 is to form a ‘bridge’ between chromatin and the co-repressor complex 
to regulate gene expression. To test this ‘bridge’ hypothesis, I have made an allelic 
series of knock-in mice with truncated forms of MeCP2 to determine whether the 
other regions are dispensable for protein function. The three other regions of MeCP2 
(the N-terminus before the MBD, the Intervening region between the MBD and the 
NID, and the C-terminus after the NID) were deleted in a step-wise manner to 
produce progressively smaller truncated proteins. Knock-in mice which lack just the 
N-terminus or both the N- and C-termini are phenotypically normal. Therefore, these 
regions, which together make up 46% of the protein sequence, are dispensable for 
MeCP2 function in vivo. Additional deletion of the Intervening region, retaining only 
34% of the original sequence, results in mild RTT-like symptoms in the knock in 
mice. This is likely to be caused by this protein’s decreased stability and reduced 
ability to bind the NCoR/SMRT complex in the brain. The most severely truncated 
protein is nevertheless able to reverse the Mecp2-null phenotype when reactivated 










Every cell in our bodies contains the same set of instructions, our DNA. Yet, in 
different cell types, different genes must be expressed at different levels. Chemical 
marks on the DNA and its packaging proteins help regulate whether genes are turned 
up or down. These marks are recognised by proteins that interpret their signal. One 
of the proteins that recognises marked DNA is called MeCP2 and is the subject of 
this study. It is present in high levels in the brain, and loss of its function causes a 
neurological disorder called Rett syndrome that affects 1 in 10-15,000 girls. Analysis 
of which parts of MeCP2 protein are damaged in patients with Rett syndrome 
highlights two essential regions: the segment that binds to marked DNA and a second 
segment that binds to a complex of proteins, which turn down gene expression. I 
therefore proposed that MeCP2 functions as a bridge between marked DNA and this 
protein complex. To test this theory, I removed all other parts of the protein leaving 
just these two segments. I have made genetically modified mice where MeCP2 has 
been replaced with this minimal version. These mice only have very mild symptoms 
compared to mice that model Rett syndrome, suggesting that this bridge is indeed the 
most important role of MeCP2. This study furthers our understanding of gene 
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Chapter 1 – Introduction 
 
1.1 Epigenetic modifications: what, where, when and how? 
 
The human genome consists of three billion nucleotides. Each cell in our bodies has 
two copies - one paternal and one maternal – divided into 23 pairs of chromosomes. 
This DNA is neatly packaged around proteins called histones, together making up 
‘chromatin’. The first level of this packaging is the wrapping of 147 base pair (bp) 
segments of DNA around histone octamers to form nucleosomes. The histone 
octamers consist of two molecules of each of the core histones: H2A, H2B, H3 and 
H4. This structure can then be folded further to form higher order structures of 
varying accessibility. These chromatin states are crucial for the proper regulation of 
gene transcription, DNA replication and DNA damage repair. In this section, I will 
give a brief overview of the small molecular marks (known as ‘epigenetic 
modifications’) that are added to the DNA itself and its packaging histones, affecting 
chromatin structure. This will cover (i) what the modifications are and their relevant 
‘writers’, ‘readers’ and ‘erasers’; (ii) where in the genome they are found; (iii) when 
during development they are added; and (iv) how they are added to the correct 
genomic sites.  
 
1.1.1 DNA methylation and histone marks 
 
In vertebrates, epigenetic modification of DNA occurs at the fifth carbon in cytosine 
rings. The most abundant and well-studied cytosine modification is methyl-cytosine 
(mC). DNA is methylated predominantly at symmetrical CpG dinucleotides by the 
de novo DNA methyltransferases, DNMT3A and DNMT3B. This mark is heritable 
through DNA replication, via the maintenance DNA methyltransferase, DNMT1, 
which targets hemi-methylated DNA (reviewed by Reik, 2007; and Seisenberger et 
al., 2013). DNA methylation can be lost passively via lack of maintenance over 
repeated cell divisions, or actively removed via its oxidation by the Ten-eleven 
Translocation (Tet) enzymes (reviewed by Dahl et al., 2011). This pathway creates 
several forms of modified cytosine: hydroxyl-methyl cytosine (hmC), fC, and CaC. 
2 
 
Demethylation is completed by conversion of fC or CaC to unmodified cytosine by 
the Base Excision Repair (BER) pathway (reviewed by Klungland and Robertson, 
2016). These other forms were originally thought to simply be intermediates in this 
demethylation process, but the most abundant and stable of these marks, hmC, is 
now considered to be a separate epigenetic signal. Unlike mC, hmC has no 
mechanism for inheritance upon cell division and can only be created by oxidation of 
mC. Recent studies have mapped mC in the asymmetric CpH context (where ‘H’ is 
A, C, or T, but not G). Establishment of CpH methylation is catalysed by the de novo 
DNA methyltransferases, but it cannot be maintained through DNA replication by 
DNMT1. The majority of CpH methylation is found at CpA dinucleotides, due to 
sequence preferences of the de novo DNA methyltransferases (Ramsahoye et al., 
2000; Ziller et al., 2011; Shirane et al., 2013; Varley et al., 2013; Guo et al., 2014; 
Gabel et al., 2015). 
 
DNA methylation is associated with transcriptional silencing (reviewed by Bird, 
2002). This can occur directly by preventing binding of transcriptional activators at 
their sequence-specific binding sites, or indirectly via the recruitment of proteins that 
bind specifically to methylated sites (reviewed by Klose and Bird, 2006). Methyl-
CpG-binding proteins induce a repressive state by recruiting additional chromatin 
modifying enzymes such as histone deacetylases (discussed in section 1.2.1). Lastly, 
methylation of CpG dinucleotides prevents binding by CxxC domain-containing 
proteins, which recognise unmethylated CpG sites and instead promote an active 
chromatin environment by recruiting enzymes such as H3K4 methyl-transferases 
(reviewed by Voigt et al., 2013). DNA methylation at CpH sites is also thought to 
promote silencing, as shown using a reporter gene by Guo et al. (2014). To date, no 
proteins that specifically bind mCpH have been identified and only of the mCpG-
binding proteins (MeCP2) can also bind mCpH sites (Guo et al., 2014). Conversely, 
hmC is thought to be activating, with a positive correlation between hmC enrichment 
and gene transcription in the nervous system (Mellén et al., 2012). The mechanism 
for this is unclear due to the lack of readers (except for proteins involved in 
demethylation) that recognise hmC in its most abundant hmCpG dinucleotide context 




All four of the core histones can acquire post-translational modifications (PTMs) that 
affect chromatin structure, either directly by altering their charge or indirectly by 
recruiting modifying or remodelling enzymes that recognise these marks (reviewed 
by Bannister and Kouzarides, 2011). The X-ray crystal structure of the nucleosome 
(Luger et al., 1997) showed that the core histones are arranged with their highly basic 
N-terminal tails protruding from the main structure, enabling them to make extensive 
interactions with the negatively charged DNA and other proteins. The majority of the 
PTMs are added to these accessible tails. These can be acetylated, methylated, 
phosphorylated, ubiquitinated, SUMOylated and poly(ADP-ribosyl)ated. 
 
Acetylation occurs at multiple lysine residues in the N-terminal tails of Histones H3 
and H4, including: H3K9, H3K14, H3K18, H4K5, H4K8 and H4K12. Histone 
acetylation is added by Histone acetyltransferases (HATs, which require acetyl-CoA) 
and removed by Histone deactylases (HDACs). There are two classes of HATs: Type 
A and Type B. Type A HATs function in the nucleus, modifying chromatin. These 
include GNAT, MYST and CBP/p300. In contrast, Type B HATs are found in the 
cytoplasm, catalysing the acetylation of free histones before their incorporation into 
chromatin. There are relatively few HDACs, which alone have limited specificity. In 
vivo, they are incorporated into large multi-unit complexes that regulate their 
activity, e.g. NuRD, NCoR/SMRT, Sin3a and Co-REST (reviewed by Bannister and 
Kouzarides, 2011; Oberoi et al., 2011). 
 
Acetylation neutralises the positive charge of the lysine residue, weakening the 
interaction between histones and DNA. Histone acetylation is an active mark that is 
highly enriched in more open chromatin structures. This mark is ‘read’ by 
bromodomain-containing proteins, e.g. Swi/Snf2 (part of the SWI/SNF remodelling 
complex) and PHD finger-containing proteins, e.g. DPF3b (part of the BAF 
remodelling complex). Both of these complexes open up chromatin structure 
(reviewed by Bannister and Kouzarides, 2011). Lastly, acetylation of some residues 





Methylation can occur at both lysine and methionine residues: lysines can be mono-, 
di- and tri-methylated; and methionines can be mono-, symmetrically di- and 
asymmetrically di-methylated. Histone methyltransferases contain a catalytic SET 
domain and require S-adensylmethionine (SAM) to modify lysines and methionines. 
Histone methylation and demethylation involves specific enzymes for each 
modification. Histone methylation does not alter the charge of these residues but 
introduces bulky chemical groups, which affect the binding of ‘readers’. Histone 
methylation can promote either an active or repressive state, depending on the 
residue that is modified (reviewed by Bannister and Kouzarides, 2011). 
 
Histone H3K4 methylation promotes an open chromatin structure. It is added by 
SET1A/B complexes and MLL1/2 histone methyltransferases (members of the 
Trithorax group). This mark is read by a variety of proteins including the ING 
protein family (via their PHD finger domain), which recruit HATs and HDACs; 
CHD1 (via its chromodomain), which remodels chromatin structure; and by JMJD2A 
(via its Tudor domain), which removes methylation from H3K9 and H3K36). Mono- 
and di- methylation of H3K4 is removed by LSD1 when it is incorporated into the 
Co-REST repressor complex (reviewed by Bannister and Kouzarides, 2011, and 
Voigt et al., 2013). 
 
Methylation of H3K9 and H3K27 both promote a repressive chromatin state. H3K9 
methylation is added by SUV39 and G9a/GLP enzymes. This mark is read by HP1, 
which dimerises and recruits both the linker histone H1 and SUV39. Together, these 
proteins established a condensed ‘heterochromatic’ state and provide a mechanism of 
inheritance through cell division (reviewed by Bannister and Kouzarides, 2011). 
H3K27 methylation is catalysed by EZH1 or EZH2, mutually exclusive components 
of the Polycomb Repressive Complex 2 (PRC2). This complex can methylate H3K27 
to a tri-methyl state. H3K27me3 is bound by PRC2 and Polycomb Repressive 
Complex 1 (PRC1). Together, these complexes establish repressive polycomb 
domains that and provide a mechanism for inheritance upon cell division (reviewed 




Ubiquitination is the addition of ubiquitin, a 76 amino acid peptide. Single or 
multiple copies of ubiquitin can be added to proteins by ubiquitin ligases. Histone 
H2A is mono-ubiquitinated at K119 by RING1A or RING1B, mutually exclusive 
enzymes in PRC1. This mark is read by PRC2 (containing AEBP2 and JARID2), and 
is therefore important in the establishment and maintenance of polycomb domains 
(reviewed by Blackledge et al., 2015). All of the four core histones can also be 
SUMOylated. This mark antagonises ubiquitination/acetylation of the same residues 
(reviewed by Bannister and Kouzarides, 2011). 
 
Phosphorylation of histone tails at serine, threonine and tyrosine residues introduces 
a negative charge. Yet, unlike histone acetylation, this does not confer a more open 
chromatin structure. Instead, it has specific roles, such as in the DNA damage 
response (phosphorylation of Ser139 of variant Histone H2AX) and establishment of 
mitotic chromatin structure (phosphorylation of H3S10) (Kuo and Yang, 2008; 
reviewed by Bannister and Kouzarides, 2011). 
 
1.1.2 The genomic location of epigenetic modifications 
 
The distribution of both unmethylated and methylated CpG dinucleotides in 
vertebrate genomes is highly non-random. CpG dinucleotides are grossly depleted in 
the bulk genome but are enriched in so-called ‘CpG Islands’ (CGIs). These are often 
founds at gene promoters and tend to be unmethylated. In contrast, CpG 
dinucleotides in the bulk genome are highly methylated (Bird et al, 1985; reviewed 
by Bird 2002; and Deaton and Bird, 2011). The non-random distribution of CpG 
dinucleotides can be explained by the higher efficiency of CT mutation at 
methylated sites, leading to their depletion in the bulk genome (Bird, 1980). The 
frequency of CpG dinucleotides in CGIs is closer to the expected frequency 
(observed/expected ratio >0.65) based on base composition (%G+C). This is 
consistent with the absence of methylation in these regions over an evolutionary 
timescale. A very small proportion (3-4%) of promoter-proximal CGIs are 
methylated in differentiated cells, causing silencing of the associated genes 
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(reviewed by Illingworth and Bird, 2009). The majority of facultatively inactive 
genes are instead repressed by polycomb marks at their promoters (reviewed by 
Reik, 2007; and Barth and Imhof, 2010). The location of DNA methylation within 
gene bodies is also important for reducing transcription, as shown by a reverse 
correlation between methylation and expression levels (Mellén et al., 2012).  
 
The location of CpH (which is predominantly CpA) methylation is highly correlated 
with CpG methylation (Ziller et al., 2011; Guo et al., 2014). This is unsurprising 
given that DNMT3A and DMNT3B are responsible for both CpG and CpH 
methylation. Strikingly, both CpG and CpH methylation are enriched over gene 
bodies, consistent with a role of both in regulating transcriptional elongation (Shirane 
et al., 2013; Guo et al., 2014; Kinde et al., 2016). A major difference between CpG 
and CpH methylation is that high levels of CpH methylation are only found in a few 
cell types: ES cells, oocytes, and mature neurons (Ramsahoye et al., 2000; Shirane et 
al., 2013; Varley et al., 2013; Lister et al., 2013). Another difference is the reduced 
percentage of methylation at each CpH sites within the cell population or tissue. 
However, the much higher abundance of CpH dinucleotides compared to CpG 
dinucleotides in the genome (due to absence of depletion) means that the total 
number of mCpH sites in the brain is similar to mCpG sites (Lister et al., 2013; 
Lagger, Connelly, Schweikert, et al., 2017). 
 
Hydroxy-methyl cytosine (hmC) is also highly abundance in mature neurons (~40% 
of modified cytosines). It is found in gene bodies and repeat regions but depleted 
from promoters (Szulwach et al., 2011). Unlike CpH, its enrichment in gene bodies 
anti-correlates with CpG methylation (Mellén et al., 2012). This may be because its 
creation by oxidation of mCpG leads to the depletion of this mark. This observation 
questions the role of hmC as an activating mark, as the higher level of expression of 
hmC-enriched genes may instead be due to lower levels of mCpG in their gene 
bodies. 
 
The location of various histone modifications has been best characterised in active 
genes and enhancers. Promoters are enriched in H3K4me2/3 and H3K9ac and gene 
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bodies are enriched in H3K36me1/2/3, H3K79me1/2/3, H2BK5me1, H3K9me1, 
H3K27me1 and H4K20me1 (Barth and Imhof, 2010). These marks are important for 
transcriptional initiation and elongation for RNA polymerase II. Active enhancers are 
enriched with H3K4me1 and H3K27ac - the mechanisms by which these marks and 
others regulate transcription is the subject of current research (reviewed by Pradeepa, 
2017). 
 
The discovery of CGI promoters marked with both H3K4me3 and H3K27me3 was a 
surprise given their opposing roles in transcriptional activation and repression, 
respectively (reviewed by Voigt et al., 2013). Further analysis found that a single 
Histone H3 tail cannot be modified with both these marks but sister H3 molecules 
within a single nucleosome can be asymmetrically modified (Voigt et al., 2012). 
‘Bivalent’ domains containing both H3K4me3 and H3K27me3 are found at the CGI 
promoters of genes encoding developmental transcription factors in cultured ES 
cells. Analysis of pluripotent epiblast cells from post-implantation mouse embryos 
found that these domains also occur in vivo, but are fewer in number due to lower 
levels of H3K27me3 (Rugg-Gunn et al., 2010; reviewed by Voigt et al., 2013). 
Genes with bivalently marked promoters are expressed at low levels: undergoing 
transcriptional activation but inefficient elongation (reviewed by Voigt et al., 2013). 
 
Lastly, targeting of DNA methylation and histone modifications to specific genomic 
regions is important for their roles in associated processes. DNA methylation is 
required for sex-specific imprinting (at Differentially Methylated Regions, DMRs) 
and silencing of transposons (reviewed by Reik, 2007). The stable silencing of one X 
chromosome (X chromosome inactivation, XCI) in humans and mice is controlled by 
multiple epigenetic marks: DNA methylation, H3K27me3, H2AK119ub, H3K9me2 
and H4K20me1. The inactive X chromosome in human cells also has domains of 
H3K9me3and its reader, HP1, and H3K20me3. Strangely, the DNA 
hypermethylation on the inactive X is restricted to the 5’ end of genes, with lower 
overall DNA methylation than the active X - including in gene bodies (Escamilla-




1.1.3 The establishment of epigenetic modifications during mammalian development 
 
An important feature of epigenetic modifications is that they are stably inherited 
though cell division, providing a mechanism for gene expression signatures to be 
remembered and transposons to remain silenced. There are times in development, 
however, when epigenetic marks must be erased and rewritten de novo: 
gametogenesis and embryogenesis. Primordial germ cells (PGCs) in developing 
embryos undergo extensive reprogramming at embryonic day E10.5-12.5. DNA 
methylation, including at imprinted Differentially Methylated Regions (DMRs), is 
erased at this point and then gamete-specific DNA methylation patterns are 
established by DNMT3A and its cofactor, DNMT3L. This includes sex-specific 
imprints. The second reprogramming stage occurs after fertilisation, when gamete-
specific DNA methylation is erased: first actively from the paternal genome and then 
passively from both the paternal and maternal genomes. This time, DNA methylation 
is retained at imprinted regions and at transposons (reviewed by Reik, 2007). As 
pluripotent cells differentiate in embryogenesis, they acquire cell type-specific 
epigenetic marks controlling transcription. This process includes the resolution of the 
vast majority of bivalently marked genes but shifting the equilibrium to either the 
active (H3K4me3-marked) or repressed (H3K27me3-marked) state (reviewed by 
Voigt et al., 2013). The later establishment of high levels CpH methylation and hmC 
makes them stand out from other epigenetic modifications. Their lack of 
maintenance mechanism means that they accumulate in non-replicating cells, e.g. 
post-mitotic neurons, with levels increasing during neuronal maturation after birth 
(Lister et al., 2013; Szulwach et al., 2011). 
 
After fertilisation of female zygotes, dosage compensation by X chromosome 
inactivation (XCI) must occur. This happens in early embryogenesis, and its then 
maintains through subsequent cell divisions. In humans, random X chromosome 
inactivation occurs in both embryonic and extra-embryonic tissues. The process in 
mice is slightly more complicated: first imprinted inactivation of the paternal X 
chromosome (Xp) occurs at the 4-8 cell stage, Xp reactivation then occurs in the 
inner cell mass of the blastocyst, followed by random X chromosome inactivation in 
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embryonic cells around implantation (embryonic day 5). In both humans and mice, 
active marks on the inactive X chromosome are lost and repressive marks are 
enriched, resulting in a highly compact chromatin structure (Escamilla-Del-Arenal et 
al., 2011). 
 
1.1.4 How epigenetic states are established: developmental and environmental 
signals, underlying DNA sequence 
 
The establishment of epigenetic states has been a subject of extensive study. Of 
particular interest is how different epigenetic signatures are established in different 
cell types in multicellular organisms. While epigenetic marks have been suggested to 
drive transcriptional profiles, it is more likely that they serve to maintain 
transcriptional states that have been dictated by transcription factors. To support this, 
blocking of transcription by small molecules led to the establishment of polycomb 
marks at previously active genes (Riising et al., 2014). Possible mechanisms for 
remembering transcriptional states involve nascent transcription or long non-coding 
RNAs to recruit epigenetic modifiers. Nascent transcription have been shown to lead 
to the acquisition of active marks at genes in yeast, with initiating RNA polymerase 
II (phosphorylated at Ser5 in its C-terminal domain) binding the methyltransferase 
that lays down H3K4 methylation, and elongating RNA polymerase II 
(phosphorylated at Ser2 in its C-terminal domain) binding the methyltransferase that 
lays down H3K36 methylation (reviewed by Bannister and Kouzarides, 2011). 
Recruitment of epigenetic modifiers to genomic loci by non-coding RNA has been a 
favoured hypothesis for some time. However, to date, only a few examples exist (e.g. 
HOTAIR and at the imprinted region, kcnq1ot1), suggesting this mechanism is not 
global (reviewed by Blackledge et al., 2015). 
 
A lot of research (and media attention) has been devoted to the idea that the 
environment can alter your epigenome. This is most convincing illustrated by a study 
that determined the DNA methylation and histone acetylation patterns in pairs of 
identical twins of different ages. Strikingly, they found that older sets of twins had 
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more divergent epigenetic signatures and consequential gene expression profiles than 
younger sets of twins (Fraga et al., 2015). 
 
Recently, Quante and Bird (2016) proposed that epigenetic modifications are 
influenced in part by the underlying DNA sequence – meaning they are hard-wired in 
the genome. The discovery of sequence-specific polycomb response elements (PREs) 
that recruit polycomb complexes to chromatin in Drosophila promoted the search for 
equivalent sequences in mammals (reviewed by Ringrose and Paro, 2007). 
Mendenhall et al. (2010) and Wachter et al. (2014) both integrated exogenous DNA 
sequences into mouse ES to determine which chromatin marks they acquired. 
Mendenhall et al. (2010) found that a CpG island (CGI) without its associated gene 
was sufficient to acquire bivalent chromatin marks in these cells. Wachter et al., 
(2014) used artificial sequences to alter the CpG density and GC-richness 
independently. They found that both features of CGIs (high CpG density and high 
GC-content) were necessary for these sequences to obtain bivalent marks. Reducing 
the GC-content led to DNA methylation in this sequence. This was found to be 
dominant, with its removal (by deletion of DNMT3A and DNMT3B) allowing the 
acquisition of bivalent marks. This result shed light on the hierarchy of crosstalk 
mechanisms. CGIs stand out from the rest of the genome by containing a high 
density of unmethylated CpG dinucleotides. These are ‘read’ by CxxC domain-
containing proteins. The H3K4 methyltransferase complexes, SET1A/B and 
MLL1/2, all contain subunits with CxxC domains, consistent with the presence of 
this mark in the majority of unmethylated CGIs (reviewed by Voigt et al., 2013). The 
recruitment of polycomb to these domains was more of a mystery. Farcas et al. 
(2012) showed that another CxxC domain-containing protein, KDM2B, could be the 
missing link, as it recruits PRC1 to chromatin. Quante and Bird (2016) build on these 
observations to hypothesise that DNA sequence composition is a major determinant 
of how epigenetic marks are deposited, proposing a mechanism involves a number of 
proteins that interact with short (2-4 bp) sequences e.g. AT runs. Base composition 
can be used to divide mammalian genomes into large domains, with higher gene 
density associated with GC-richness. The observation by Quante and Bird that the 
frequency of short AT-runs is affected non-linearly by base composition provides a 
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mechanism by which AT-binding proteins can differentiate between these domains. 
The expression levels of these proteins vary between different cell types, so could 
contribute to their distinct epigenetic signatures. 
 
1.2 Readers the DNA methylome: MeCP2 and other members of the MBD 
protein family 
 
1.2.1 The MBD protein family 
 
This study focuses of Methyl-CpG Binding Protein 2 (MeCP2), the founding 
member of the MBD protein family. It was discovered in Adrian Bird’s lab by its 
ability to bind to DNA in a methyl-specific manner (Lewis et al., 1992). The domain 
responsible was mapped to residues 78-162, and termed the methyl-CpG binding 
domain (MBD) (Nan et al., 1993). The MBD sequence was use to screen expressed 
sequence tags (ESTs) to identify other methyl-CpG-binding proteins. To date, eleven 
proteins have been discovered that contain this domain: MeCP2, MBD1-6, 
BAZ2A/TIP5, BAZ2B, CLLD8 and SETDB1 (Cross et al., 1997; Hendrich and Bird, 
1998; Roloff et al., 2003; reviewed by Du et al., 2015). However, only three of these 
(MBD1, MBD2 and MBD4) have been shown to bind DNA in a methyl-specific 
manner (Hendrich and Bird, 1998; reviewed by Du et al., 2015). The high sequence 
conservation of this domain and identical location of an intron within it (Fig. S1) 
indicate that these proteins arose from gene duplication during evolution. Strikingly, 
the sequences of these proteins outside the MBD are highly divergent, and contain 
different functional domains (Fig. 1.2.1). Despite this, all four proteins have been 
implicated in transcriptional repression, by recruiting chromatin modifiers such as 
HDACs and H3K9 methyltransferases to methylated DNA (Table 1.2.1; reviewed by 
Du et al., 2015). This role is consistent with DNA methylation being a repressive 
mark. Extensive study of these proteins has identified additional functions of these 
proteins. The functionality of MeCP2 is the most controversial, with proposed roles 
in transcriptional activation, chromatin compaction, alternative splicing and miRNA 
processing (reviewed by Lyst and Bird, 2015; see section 1.5). As a result, the 
general view is that MeCP2 is a ‘multifunctional protein’. MBD1 has been reported 
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to recruit several different effector proteins to chromatin, but all of these promote a 
repressive state, either by histone deacetylation (by HDAC3) or by H3K9 
methylation (by SUV39 and SETDB1). MBD1 has been shown to be involved in 
heterochromatin formation and its inheritance through DNA replication (Villa et al., 
2006; reviewed by Du et al., 2015). MBD2 is well-characterised as a transcriptional 
repressor, recruiting the HDAC1/2-containing NuRD complex to chromatin, 
resulting in histone deacetylation and ATP-dependent chromatin remodelling 
(reviewed by Wood and Zhou, 2016). Additionally, it can recruit PRMT1 or PRMT5 
arginine methyltransferases, which modify H4R3 with asymmetrical di-methylation 
(an active mark) and symmetrical di-methylation (a repressive mark), respectively 
(Le Guezennec et al., 2006; reviewed by Du et al., 2015). MBD4 is unique among 
the MBD protein family in having a glycosylase domain. This is required for its well-
characterised role in base excision repair (BER) repair at CpG dinucleotides; with the 
MBD domain of MBD4 binding to 5mCpG/TpG mismatches as well as 
symmetrically modified mCpG/mCpG dinucleotides (Hendrich et al., 1999; reviewed 
by Bellacosa and Drohat, 2015). 
 
Another key difference between these proteins is their spatial and temporal 
expression patterns, which are closely linked to the phenotypic effects of their 
mutation and overexpression. MeCP2 is expressed in all somatic tissues, with 
extremely high levels in post-mitotic neurons (Skene et al., 2010; Ross, Guy et al., 
2016). It is believed to be required for the proper function of mature neurons, with 
loss of function mutations and overexpression both resulting in severe neurological 
symptoms in human patients (see section 1.3) and mouse models (see section 1.4). 
As the MECP2 gene (Mecp2 in mice) is X-linked and subjected to X chromosome 
inactivation (Quaderi et al., 1994; Alder et al., 1995; Vilain et al., 1996; D’Esposito 
et al., 1996), these phenotypes are sex-specific. Loss of function mutations cause a 
severe neurological disorder called Rett syndrome in heterozygous female patients 
(Amir et al., 1999) and the same mutations result in neonatal encephalopathy and 
early death in hemizygous males (Kankirawatana et al., 2006). Duplication of the 
MECP2 gene also results in neuronal dysfunction, with more severe symptoms in 
male patients as the duplication usually occurs on the X chromosome (van Esch et 
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al., 2005). These “MECP2-related disorders” have all been modelled in mice, which 
recapitulate the neurological symptoms, dramatically furthering our understanding 
about the underlying biology of these diseases (Guy et al., 2001; Chen et al., 2001; 
Collins et al., 2004).   
 
MBD1 is also most highly expressed in the brain, but decreases rather than increases 
with age (Wood et al., 2016). Like MeCP2, MBD1 is more highly expressed in 
neurons than glia (Zhao et al., 2003). This expression pattern fits with a role of 
MBD1 in neurogenesis, which is decreased in MBD1-/- mice (Zhao et al., 2003). 
Loss of MBD1 has also been reported to cause autism-like features such as reduced 
social interaction in these mice (Allan et al., 2008), and MBD1 mutations have been 
identified in individuals with autism (Li et al., 2005). Although mutations in MeCP2 
and MBD1 both result neurological symptoms in humans and mice, it is important to 
note that MECP2-related disorders are much more severe. MBD2 and MBD4 both 
show a broader expression pattern in somatic tissues (Wood et al., 2016; Hendrich 
and Bird, 1998) and MBD4 is the only member of the family to be expressed in ES 
cells (Hendrich and Bird, 1998). Like MBD1-/- mice, both MBD2-/- and MBD4-/- 
mice have mild phenotypes (Table 1.2.1). The only adverse phenotypes reported in 
MBD2-/- mice are hypoactivity (Wood et al., 2016) and defects in maternal 
behaviour (Hendrich et al., 2001). Loss of MBD4 results in a three-fold increase of 
CT transitions at CpG sites, consistent with its role in base excision repair. While 
this increased mutation rate is insufficient to cause tumorigenesis alone, this occurred 
more frequently in MBD4-/- mice when one copy of the Apc gene was mutated 
(Millar et al., 2002; Wong et al., 2002). Like numerous other DNA repair proteins, 
MBD4 is frequently mutated in cancer – mostly in tumours with microsatellite 
instability (reviewed by Du et al., 2015). The other three MBD protein members 
have also been found to be mutated and/or overexpressed in a variety of types of 
cancer (reviewed by Du et al., 2015). Surprisingly, deletion of MBD2 prevents the 
development of intestinal tumours in Apc mutant mouse models (Sansom et al., 
2003). Epigenetic modifiers are another group of proteins frequently mutated in 
cancer, as altered epigenetic programming can cause gene expression changes that 




Despite their diverse domain structure and biological roles, the shared binding sites 
of the MBD protein family and their repressive effect of gene transcription beckons 
the question of whether these proteins can compensate for each other. To date, there 
is little evidence that this is the case. Deletion of these proteins does not result in 
upregulation of the others (Martín Caballero et al., 2009), nor does double mutation 
result in compound phenotypes. In fact, double knock-out mice lacking both Mecp2 
and MBD2 resembled Mecp2-nulls in terms of disease severity (Guy et al., 2001; 
Martín Caballero et al., 2009). Double knock-out mice do, however, have slightly but 
significantly reduced survival compared to mice only lacking Mecp2 after 
backcrossing onto a C57BL/6 inbred background (Martín Caballero et al., 2009). The 
greater expression pattern overlap between MeCP2 and MBD1 proteins would 
predict that they could compensate for each other more than the others. While a 
reduced survival effect upon deletion of MBD1 in an Mecp2-null background was 





Figure 1.2.1: The MBD protein family 
Schematic diagram of the members of the MBD protein family that can bind DNA 
in a methyl-specific manner: MeCP2 (Accession NP_001104262), MBD1 
(Q9UIS9), MBD2 (Q9UBB5.1) and MBD4 (O95243). The major human isoform of 
each is shown. Domains: MBD (Methyl-CpG Binding Domain); TRD 
(Transcriptional Repression Domain); NID (NCoR/SMRT Interaction Domain); 
H1/2 (AT-hook); CxxC (Unmethylated-CpG-binding zinc finger); G/R-rich 
(Glycine/arginine-rich domain); CC (Coiled-coil domain); Glycosylase (DNA 
glycosylase). Note: the TRD overlaps other domains in MeCP2 and MBD2. 
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Table 1.2.1: MBD protein family References: 1. reviewed by Lyst and Bird, 2015; 2. Skene et 
al., 2010; 3. Ross, Guy et al., 2016; 4. Amir et al., 1999; 5. Van Esch et al., 2005; 6. Neul, 2012; 7. 
Zeev et al., 2002; 8. Wada et al., 2010; 9. Guy et al., 2001; 10. Chen et al., 2001; 11. Collins et al., 
2004; 12. reviewed by Du et al., 2015; 13. Wood et al., 2016; 14. Zhao et al., 2003; 15. Li et al., 2005; 
16. Zhao et al., 2003; 17. Allan et al., 2008; 18. Hendrich et al., 2001; 19. Sansom et al., 2003; 20. 
reviewed by Bellacosa and Drohat, 2015; 21. Hendrich and Bird, 1998; 22. Cukier et al., 2010; 23. 
Millar et al., 2002; 24. Wong et al., 2002. 
 
1.2.2 The MECP2 gene encodes two isoforms: e1 and e2  
 
The MECP2 gene consists of four exons, from which mRNA is transcribed and 
spliced to produce two isoforms (Kriaucionis and Bird, 2004; Mnatzakanian et al., 
2004). The more abundant isoform, e1, is translated from mRNA comprising of 
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exons 1, 3 and 4, from a start codon in exon 1. A splice variant containing all four 
exons encodes the shorter and less abundant isoform, e2, which is translated from a 
downstream start codon in exon 2 (Fig. 1.2.2). Isoform e1 is considered to be the 
ancestral form, with higher conservation across evolution including vertebrate 
species that have only one isoform (Fig. S2). The additional isoform, e2, is only 
present in mammalian species. The majority of the open reading frame for both 
isoforms is encoded in exons 3 and 4, so they only differ at the extreme N-terminus. 
These different N-terminal sequences are both very short: 21 amino acids in the 
human e1 isoform (26 amino acids in mice); and 9 amino acids in the e2 isoform. By 
convention, residues are numbered according to the e2 isoform since it was 
discovered first. This has the advantage that the numbering is the same for the human 
and mouse proteins for the majority of the sequence: until a two amino acid insertion 
(residues 385-386) in human MeCP2. Human and mouse e2 isoforms are 486 and 
484 amino acids in long, respectively.  The longer N-terminal sequences in the e1 





Figure 1.2.2: Alternative splicing of the mammalian MECP2 gene to produce 
two isoforms: e1 and e2 
Schematic diagram of the MECP2 gene structure, which consists of four exons. 
Above: Isoform e1 mRNA formed by splicing together exons 1,3 and 4. The 
protein is translated from exon 1. Below: Isoform e2 mRNA formed by splicing 
together all four exons. The protein is translated from exon 2. (The upstream 
start codon causes translational interference.) Only the first of four alternative 
polyadenylation sites was drawn for simplicity. This produces transcripts 1.8 kb in 
length. The open reading frame is shown is grey except for the different N-





1.2.3 Spatial and temporal MeCP2 expression in mammalian tissues 
 
In adult mice, MeCP2 is most highly expressed in the brain, around one order of 
magnitude higher per cell than all in other tissues tested: heart, lung, liver, spleen, 
kidney and skeletal muscle (Meehan et al., 1992; Ross, Guy et al., 2016). This high 
expression is observed in the forebrain, mid/hindbrain and spinal cord, but is 
considerably lower in the cerebellum (Ross, Guy et al., 2016). 
Immunohistochemistry using mouse and human brain slices shows that MeCP2 is 
highly expressed in neurons but much lower in glia (Shahbazian et al., 2002a; 
Balmer et al., 2003; Kishi and Macklis, 2004). Quantitative western blotting was 
used to estimate the number of MeCP2 in neuronal nuclei (positive for the marker 
NeuN) and non-neuronal brain nuclei (NeuN negative – mostly glia). MeCP2 was 
found to approach histone levels in neuronal nuclei: around 16x10
6
 molecules per 
nucleus. The level in non-neuronal brain nuclei was 6-8 fold lower: ~2x10
6
 
molecules per nucleus. In the liver, MeCP2 levels were lower still: 0.5x10
6
 per 
nucleus (Skene et al., 2010).  
 
Analysis of embryonic tissue found much lower levels of MeCP2 in the brains of 
both humans and mice. Proteins levels increase with neuronal maturation during 
postnatal development (Shahbazian et al., 2002a; Balmer et al., 2003). Levels reach a 
plateau at 5 weeks of age in mice (Skene et al., 2010) and around 10 years of age in 
humans (Shahbazian et al., 2002a). This increase was recapitulated using an in vitro 
system: neural precursors derived from embryonic mice were differentiated in 
culture into a mixture of neurons and glia. MeCP2 was shown to increase during 
differentiation reaching high levels in the resulting neurons but not in the glia. 
Despite its increased protein levels in maturing neurons, MeCP2 was found not to be 
required for determination of cell fate, as in vitro differentiation of neural precursors 
derived from Mecp2-nullmouse embryos resulted in the same ratio of neurons to glia 
(Kishi and Macklis, 2004). It is now believed that MeCP2 is required for the 





The regulation of MeCP2 protein levels is highly complex. Northern blot analysis 
detects MECP2/Mecp2 transcripts of four different lengths: 1.8 kb, 5.4 kb, 7.5 kb and 
10.2 kb (D’Esposito et al., 1996; Shahbazian et al., 2002a; Pelka et al., 2005). These 
are produced by the use of different polyadenylation sites in the long 3’UTR. Of 
these, the longest (10.2 kb) transcript is most abundant in human and mouse brains. It 
is also the most dynamic during embryonic and postnatal development: first 
decreasing in abundance and then increasing again in adulthood (Samaco et al., 
2004; Pelka et al., 2005). Shahbazian et al. (2002a) compare the levels of the two 
most abundant MECP2/Mecp2 transcripts (1.8 kb and 10.2 kb) to MeCP2 protein 
levels in a variety of human and mouse tissues and show that there is no correlation. 
The discovery of multiple miRNA target sites in the long 3’UTR partly explains this 
result (reviewed by McGowan and Pang, 2015). Several of these miRNAs have been 
shown to regulate MeCP2 translation, for example miR-132 (Klein et al., 2007). 
 
The Northern blot analysis mentioned above is unable to distinguish between the two 
splice variants of MECP2/Mecp2 due to the small size (124 bp) of the variant exon 
(exon 2). Kriaucionis and Bird (2004) showed that translation of the e2 isoform is 
less efficient due to interference from an upstream start in exon 1 (Fig. 1.2.2), adding 
further complexity to the regulation of MeCP2 protein levels. mRNA encoding the 
longer isoform, e1, is most abundant in the brains of human and mice. The increased 
abundance and translational efficiency together result in 10-fold higher levels of e1 
protein compared to e2 protein in the brain. The higher ratio of e2 transcripts in other 
tissues (e.g. liver) may be partly responsible for the lower levels of MeCP2 protein 
detected in these tissues (Kriaucionis and Bird, 2004; Mnatzakanian et al., 2004).  
 
1.2.4 The DNA binding specificities of MeCP2 
 
The ability of MeCP2 to bind DNA probes that had been symmetrically methylated 
at CpG dinucleotides led to its initial discovery using Southwestern blotting (Lewis 
et al., 1992). This binding specificity has been proved repeatedly with in vitro 
techniques using a variety of DNA probes containing single or multiple mCpG sites 
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(Meehan et al., 1992; Valinluck et al., 2004; Klose et al., 2005; Mellén et al., 2012). 
MeCP2 binding to the methylated pericentromeric repeats in vivo was visualised in 
both mitotic (Lewis et al., 1992) and interphase (Nan et al., 1996) cultured cells and 
later in sections of brain tissue (Shahbazian et al., 2002a). In interphase mouse cells, 
the pericentromeric repeats can be visualised by Hoechst or DAPI staining as bright 
spots. The localisation of MeCP2 at these heterochromatic foci has been detected by 
immunohistochemistry or by fusion with visible tag (Nan et al., 1996; Shahbazian et 
al., 2002a; Kudo et al., 2003; Baubec et al., 2013).  Chromatin immunoprecipitation 
followed by PCR (ChIP-PCR) or high throughput sequencing (ChIP-seq) has been 
used in a great number of studies to find where MeCP2 binds in the genome. MeCP2 
was shown to preferentially bind to the methylated allele of the imprinted gene, 
U2af1-rs1, in mouse liver (Gregory et al. 2001). Unlike transcription factors, which 
show distinct peaks at their target sites, the MeCP2-binding signal in the murine 
brain is relatively flat, indicating binding over the majority of the genome. This is 
consistent with its high abundance, allowing it to occupy a large fraction of 
methylated cytosines, which occur at an average frequency of one every ~150 bp in 
the bulk genome. The MeCP2 binding signal was shown to track CpG methylation, 
decreasing dramatically at unmethylated CpG islands (Skene et al., 2010; Lagger, 
Connelly, Schweikert, et al., 2017). 
 
The discovery that hmC and mCpH (where H is A, T or C) accumulate during 
neuronal maturation, correlating with the upregulation of MeCP2 (Lister et al., 2013; 
Guo et al., 2014; Szulwach et al., 2011) prompted investigations into whether 
MeCP2 is able to bind these modifications. MeCP2 was shown to bind hmC-
containing probes in vitro, leading to the proposal that is also acted as a reader of this 
mark in vivo (Mellén et al., 2012). More recently, studies have shown that this 
binding is restricted to hmC in the CAC trinucleotide (and to a lesser extent the CAT 
trinucleotide) context (Lagger, Connelly, Schweikert, et al., 2017). This is consistent 
with earlier studies that show MeCP2 is unable to bind symmetrically modified 
hmCpG/hmCpG, and has weak affinity for asymmetrical hmCpG/mCpG sites 
(Valinluck et al., 2004; Hashimoto et al., 2012). The extremely low abundance of 
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hmCAC or hmCAT sites in neuronal DNA (Lister et al., 2013) suggests that its 
ability to recognise them has little biological relevance. 
 
MeCP2 was also able to bind a probe containing mCpH sites in vitro (Guo et al., 
2014). As with hmCpH, its recognition sequence was refined to mCAC and (more 
weakly) mCAT (Lagger, Connelly, Schweikert, et al., 2017). Despite the relatively 
low modification frequency (1.3-1.5% of CpH residues are methylated), the higher 
abundance of CpH compared to CpG nucleotides enables this mark to reach similar 
levels to mCpG sites (Lister et al., 2013). Furthermore, motif analysis of CpH 
methylation in adult dentate gyrus found a strong preference for the mCAC 
dinucleotide (Guo et al., 2014), making the vast majority of methylated CpH 
dinucleotide potential MeCP2 binding sites. This finding greatly increases the 
number of MeCP2 binding sites in the genome, including in CpG-depleted regions 
(Guo et al., 2014). Recent examination of MeCP2 ChIP-seq datasets using summit 
analysis confirms a preference for mCAC (but not mCAT) in mouse brains (Lagger, 
Connelly, Schweikert, et al., 2017). 
 
Overall, these findings are consistent with the view that MeCP2 is a reader of the 
DNA methylome, recognising both mCpG and mCAC sites. How it interprets these 
signals has been the subject of extensive study, with multiple proposed roles that 
involve its ability to bind and recruit cofactors to genomic regions (see section 1.5). 
Analysis of these roles has furthered our understanding of how MeCP2 regulates 
proper neuronal function and how it is affected in MECP2-related disorders, such as 
Rett syndrome. 
 
1.3 Rett syndrome and other MECP2-related disorders 
 
1.3.1 Rett syndrome 
 
Rett syndrome (RTT; Online Mendelian Inheritance in Man #312750) was first 
described in 1966 in a report published in German by Andreas Rett, an Austrian 
paediatrician. Subsequent reports describing patients in multiple countries attribute 
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Rett’s name to the disorder (Hagberg et al., 1983; Kerr and Stephenson, 1985). RTT 
patients are almost all female, and female gender was initially a requirement for the 
diagnosis (Hagberg et al., 1985). Its prevalence is estimated to be 1 in 10-15,000 
female live births (Hagberg, 1985). RTT is a severe neurological disorder and is 
often referred to as an autism spectrum disorder (Hagberg et al., 1983; Neul, 2012). 
Before the disease was fully described or well-known, patients were often 
misdiagnosed as autistic (Kerr and Stephenson, 1985). However, the differences in 
these conditions, particularly the motor defects displayed in RTT, suggest that this 
association is misleading (Kerr and Stephenson, 1985; Percy et al., 1988). 
 
‘Classical’ RTT follows a well characterised clinical progression beginning at 6-18 
months of age. Crucially, before the onset of symptoms at this time, patients present 
no neurological symptoms and at birth their weight and head circumference are 
within normal limits (Hagberg et al., 1985; Nomura et al., 1984). Most patients are 
born at term without complications after a usually uneventful pregnancy (Hagberg et 
al., 1983). This period of normal development for up to 6 months is essential for the 
diagnosis of RTT (The Rett syndrome Diagnostic Criteria Work Group, 1988).  
 
The disease presents itself in four stages (Haas, 1988; Neul et al., 2010). Firstly, a 
period of stagnation (stage 1) occurs where patients fail to meet developmental 
milestones at the expected ages (Neul, 2012). Although this stage is often associated 
with onset of acquired microcephaly (Hagberg et al., 1985; Nomura et al., 1984), this 
is no longer deemed essential for diagnosis (Hagberg et al., 2001).  
 
The most striking stage of Rett syndrome progression is the period of regression 
(stage two), beginning at 1 – 4 years of age (Hass, 1988; The Rett syndrome 
Diagnostic Criteria Work Group, 1988). Key features of this stage are the partial or 
complete loss of purposeful hand movements and speech, and gait ataxia (Hagberg et 
al., 1985; Hass, 1988; Neul et al., 2010). Hand movements begin to be replaced with 
stereotypies such as ‘wringing’, and some patients are no longer able to walk 
independently. Autistic behaviour is frequently reported at this stage, with patients 
displaying increased anxiety and loss of interest in their surroundings (Hagberg et al., 
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1983; Neul 2012). Other common symptoms include progression of microcephaly 
(Kerr and Stephenson 1985), respiratory problems (reviewed by Lombardi et al., 
2015), tremors (Neul, 2012) and the onset of seizures in some patients (Hagberg et 
al., 1983).  
 
Stage three involves a period of relative stabilisation beginning at 4 – 10 years of age 
(The Rett syndrome Diagnostic Criteria Work Group, 1988; Neul, 2012), where 
patients may even show some improvement (Neul et al., 2010). Autistic behaviour 
often improves during this stage, with patients showing increased interest in social 
interaction (Neul, 2012). Despite a relatively stable mental status over this period, 
motor problems slowly progress. This includes further manifestation of hand 
stereotypies, bruxism (teeth grinding), worsening of gait impairment and the onset of 
scoliosis (sideways curvature of the spine). Seizure onset is also common at this 
stage (Neul, 2012; reviewed by Lombardi et al., 2015).  
 
The fourth and final stage of disease progression is late motor deterioration starting 
in patients’ teens or early twenties (Neul, 2012). Historically, this stage was 
associated with complete loss of ability to walk, but this varies between patients 
(Neul, 2012). Patients in later stages of RTT suffer from progressive scoliosis, 
muscle wasting and Parkinsonism (Syndrome Diagnostic Criteria Work Group, 
1988; Neul, 2012). The rate of symptom progression at this stage is much slower 
than during stage two. 
 
Consistent with reduced head circumference, RTT patients have a smaller brain size 
(Jellinger and Seitelberger, 1986). This is not due to neuronal death, but to reduced 
cell size. These smaller cells are more densely packed in RTT brains (Bauman et al., 
1995). They also show decreased complexity, with a reduced density of dendritic 
spines (Armstrong et al., 1995). 
 
Despite the appearance of severe symptoms in early childhood, RTT patients usually 
live long into adulthood. A recent longitudinal study based in the USA estimated 
survival at 50 years to be 70% (Tarquinio et al., 2015). The most common cause of 
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death is cardiorespiratory problems. Shorter lifespan correlates with factors 
indicating disease severity, e.g. reduced ambulation or low body weight. Survival 
may be improved by treatments that alleviate the symptoms of the disease: anti-
seizure medication, physiotherapy, and nutritional plans or the use of a feeding tube 
in severe cases (Tarquinio et al., 2015; Neul, 2012). The decrease in number of 
deaths from frail condition supports the positive effect of these therapies (Tarquinio 
et al., 2015). 
 
The fact that almost all RTT patients are female made a genetic cause seem likely. 
This was backed up by reports of complete concordance in monozygotic twins and 
the absence of female dizygotic twins who are both affected (Naidu et al., 1988; 
Zoghbi, 1988). It was predicted that RTT was a dominant X-linked disorder, with the 
absence of male cases explained by male embryonic lethality (Hagberg et al., 1983). 
The gene was difficult to map as cases were usually sporadic. However, a small 
number of RTT families (0.5-1% of cases) were reported containing multiple females 
with the diagnosis of RTT. In these families, obligate carrier females were protected 
from the disease by skewed X chromosome inactivation (XCI) or somatic 
mosaicism. Studies involving these families facilitated exclusion mapping using 
microsatellite markers on the X chromosome, pinpointing Xq28 as the responsible 
locus (Schanen et al., 1997; Sirianni et al., 1998). This finally led to the identification 
of MECP2 as the causative gene in 1999 (Amir et al., 1999). This paper reported 
several causative mutations in MECP2 - both missense and truncating - suggesting 
that the mutations disrupt protein function. RTT patients are heterozygous for a loss-
of-function mutation in MECP2, with mosaic expression of the wild-type and mutant 
alleles due to XCI. Now, this locus is routinely sequenced in RTT patients and 
mutations are submitted to RettBASE, an online database 
(http://mecp2.chw.edu.au/). Sequencing data from patients’ parents distinguish 
between inherited and sporadic mutations and help to determine causality. 
 
Analysis of specific MECP2 mutations in patients diagnosed with classical RTT has 
identified genotype-phenotype correlations. Unsurprisingly, large-scale genomic 
changes such as large deletions, insertions and splice-site mutations, result in more 
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severe disease symptoms. Within the protein coding sequence, early truncations (up 
to R270X) are more severe than more C-terminal truncations (Cheadle, 2000; 
Cuddapah et al., 2014). In general, point mutations located within the methyl-CpG 
binding domain (MBD) e.g. R106W, are more severe than those in the C-terminus, 
e.g. R306C. An exception to this is the milder mutation, R133C - an MBD mutant 
that retains some DNA binding (Cuddapah et al., 2014; Kudo et al., 2003; Brown, 
Selfridge et al., 2016). The presence of mutations in exon 1 suggests that loss of the 
more abundant isoform (e1) is sufficient to cause RTT. Truncating mutations in this 
exon result in disease at the more severe end of the RTT spectrum, consistent with 
other early truncating mutations (Cuddapah et al., 2014).  To date, no RTT-causing 
mutations have been reported in exon 2, which would only affect isoform e2 
(http://mecp2.chw.edu.au/). Although RTT-causing mutations in the 3’UTR have 
been identified in several patients (Fendri-Kriaa et al., 2010; 
http://mecp2.chw.edu.au/), it is yet to be established how they impact MeCP2 protein 
levels. 
 
Despite the identification of MECP2 mutations in 95-97% of RTT patients, it has not 
been added to the list of inclusion criteria for diagnosis, which remains purely 
clinical (Neul et al., 2010). The major cause of phenotypic variation is protective 
skewed X chromosome inactivation (reviewed by Chahrour and Zoghbi, 2007). A 
recent report of four patients with well-established common RTT-causing mutations 
and random XCI that exhibit much milder symptoms indicates that MECP2 mutation 
and RTT are not always associated (Suter et al., 2014; see section 1.4.7).  
 
1.3.2 Atypical Rett syndrome 
 
Patients who meet some but not all the essential criteria for classical Rett syndrome 
are given the diagnosis of ‘atypical RTT’ (also referred to as ‘variant RTT’). 
Atypical RTT can be subdivided into three clinically different groups: preserved 
speech variant, early-seizure onset variant, and congenital variant. Surprisingly, 
causative mutations in MECP2 could only be identified in 50-70% of cases of 
atypical RTT (Neul et al., 2010). The latter two subgroups have been shown to 
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mostly be due to mutations in different genes: CDKL5 and FOXG1 in early-seizure 
onset variant and congenital variant, respectively. Recent reports have suggested that 
both these conditions often lack a clear period of regression – which is essential for a 
diagnosis of atypical RTT (Neul et al., 2010). Therefore, these disorders could 
instead be classed as distinct clinical entities (Neul, 2012). The third class of atypical 
RTT, the preserved speech variant, is mostly caused by mutations in MECP2 (Neul 
et al., 2010). As its name suggests, patients are capable of some spoken language, 
sometimes forming sentences. Overall, it is a milder form of RTT, with increased 
mobility and a closer resemblance to autism than classical RTT (Neul, 2012). 
Interestingly, patients diagnosed with the preserved speech variants have the same 
causative mutations as classical RTT patients (http://mecp2.chw.edu.au/), further 
suggesting that MECP2 mutations in patients cannot completely predict clinical 
manifestation. 
 
1.3.3 RTT-causing mutations in males 
 
The mosaic expression of the wild-type and mutant alleles of MECP2 in RTT 
patients can only occur in heterozygous females. Exceptions where similar patterns 
of expression occur in males are a result of additional mechanisms: either Kleinfelter 
syndrome (XXY) or somatic mosaicism (resulting from a somatic mutation). The 
extension of the diagnostic criteria for Rett syndrome to include males (The Rett 
syndrome Diagnostic Criteria Work Group, 1988) permitted the identification of 
such cases (Salomão Schwartzman et al., 1999; Silberstein et al., 2001; Clayton-
Smith et al., 2000). 
 
For a long time it was believed that inheritance of RTT-causing mutations by 
hemizygous males resulted in lethality (Hagberg et al., 1983). This theory was put 
into question, however, by the absence of spontaneous abortions in RTT families 
(Schanen et al., 1997). In 1998, the first report of two cases of males with neonatal 
encephalopathy in RTT families was published, predicting the male phenotype of 
RTT-causing mutations (Schanen et al., 1998). This was confirmed by the discovery 
of MECP2 as the causative gene the following year (Amir et al., 1999), which led to 
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sequencing of this allele in male patients with this condition: firstly in congenital 
cases where family members had been diagnosed with RTT and later in sporadic 
cases (Zeev et al., 2002; Kankirawatana et al., 2006). The remarkably low number of 
sporadic cases in hemizygous males may have been a contributing factor to the long-
held belief that these mutations are lethal. This phenomenon is instead explained by 
the fact that most RTT patients inherit de novo mutations from their father due to the 
higher mutation rate in spermatogenesis compared to oogenesis (Trappe et al., 2001). 
Male babies inherit their sole MECP2 allele on their mother’s X chromosome, 
meaning their chance of inheriting de novo RTT-causing mutations is substantially 
lower.  
 
It is now established that mutations that cause RTT in heterozygous females cause 
severe neonatal encephalopathy in karyotypically normal hemizygous males. These 
patients are diagnosed as new-borns with severe neurological problems, 
microcephaly, respiratory insufficiency, hypotonia and feeding difficulties 
(Kankirawatana et al., 2006). This condition results in premature death before the age 
of three due to respiratory problems (Kankirawatana et al., 2006; Schüle et al., 2008). 
A less severe condition has been reported in hemizygous males carrying certain 
RTT-causing mutations, including the common mild RTT mutation, R133C 
(Masuyama et al., 2005). 
 
1.3.4 Other mutations in MECP2 
 
Neul et al. (2010) proposed the term ‘MECP2-related disorders’ to encompass all 
neurological conditions caused by mutations in MECP2. This includes classical and 
atypical RTT and male neonatal encephalopathy (described above) as well as milder 
forms of mental retardation. 
 
Some MECP2 mutations have been reported to cause ‘male variant’ RTT in 
karyotypically normal hemizygous boys. These patients present a disease similar to 
female RTT patients. The mutations responsible have not been found to cause RTT 
in females and would be predicted to retain more protein function. One example of 
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this is a 21 year old male with a de novo point mutation (P225L) in an 
uncharacterised region of the protein (Moog et al., 2003). 
 
Milder mutations in MECP2 have been identified as the cause of X-linked 
intellectual disability and autism in both male and female patients (Neul, 2012). Most 
of these mutations are single amino acid changes in the C-terminal region or short 
truncations of the end of the C-terminus (Zeev et al., 2002; Moog et al., 2003). 
Interestingly, the most common and well-studied of these mutations (A140V) is 
located in the methyl-CpG binding domain (MBD), but it does not disrupt DNA 
binding (Nan et al., 2007). This mutation causes mental retardation in males and very 
minor abnormalities in females, including their carrier mothers (Moog et al., 2003; 
Neul, 2012). 
 
Despite the high level of evolutionary conservation and the range of disease-causing 
mutations in MECP2, the Exome Aggregation Consortium (ExAC) database reports 
a large number of mutations in MECP2 in healthy individuals 
(http://exac.broadinstitute.org/). To date, this database contains genetic information 
from 60,706 people from diverse ethnic backgrounds (Lek et al., 2016). Within the 
coding sequence of the MECP2 gene, the vast majority of mutations are single amino 
acid changes. Several short in-frame deletions and truncating mutations near to the 
C-terminus have also been found. Importantly, many of these mutations were found 
in hemizygous males, the most common of which were also found in homozygous 
females, providing strong evidence that these mutations do not disrupt protein 
function.  
 
1.3.5 MECP2 duplication syndrome 
 
Following the characterisation of MeCP2 overexpression in mice, which resulted in 
neurological symptoms (Collins et al., 2004; see section 1.4.3), MECP2 duplication 
was identified a cause of X-linked intellectual disability in male patients (Meins et 
al., 2005; van Esch et al., 2005). The patient described in the first reported case study 
had a duplication of a 430 kb region in Xq28 containing the complete coding 
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sequence of 12 genes. MECP2 duplication was predicted to be the cause of his 
condition as it is the only candidate gene with previous links to intellectual disability 
(Meins et al., 2005). Following the identification of more patients, molecular analysis 
of their DNA narrowed down the minimal duplication region to MECP2 and its 
neighbouring gene, IRAK1, which encodes IL receptor-associated kinase 1(van Esch, 
2011).  
 
Patients with MECP2 duplication syndrome have moderate to severe intellectual 
disability with impaired spoken language and autistic features. They have early 
infantile hypotonia and develop movement problems, such as gait abnormalities. 
They also suffer from tremors and seizures (van Esch et al., 2005; van Esch, 2011; 
Neul et al., 2012). This disorder results in premature death (around 25 years of age) 
from infections due to immunological dysfunction, which may be connected to the 
duplication of IRAK1 (van Esch et al., 2005; van Esch, 2011). Unlike Rett syndrome, 
most cases of MECP2 duplication syndrome are familial: with carrier mothers 
displaying no or much milder symptoms, such as anxiety and depression. Strikingly, 
this is due to extreme skewing (>85%) of X chromosome inactivation in most 
carriers (Esch et al., 2005; reviewed by Lombardi et al., 2015). The degree of disease 
severity is closely linked to XCI skewing: female family members with skewed XCI 
ratios around 70:30 display some mild symptoms (van Esch, 2011). Cases of 
sporadic intellectual disability in females that are due to MECP2 duplication have 
been reported. The majority of these patients have a duplication of MECP2 onto an 
autosome, resulting in symptoms resembling male patients (van Esch, 2011). To 
date, only two female patients with de novo MECP2 duplications on their X 
chromosome and random XCI have been reported. They display moderate 
intellectual disability due to absence of protective XCI skewing (Grasshoff et al., 
2011). The high incidence of phenotypically protective XCI skewing in females in 
familial cohorts suggests the presence of a mechanism for preferential silencing of an 
inherited X chromosome containing the duplicated region (van Esch, 2011). Overall, 
characterisation of the effects of MECP2 gene duplication to all or a fraction of cells 




1.4 Mouse models with Mecp2 mutations 
 
Mouse models have been used extensively to study the function of MeCP2 in vivo. 
There are several key advantages of using mouse models to study MeCP2 function 
and RTT. Inbred laboratory mouse strains enable the production of large cohorts of 
isogenic animals, resulting in strong genotype-phenotype correlations. It is also 
possible to carry out histological and biochemical analysis of relevant tissues 
(including the brain) at multiple ages or stages of disease progression. Finally, 
genetic editing techniques enable the design of mutant mouse models to answer 
specific scientific questions, e.g. tissue-specific knock-outs. 
 
Both Mecp2-null and RTT-mutation knock-in mice recapitulate the symptoms of the 
disease and facilitate characterisation of molecular phenotypes. Cell type-specific 
knock-outs show that these phenotypes are due to neuronal dysfunction, and 
hypomorph and overexpression models have highlighted need for correct MeCP2 
dosage. Excitingly, it has been shown that reintroduction of MeCP2 after the onset of 
symptoms in null mice using genetic manipulation techniques leads to disease 
reversal. This ground-breaking experiment proves that Rett syndrome is theoretically 
curable. MeCP2 mouse models are now being used to test therapeutic strategies with 
the hope that they will be used for RTT patients in the future. 
 
1.4.1 Mecp2-null mice recapitulate the symptoms of patients with Rett syndrome 
 
Initial attempts to produce Mecp2-null mice in Adrian Bird’s lab resulted in lethality 
of the chimaeras, except when the contribution of null ES cells was negligible (Tate 
et al., 1996). In this study, exons 3 and 4 – which contain almost all of the protein 
coding sequence – were replaced with β-galactosidase fused to a Neomycin 
resistance gene (β-geo). Without the knowledge that mutations in MECP2 cause RTT 
in humans, it was accepted that the presence of Mecp2-null cells in the chimaeras 
was fatal.  To determine whether this is the true mouse phenotype or whether 
lethality was due an adverse effect of the β-geo transgene, an alternative approach 
was employed. The Bird and Jaenisch labs both used Cre-loxP technology to produce 
conditional Mecp2 alleles (Guy et al., 2001; Chen et al., 2001). LoxP sites were 
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inserted into the Mecp2 locus flanking vital exons: exons 3 and 4 (Guy et al., 2001) 
or exon 3 (Chen et al., 2001) in ES cells. These targeted ES cells were used to 
produce viable chimaeras, leading to the establishment of conditional mouse lines. 
Both labs successfully produced viable heterozygous female (-/+) and hemizygous 
male (-/y) mice after recombination of the conditional alleles with ubiquitous deleter 
(CMV-Cre) mice, proving that loss of Mecp2 does not cause lethality. Furthermore, 
wild-type and null males were born at Mendelian ratios (Guy et al., 2001). This result 
is consistent with the effect of loss-of-function mutations in MECP2 in humans 
(Amir et al., 1999; Zeev et al., 2002). 
 
Since RTT occurs in female patients who are heterozygous for MECP2 mutations, 
heterozygous female mice could be considered to be the ‘true’ models of RTT. Both 
studies detected disease symptoms in these animals, including inertia, gait ataxia and 
hind limb clasping (Guy et al., 2001; Chen et al., 2001). Astonishingly, these 
symptoms did not appear until 3-12 months of age. Comparison to human RTT 
patients suggests that disease progression due to the absence of Mecp2 more closely 
follows absolute time than developmental time. While this discovery furthers our 
knowledge of how the disease develops, and enables heterozygous females to be 
used for breeding purposes before symptom onset, it makes the study of RTT 
phenotypes in female mouse models very slow. 
 
Another surprising result was that hemizygous male mice are not only viable at birth, 
they remain symptom-free for 3-5 weeks (Guy et al., 2001; Chen et al., 2001). After 
this period, symptoms rapidly progress, resulting in premature death between 6 and 
12 weeks of age. Symptoms include hypoactivity, gait abnormalities, hind limb 
clasping, trembling, irregular breathing, irregular wearing of the teeth and jaw 
misalignment. Both studies report an obesity phenotype in null animals on a mixed 
genetic background, but the biological relevance of this is unclear as Guy et al. 
(2001) show that backcrossing onto a C57BL/6 background causes Mecp2-null 
animals to instead be underweight compared to their wild-type littermates. Perhaps 
more relevant is the finding that the outbred Mecp2-nulls have smaller brains, despite 
their increased body weight. Further analysis of the brains of null mice shows that 
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they consist of smaller, more densely packed neurons with fewer dendritic branches 
(Chen et al., 2001; Kishi and Macklis, 2004). Behavioural analysis has confirmed the 
reduced activity phenotype, and shown that these mice have motor impairment on the 
Accelerating Rotarod. They also display decreased anxiety: spending more time in 
the open regions of the Elevated Zero Maze. Lastly, abnormal electrophysiology has 
been reported in these animals, including by EEG (electroencephalogram) 
recordings, although none of these studies report the presence of seizures (Asaka et 
al., 2006; Goffin et al., 2012). These results are summarised in Table S1A. 
 
Overall, the symptoms present in the Mecp2-null mice recapitulate many features of 
RTT, including motor defects, gait abnormalities, breathing problems, tremors, 
abnormal electrophysiology, decreased brain and nuclear size and reduced dendritic 
branching (Guy et al., 2001; Chen et al., 2001; Kishi and Macklis, 2004; Asaka et al., 
2006; Goffin et al., 2012). While it is tempting to make a connection between the 
characteristic hand stereotypies of RTT patients and the hind limb clasping displayed 
by Mecp2-null mice, there is no evidence to support this. In fact, hind limb clasping 
is a common feature of mice with neurological dysfunction (reviewed by Lalonde 
and Strazielle, 2011). The decreased anxiety phenotype of the Mecp2-null mice is 
surprising as RTT patients tend to display autistic behaviours with heightened 
anxiety. This may be explained by the fact that mice are naturally very anxious with 
high risk perception: behaviours that could become impaired with suboptimal 
neurological function. 
 
1.4.2 Mecp2 knock-in mice with RTT-causing mutations and milder mutations reflect 
the severity scale in patients and help determine the importance of domains in 
MeCP2 
 
Several knock-in mouse models with Mecp2 mutations have been produced to date 
(Fig. S3). In the majority of cases, it is hemizygous males rather than heterozygous 
females that have been studied. This is due to the delayed onset and mildness of the 
symptoms in heterozygous females: for example they are only just detectable at ~10 
months in R133C knock-in mice. Mice with RTT-causing mutations include three of 
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the most common missense mutations (R133C, T158M and R306C; summarised in 
Table S1B-C) and three of the most common nonsense mutations (R168X, R255X 
and R270X; summarised in Table S1D). A mouse carrying another RTT-causing 
mutation, T158A, demonstrates the importance of the threonine residue at position 
158 without introducing the bulky methionine residue. The R273X mouse indicates 
that truncating mutations located further towards the C-terminus cause disease 
symptoms that progress more slowly. 
 
The mouse models of RTT resemble the phenotype described in the male null mice, 
developing symptoms after weaning, which result in premature death. However, the 
presence of mutant forms of MeCP2 protein tends to lead to slightly milder 
phenotypes. This is particularly evident in the median survival of the hemizygous 
males, for example the median survival of R273X mice is 29 weeks, compared to ~9 
weeks in nulls (Baker et al., 2013; Guy et al., 2001; Chen et al., 2001). Guy et al., 
(2007) developed a scoring method for quantifying six symptoms associated with the 
RTT-like phenotype in mice: hypoactivity, gait abnormalities, hind-limb clasping, 
tremor, breathing problems, and degeneration of general condition. This method can 
be repeated multiple times with the same animals, tracking symptom progression. It 
is a vital tool for comparing the severity of different mouse lines. Brown, Selfridge et 
al. (2016) show that mice with the three most common missense mutations mirror the 
severity spectrum of RTT patients (T158M>R306C>R133C), in terms of symptom 
progression and age of death. A separate study characterising the phenotype of mice 
with the A140V mutation (which causes intellectual disability in boys) has shown 
that hemizygous male mice have a normal lifespan and no RTT-like symptoms were 
detected (Table S1E). They do, however, have abnormal electrophysiology (Ma et 
al., 2014) and histological analysis shows increased cell packing density in the brain 
and decreased dendritic branching (Jentarra et al., 2010). 
 
Analysis of truncating mutations in both male and female patients has shown that 
early truncations (up to R270X) have a more severe condition than later truncations 
(G273fs or later) (reviewed by Villard, 2007; Cuddapah et al., 2014). The three 
knock-in male mice with early truncations (R168X, R255X and R270X) all closely 
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resemble Mecp2-nulls, with rapid symptom onset and a median survival of 9-12 
weeks (Lawson-Yuen et al., 2007; Baker et al., 2013; Pitcher et al., 2015). This 
phenotype could be explained in the R168X and R255X mice by the great reduction 
or absence of the mutant protein. The presence of a normal level of protein in the 
R270X mice proves that these symptoms must be due to reduced functionality of the 
truncated protein (Baker et al., 2013). Crucially, G273X mice display a milder 
phenotype with slower symptom progression and increased survival time, despite 
only having three additional three amino acids. The most C-terminally truncated 
mouse produced so far, ‘308/y’, expresses a protein consisting of residues 1-308. 
This mutation has not been identified in patients, but was predicted to enable 
prolonged survival in male mice (Shahbazian et al., 2002b). This was indeed the 
case, with 90% surviving more than one year (the others died of unknown causes 
after 10 months). Although their phenotype is much milder, extensive testing has 
identified hypoactivity, increased anxiety, impaired motor function, abnormal social 
behaviour, abnormal electrophysiology and seizures in these mice (Table S1E; 
Shahbazian et al., 2002b; Moretti et al., 2005; McGill et al., 2006). 
 
It is clear from the results of these studies that mouse models provide a reliable and 
relatively quantifiable assay of MeCP2 protein activity; and can be used to determine 
the importance of specific residues or domains for protein function in vivo. 
 
1.4.3 Mecp2 overexpression and hypomorph mice highlight the important of correct 
dosage 
 
Prior to the discovery of MECP2 duplication syndrome, Collins et al., (2004) 
produced a transgenic mouse line that overexpressed MeCP2 at ~2 fold. This was 
achieved by the random insertion of a human transgene containing the entire MECP2 
genomic locus. When bred onto a Mecp2-null background, this transgene could 
rescue the loss-of-function phenotype: indicating that the human and mouse genes 
are functionally equivalent. This study extensively characterised the mouse 
overexpression phenotype: the animals showed no symptoms for the first 10-12 
weeks, followed by the development of hypoactivity, forepaw clasping, seizures, 
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abnormal electrophysiology and eventually kyphosis. Overexpression also affects 
survival, with 30% of animals dying between 20 weeks and one year (Table S1F). 
Many of these symptoms resemble those in loss-of-function mouse models, although 
contrastingly these mice displayed increased anxiety and enhanced learning in both 
motor function and contextual fear conditioning (Collins et al., 2004; Sztainberg et 
al., 2015). 
 
Mild RTT-like phenotypes have also been reported in a floxed allele of Mecp2, 
which has been shown to have reduced expression. The insertion of a human β-
globin intron and polyadenylation signal followed by a TK-Neo selection cassette and 
loxP site at the beginning of the long 3’UTR before the alternative polyadenylation 
sites prevents their usage (Guy et al., 2001; Kerr et al., 2008). This lowers protein 
levels to between 30-90% of wild-type controls in different brain regions, resulting in 
it being referred to as a ‘hypomorph’. This reduction in MeCP2 levels has no effect 
on survival, but causes weight gain, breathing problems and hind limb clasping. 
Extensive behavioural testing has detected decreased anxiety, motor defects, learning 
defects and abnormal social interaction in these mice (Table S1F; Samaco et al., 
2008; Kerr et al., 2008). 
 
Together, these studies indicate that the levels of MeCP2 protein are of vital 
importance for proper neurological function.  
 
1.4.4 Tissue-specific deletion or expression of Mecp2 shows that RTT-like 
phenotypes are due to abnormal neuronal function 
 
Although MeCP2 is most highly expressed in the brain, it is present in all tissues. To 
determine whether the RTT-like symptoms displayed by the null mice were due to 
abnormal CNS function or to the absence of MeCP2 in peripheral tissues, both 
original studies also produced brain-specific knock-outs (Guy et al., 2001; Chen et 
al., 2001). To do this, they crossed floxed Mecp2 mice with mice containing a 
transgene expressing Cre recombinase under a Nestin promoter (Nestin-Cre). This 
results in the deletion of Mecp2 from over 90% of neuronal and glial cells in the 
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brain (Chen et al., 2001). The phenotype of these mice is indistinguishable from the 
nulls in both studies, showing that CNS dysfunction is the major contributor to RTT 
pathogenicity. 
 
Several other cell-type specific Mecp2 knock-out mice have now been produced to 
determine the importance of different neuronal subtypes to the RTT phenotype 
(reviewed by Guy et al., 2011). Mecp2 deletion from GABAergic neurons (using 
Viaat-Cre) has the most severe phenotype, and is the only one of these lines that has 
a reduced survival. The importance of MeCP2 function in GABAergic neurons is 
consistent with its high protein levels: ~50% higher than other neuronal subtypes 
(Chao et al., 2010). Despite this strong correlation, it is important to consider the 
number of cells from which MeCP2 has been deleted in each cell-type specific 
knock-out as well as their type. Removal of MeCP2 from only the GABAergic 
neurons in the forebrain (using Dlx5/6-Cre) results in a much milder phenotype 
(Chao et al., 2010). Another complicating factor may be the difference in the timing 
of these deletions (which occur when the Cre transgenes are activated).  
 
A recent study produced a novel mouse model with brain-only Mecp2 expression to 
determine the phenotypic consequences of the loss of MeCP2 in peripheral tissues 
(Ross, Guy et al., 2016). The Mecp2 gene was inactivated by the insertion of a floxed 
transcriptional stop cassette in intron 2, which terminates transcription (Guy et al., 
2007). This silencing was retained in the periphery but alleviated in 90% of neurons 
and glia by excision of the stop cassette using a Nestin-Cre transgene. These mice 
did not present any of the overt symptoms associated with RTT models, but rigorous 
testing at 14-16 weeks of age identified milder phenotypes including reduced 
spontaneous activity, increased exercise fatigue, abnormal kidney histology and bone 
defects. Additional abnormalities in peripheral tissues observed in null controls were 
not present in the peripheral knock-out mice. This mouse model reveals important 
roles of MeCP2 in peripheral tissues but confirms that other peripheral abnormalities 




Luikenhuis et al. (2004) showed that neuronal-only expression of MeCP2 from the 
Tau locus rescues the Mecp2-null phenotype. The absence of symptoms in these 
mice is surprising as the level of the Tau-MeCP2 protein was 2-4 times that of wild-
type MeCP2. Heterozygous Tau-MeCP2 expression on a wild-type background 
(bringing the total protein levels to 3-5 fold) still did not result in neurological 
dysfunction. Symptoms were only apparent when these levels were elevated even 
further in homozygous Tau-Mecp2 mice on either a null (total levels 4-8 fold) or 
wild-type (total levels 5-9 fold) background (Luikenhuis et al., 2004). This study was 
carried out before the characterisation on the transgenic 2-fold overexpression mice 
(Collins et al., 2004) or the identification of MECP2 duplication in patients with 
intellectual disability (van Esch et al., 2005). With this knowledge, these results 
suggests that neurons are more tolerant to high levels of MeCP2 than other cell types, 
and that MECP2 duplication syndrome may partly be a consequence of elevated 
protein levels in other cell types. Although a stronger phenotypic effect by additional 
expression of the human protein in the transgenic mice (Collins et al., 2004) should 
also be considered when comparing these two mouse models. 
 
1.4.5 Inactivation of Mecp2 after development causes symptom onset and premature 
death 
 
The low levels of MeCP2 protein in the early stages of postnatal development 
(Shahbazian et al., 2002a) and the delay of symptom onset in null mice (Guy et al., 
2001; Chen et al., 2001) questioned the requirement for MeCP2 function in 
embryonic development. Furthermore, postnatal deletion of Mecp2 in forebrain 
excitatory neurons using CamK-Cre results in the development of RTT-like 
symptoms, albeit with delayed onset (Chen et al., 2001). It therefore seemed likely 
that Mecp2-null phenotypes are not due to its absence during development: rather 
MeCP2 is required for proper function of mature neurons. To test this, an inducible 
Cre allele (CreER
T
, fused to a modified oestrogen receptor), facilitated the deletion 
of the conditional Mecp2 allele at a range of stages of postnatal development upon 
Tamoxifen injection (McGraw et al., 2011; Cheval, Guy et al., 2012; Nguyen et al., 
2012; Du et al., 2016). At all ages, removal of Mecp2 resulted in the development of 
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RTT-like symptoms (quantified by the scoring system described above), resulting in 
premature death. Although comparison of the dynamics of disease progression post-
injection in different studies is complicated by differences in injection regimes, two 
separate studies show that symptoms progress more rapidly when Mecp2 is 
inactivated at later stages in development (Cheval, Guy et al., 2012; Du et al., 2016). 
This effect is particularly dramatic in the most recent study where Mecp2 
inactivation in adult mice ≥15 weeks of age results in rapid symptom progression and 
lethality with 50% survival after 7 days (Du et al., 2016). 
 
Microcephaly and reduced brain size in RTT patients and hemizygous male mice is 
associated with deceleration of head growth as symptoms progress during post-natal 
development. Strikingly, removal of Mecp2 from fully grown adult mice (10 or 15 
weeks of age) also results in reduced brain weight and neuronal nuclear size, 
suggesting shrinkage has occurred. The dynamics of brain shrinkage mirror the rate 
of symptom progression in these mice (Nguyen et al., 2012; Du et al., 2016). 
 
1.4.6 Proof-of-principle experiments using genetically engineered mice show that 
Rett syndrome and MECP2 duplication syndrome are both theoretically curable  
 
A major breakthrough in the RTT field was the discovery that induced activation of 
the Mecp2 gene in null mice before and after the onset of symptoms prevented or 
reversed the disease, respectively. The initial study by Guy et al. (2007) and a 
follow-up study by Robinson et al. (2012) used genetic manipulation in mice to 
engineer a proof-of-principle experiment showing that RTT is theoretically curable. 
A transcriptional stop cassette (flanked with loxP sites) was inserted into intron 2 of 
the endogenous Mecp2 allele, leading to transcriptional silencing. The resulting male 
mice had ~2.5% of wild-type levels of MeCP2 protein in the brain, which led to the 
onset of severe symptoms and premature death, closely resembling null mice. 
Heterozygous Stop/+ females were crossed to males that carried a transgene 
encoding Tamoxifen-inducible Cre (CreER
T
) to produce Stop/y CreER
T
 males. In the 
absence of Tamoxifen, this has no effect on the phenotype, proving the robustness of 
the system. Following injection with Tamoxifen, the CreER
T
 protein was 
38 
 
translocated into the nucleus where it excised the transcriptional stop cassette, 
leading to gene activation. Unexpectedly, rapid activation of the Mecp2 gene before 
symptom onset (3-4 weeks of age) led to toxicity. This was overcome by a more 
gradual injection regime, preventing disease onset in these mice. This same regime 
was used in symptomatic animals (11-17 weeks of age), leading to amelioration of 
RTT-like symptoms and improved survival. Disease reversal was also possible in 
symptomatic heterozygous female mice (with injections beginning between 20 and 
42 weeks of age). 
 
A recent study has demonstrated rescue of the Mecp2 overexpression phenotype in 
mouse models using either genetic manipulation or antisense oligonucleotides 
(Sztainberg et al., 2015). Mecp2 overexpressing mice with a human transgene 
(Collins et al., 2004; described in section 1.4.3) were crossed with ‘floxed’ mice – 
with loxP sites either side of exon 3 (Chen et al., 2001). Unlike the hypomorphic 
allele (described in section 1.4.3), this alternative floxed allele has no effect on 
protein level. The resulting Mecp2
lox
 MECP2tg male mice resemble the 
overexpression mice, displaying enhanced motor performance on the Accelerating 
Rotarod, impaired social behaviour and abnormal electrophysiology. The presence of 
Tamoxifen-inducible Cre recombinase (CreER
T
) facilitated genetic rescue by 
excision of the floxed allele. Treatment with a 4-week long regime of Tamoxifen 
injections (starting at 8-9 weeks of age) led to an almost 2-fold reduction in the 
amount of MeCP2 protein. A second cohort of Tamoxifen-treated mice underwent 
extensive behavioural testing, displaying no phenotype in any of the tests performed. 
Control Mecp2
lox
 MECP2tg mice underwent vehicle-only injections and displayed 
symptoms such as hypoactivity, increased anxiety and increased motor learning in 
these tests. This study also demonstrated a more therapeutic approach to reduce 
protein level in the transgenic mice: using antisense oligonucleotides (ASOs). ASOs 
were designed to target the human transgenic allele, reducing total protein levels by 
almost 2-fold. As observed with the mice in the genetic rescue cohort, the ASO-
treated mice did not display any of the phenotypes associated with Mecp2 
overexpression. This study shows that, like Rett syndrome, MECP2 duplication 




1.4.7 Several therapeutic therapies are currently being developed, with relative 
success in preliminary studies using mouse models  
 
After the discovery that delayed activation of the endogenous Mecp2 gene in null 
mice was able to reverse neurological symptoms (Guy et al., 2007), the search began 
for a cure that could be administered to RTT patients. Mouse models have been used 
to test multiple strategies, each with their own benefits and complications, which I 
shall discuss briefly here. 
 
The first strategy is introduction of exogenous MeCP2, either by Gene Therapy or by 
Protein Replacement Therapy (reviewed by Katz et al., 2016). AAV viruses are the 
preferred choice for Gene Therapy studies as they can cross the blood brain barrier 
(BBB); infect both neuronal and non-neuronal cells with a high transduction 
efficacy; and the viral DNA persists as a stable episome – providing long-lasting 
treatment and avoiding problems associated with insertional mutagenesis (reviewed 
by Gadalla et al., 2011). To date, several studies have used AAV vectors to introduce 
human or mouse Mecp2/MECP2 cDNA into Mecp2-null male mice, resulting in 
phenotypic rescue (Table 1.4.7; Gadalla et al., 2013; Garg et al., 2013; Matagne et 
al., 2017; Gadalla et al., 2017). These studies have varied a number of parameters to 
maximise phenotypic rescue (prolonged survival and amelioration of neurological 
symptoms) and to increase transduction efficiency in the brain whilst reducing toxic 
effects from overexpression (which most frequently occurred in the liver). The varied 
parameters include: vector design (regulatory sequences), AAV serotype, injection 
route and dosage (summarised in Table 1.4.7). So far, vectors have only been 
introduced into pre-symptomatic mice, the oldest of which were 4-6 weeks of age 
(Gadalla et al., 2013; Garg et al., 2013; Matagne et al., 2017). Further work is needed 
to determine whether virally-delivered Mecp2/MECP2 can result in symptom 
reversal. At present, there have been no experimental trials of Protein Replacement 
Therapy in mice. A priority for developing this strategy is designing modifications to 
MeCP2 protein that enable it to cross the brain barrier and enter cells. Possible tags 
include the TAT sequence from HIV (Lin et al., 2004). A major concern for both 
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Gene Therapy and Protein Replacement Therapy is MeCP2 dosage given the 
deleterious effects of its overexpression. The mosaic pattern of expression in female 
RTT patients further complicates this. It is important to note, however, that female 
patients with X-linked MECP2 duplication and random XCI have much milder 
symptoms than males with MECP2 duplication syndrome (Grasshoff et al., 2011), 
suggesting that introduction of MeCP2 to all cells will still greatly improve RTT 
patients’ quality of life. Phenotypic improvement was been demonstrated in 
heterozygous (-/+) female mouse models after systemic injection of scAAV9/Mecp2 
at 10-12 months of age. Vector-treated mice displayed  symptom stabilisation and 
performed better in behavioural paradigms than controls that had been injected with 
scAAV9 lacking a viral insert (Table 1.4.7; Garg et al., 2013). High transduction 
efficiency and near-physiological protein level is also a requirement for Protein 
Transduction Therapy. Though, as the exogenous protein would not persist, dosage 
can be altered over time. 
 
An alternative method for introducing wild-type MeCP2 protein into only the mutant 
cells in female RTT patients is activation of the silenced allele on the inactive X 
chromosome. Current work is developing small molecules that either activate several 
X-linked genes or just MeCP2 (reviewed by Katz et al., 2016).  
 
If successful, all of the strategies described above would result in the presence of 
both wild-type and mutant proteins in the same cells. This could be deleterious if the 
mutant protein has a dominant negative effect. The use of Mecp2-null males and -/+ 
females by the Gene Therapy studies does not address this concern. Only the most 
recent paper (Gadalla et al., 2017) used Mecp2-mutant mice, successfully 
demonstrating phenotypic rescue in T158M-EGFP males. Additional experimental 
evidence using overexpressing mouse models suggests that the presence of mutant 
MeCP2 on top of normal levels of wild-type protein does not have phenotypic 





















at P0-2. Dose: 
4.8x10
10
 vg (viral 
genomes)/mouse 
 
~7-42% cells in different brain 
regions transduced, around 
physiological levels. 
Prolonged lifespan (increased by 
~7 weeks), reduced symptom 
severity, reduced phenotypes in 
behavioural tests (hypoactivity 
and motor ability). No rescue of 
reduced body weight phenotype 
or breathing apneas. 
Note: no adverse effects in 
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~2-4% cells in different brain 
regions transduced (mostly in 
neurons). Highest transduction in 
liver and spleen. 
Prolonged lifespan (increased by 
~5 weeks). No rescue of reduced 
body weight phenotype. Liver 
toxicity reported. 
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Males: ~8-25% cells in different 
brain regions transduced 
(proteins expressed at around 
physiological levels). Prolonged 
lifespan, reduced symptom 
severity. 
Females: scores stabilised ~1 
(vehicle-only controls scores ~6), 
reduced phenotypes in 
behavioural tests (e.g. motor 
ability). No seizures (observed in 
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regions transduced. 
Prolonged lifespan (increased by 
~6 weeks), reduced phenotypes 
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and motor ability), partial rescue 
of decreased weight phenotype, 
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~20-40% cells transduced, most 
at physiological levels (some 
overexpressing) 
Greatly prolonged lifespan 
(increased by ~26 weeks), 
reduced symptom severity. No 
rescue of decreased body weight 
phenotype. 
 




Several other therapeutic strategies are being developed that focus on repairing the 
mutant allele. These could be more promising given the importance of obtaining the 
correct levels of MeCP2 protein expression. These strategies include gene editing, 
RNA editing and the read-through of nonsense mutations (reviewed by Katz et al., 
2016). Gene editing would provide a permanent cure with the correct level of 
expression, making it the most appealing method. Unfortunately, despite vast 
development in the relevant technologies, this is not yet possible (discussed in more 
detail below). RNA editing enzymes, Adenosine deaminases, perform transitions 
from adenine to iosine (read as guanine).  Adenosine deaminase has been engineered 
to require an RNA guide (ADAR: Adenosine Deaminase that Acts on RNA), 
enabling transcript specificity (Schneider et al., 2014). Development of this 
technology is required to optimise delivery and efficiency of this enzyme (reviewed 
by Katz et al., 2016). While off-target editing may occur, this is less of a problem 
than in gene editing as edited RNAs do not persist in cells. Nonsense mutations can 
be targeted with small molecules that promote read-through. This was shown to be 
successful in Gentamicin-treated fibroblasts derived from R255X knock-in mouse 
embryos (Pitcher et al., 2015). Although both of these strategies are limited to 
specific kinds of RTT-causing mutations, a high proportion of patients have relevant 
mutations (particularly non-sense mutations).  
 
Advances in gene editing using CRISPR/Cas9 technology have brought great hope to 
the field. The CRISPR (clustered regularly interspaced short palindromic repeats)-
associated RNA-guided endonuclease, Cas9, is a bacterial DNA endonuclease from 
Streptococcus pyogenes that is involved in its adaptive immune system. Cas9 makes 
a double-stranded cut in DNA at a site determined by the sequence of a guide RNA 
(gRNA). This break is repaired in one of two ways: either by non-homologous end 
joining, which is usually imprecise; or by homology-directed repair using a 
homologous template (reviewed by Hsu et al., 2014). Over the last few years, 
substantial progress has been made in our understanding of this technology, 
particularly in the design of guide RNAs to minimise off-target hits and maximise 
homology-dependent repair. Several alternative endonucleases from different 
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bacterial species have now been identified and characterised, including ones that are 
small enough to be packaged into viral vectors (Ran et al., 2015). Despite these 
advancements, rates of homologous repair using an introduced donor molecule are 
very low in somatic cells (Shah et al., 2016). Gene editing protocols using cell lines 
involve steps to select and grow up correctly targeted clones, but this is impossible in 
existing tissues. Sadly, trials using drugs to promote homology-directed repair by 
inhibiting the alternative mechanism (non-homologous end joining, NHEJ) have so 
far been unsuccessful. Prospects are perhaps more hopeful for patients with MECP2 
duplication syndrome: using CRISPR-mediated cleavage followed by improper 
repair by NHEJ to destroy the additional MECP2 allele. Strategies would have to be 
carefully designed, potentially using patient-specific SNPs, to only target one of the 
copies of MECP2. 
 
The study by Sztainberg et al. (2015), described in section 1.4.6, proposes antisense 
oligonucleotides (ASOs) as a potential therapeutic strategy for patients with MECP2 
duplication syndrome. The initial experiments with mouse models presented in this 
study look promising: protein levels were successfully reduced and the mice did not 
display neurological symptoms. Administration to patients will be more challenging 
as the design of this study takes advantage of the differences in the sequences of the 
endogenous mouse allele and the human transgene, enabling ASOs to be made that 
specifically target the human allele. To develop this strategy further to administer 
ASO treatment to patients, great care will have to be taken to determine dosage. This 
paper also highlights the need for continuous treatment, with the levels of MeCP2 
protein increasing after its cessation. 
 
An alternative genetic strategy for the development of potential therapies for RTT 
and other MECP2-related disorders is the identification of modifying mutations. The 
case report describing four patients with common RTT-causing mutations but much 
milder symptoms proposes that they carry additional genetic modifying mutations 
(Suter et al., 2014). However, until a larger number of patients like this are 
discovered, identification of the relevant mutations from genome sequencing would 
be very difficult. Buchovecky et al. (2013) have carried out a mutagenesis screen 
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using the chemical mutagen N-ethyl-N-nitrosourea (ENU) to discover mutations that 
suppress the phenotype of Mecp2-null male mice. They describe a nonsense mutation 
in Sqle, the gene encoding squalene epoxidase, that improves longevity, activity and 
motor abilities. Since SQLE is involved in cholesterol biosynthesis, it was proposed 
that statins might have a similar effect on the null phenotype. This proved to be the 
case, with better results than the Sqle mutation. Several other candidate genes were 
identified in the screen, including several known interaction partners of MeCP2 
(Monica Justice, personal communication). Further work is required to understand 
the modifying mechanisms of these proteins. Additionally, it is important to 
determine whether genetic modifiers identified in studies using null mice have the 
same effect in mice expressing mutant forms of the protein that retain some 
functionality. 
 
1.5 MeCP2: a multifunctional protein? 
 
While the studies described above detail the spatial and temporal requirement of 
MeCP2 activity in vivo, they tell us very little about its molecular function. These 
Mecp2-mutant mouse models as well as cell culture-based systems and in vitro 
assays have been used to determine the functions of MeCP2 protein and how these 
are disturbed in MECP2-related disorders. MeCP2 has been implicated in several 
cellular processes leading to it commonly being referred to as a multifunctional 
protein. These processes involve its interaction with over forty binding partners (Fig. 
1.5). Here, I will present the evidence for each of these in turn. At the end of this 
section, I will discuss how these activities may be regulated by neuronal activity-






Figure 1.5: Binding sites of MeCP2 interaction partners 
Schematic showing the binding sites of MeCP2 interaction partners characterised 
by their proposed function when complexed with MeCP2. Protein interaction sites 
are shown in black, DNA in blue and RNA in purple. The minimal domain 
required for transcriptional repression of a reporter gene (the TRD) is shown in 
red. Unmapped interactions are shown as dotted lines. Interactions with YB-1 
and DGCR8 require phosphorylation of Ser80 (shown in orange). 
References: KPNA3/4 (Baker et al., 2015); TRD (Nan et al., 1998); NCoR/SMRT complex 
components - directly with TBLX1/TBLR1 (Lyst et al., 2013); SIN3A (Nan et al., 1998; Lyst et al., 
2013); c-SKI (Kokura et al., 2001); PU.1 (Suzuki et al., 2003); YY1 (Forlani et al., 2010); TFIIB 
(Kaludov et al., 2000); CBF1 (Mann et al., 2007); PRMT6 (Chawan et al., 2011); SP3 (Hwang et al., 
2010); SOX2 (Szulwach et al., 2010); BRAHMA (Harikrishnan et al., 2005); CREB1 (Chahrour et 
al., 2008); MYCN (Murphy et al., 2011); methylated DNA [MBD] (Nan et al., 1993); AT-rich DNA 
[AT-hook 1/2] (Baker et al., 2013; Lyst, Connelly et al., 2016); DNA [‘basic patch’] (Heckman et al., 
2014); ATRX (Nan et al., 2007); HP1ɣ (Agarwal et al., 2007); SMC1/3 (Kernohan et al., 2010); 
Lamin B (Guarda et al., 2009); DNMT1 (Kimura et al., 2003); TET1 (Cartron et al., 2013); G9a 
(Subbanna et al., 2014); HLCS (Xue et al., 2013); YB-1 (Young et al., 2005; Gonzales et al., 2012); 
FBP11 and HYPC (Buschdorf and Strätling, 2004); PRPF3 (Long et al., 2011); LEDGF, DHX9, 
TDP-43 and FUS (Li et al., 2016); RNA (Jefferey and Nakielny, 2004);miRNA processing complex 
components – directly with DGCR8 (Cheng et al., 2014a); FOXG1 (Dastidar et al., 2012); HIPK2 
(Bracaglia et al., 2009); CDKL5 (Mari et al., 2005); IKKα (Knoshman et al., 2012); p300 and SIRT1 
(Zocchi and Sassone-Corsi, 2012); PIAS1 (Tai et al., 2016); HMGB1 (Dintilhac et al., 2002); 




1.5.1 MeCP2 as a transcriptional repressor 
 
Methylation of DNA sequences such as repeat elements, imprinted control regions, 
the inactive X chromosome, and CpG islands has long been associated with 
transcriptional repression (reviewed by Bird, 2002). More recently, both mCpG and 
mCpA methylation in gene bodies was shown to negatively correlate with 
transcription levels (Mellén et al., 2012; Guo et al., 2014). The discovery of MeCP2 
as a methylated DNA-binding protein led to the prediction that it acted as a mediator 
for indirect silencing of methylated regions in the genome (reviewed by Tate and 
Bird, 1993). 
 
Transcriptional repressive activity of MeCP2 was first demonstrated by Nan et al., 
(1997), who showed that MeCP2 could preferentially silence a methylated reporter 
gene over a non-methylated one. This repressive activity required the methyl-CpG 
binding domain (MBD) to be intact and was affected by mCpG density. To map the 
region required for recruiting co-repressors, fragments of MeCP2 were fused to the 
GAL4 DNA-binding domain. Residues 207-310 were sufficient to repress a reporter 
gene downstream of GAL4 binding sites: a region that became known as the 
Transcriptional Repression Domain (TRD; Fig. 1.5.1). The involvement of histone 
deacetylases (HDACs) was indicated by the partial disruption of this repressive 
activity by the HDAC inhibitor, Trichostatin A (Nan et al., 1998). The discovery that 
two HDAC-containing co-repressor complexes, SIN3A and NCoR/SMRT, directly 
interact with the TRD of MeCP2 provides a mechanism for its role in repression 
(Nan et al., 1998; Kokura et al., 2001; Lyst et al., 2013). Furthermore, mutations in 
MeCP2 that specifically disrupt these interactions lead to a loss of repressive activity 
(Yu et al., 2000; Lyst et al., 2013). Several other relevant binding partners have been 
reported including three co-repressors that interact with the SIN3A or NCoR/SMRT 
complexes: cSki (Kokura et al., 2001), PU.1 (Suzuki et al., 2003) and CBF1 (Mann 
et al., 2007). An HDAC-independent function in transcriptional repression has also 
been proposed (Yu et al., 2000). This may occur via the recruitment of transcription 
factors such as YY1 (Forlani et al., 2010), BRAHMA (Harikrishnan et al., 2005), 
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SOX2 (Szulwach et al., 2010) and SP3 (Hwang et al., 2010), all of which have been 
reported to have repressive activity when bound to MeCP2. Alternative mechanisms 
include MeCP2 recruitment of histone methyltransferase activity either at histone H3 
Arg2 (H3R2) by PRMT6 (Dhawan et al., 2011) or at histone H3 Lys9 (H3K9) by 
G9a or HCLS (Fuks et al., 2003; Subbanna et al., 2014; Xue et al., 2013). Lastly, 
MeCP2 has been proposed to inhibit transcription directly by binding TFIIB, 
preventing its incorporation into the preinitiation complex (Kaludov et al., 2000). 
Fig. 1.5 shows the domains in MeCP2 required for these interactions, several of 
which have not been mapped. 
 
The repressive activity of MeCP2 described in many of these studies was 
characterised using artificial reporter genes. Subsequent studies have used mouse 
models, patient tissues and cell lines to characterise its repressive function in vivo. 
Global transcriptional effects were predicted as the extremely high levels of MeCP2 
in neurons mean that it is able to coat chromatin, tracking mCpG and mCAC sites 
genome-wide (Skene et al., 2010; Lagger, Connelly, Schweikert, et al., 2017). 
Additionally, the loss of MeCP2 activity in mouse neurons results in increased total 
histone acetylation (Shahbazian et al., 2002b; Skene et al., 2010). Two studies 
showed that MeCP2 is important for silencing transcriptional noise, resulting in 
increased expression of repetitive elements in the brains of Mecp2-null mice. 
Although these transcripts do not persist (Skene et al., 2010), their transcription leads 
to increased retrotransposition (Muotri et al., 2010). The mutagenic effect of 
retrotransposition is no doubt dangerous, but is unlikely to be the cause of RTT 
pathology as these events are irreversible, whereas phenotypic effects of MeCP2-
deficiency can be reversed in mouse models (Guy et al., 2007).  
 
High throughput methodologies, such as microarrays and RNA-sequencing, have 
been used to attempt to identify MeCP2 target genes. Several studies report large 
numbers of both up- and down-regulated genes with small changes in gene 
expression. Some of these genes show reciprocal dysregulation in Mecp2-null and 
overexpression systems (reviewed by Guy et al., 2011). Recently, Sugino et al. 
(2014) proposed that these weak effects may be due to a ‘dilution effect’ caused by 
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homogenising brain tissues that are made up of multiple cell types whose gene 
expression patterns are affected differently. They isolated cells of five subtypes and 
identified genes that are dysregulated by >1.5 fold in each. Notably, there is little 
overlap in the dysregulated genes, supporting the hypothesis of ‘dilution’. 
Surprisingly, this study also found that genes that are upregulated in the absence of 
MeCP2 tend to be longer than average. This ‘long gene effect’ is robust enough to be 
detected in multiple datasets obtained from RTT patient samples and Mecp2-mutant 
mouse tissues without cell sorting (Gabel et al., 2015). Additionally, the reverse 
effect (downregulation of long genes) was observed in the brains of mice 
overexpressing MeCP2. The extent of long-gene upregulation correlates with 
symptom progression, suggesting a link to pathogenicity. This is consistent with the 
fact that a disproportionately high number of long genes have neuronal functions. 
 
In order to distinguish between direct and indirect effects of MeCP2 activity on gene 
expression, chromatin immunoprecipitation (ChIP) datasets have been used to 
determine the level of MeCP2 binding at dysregulated genes. Recent analysis shows 
that MeCP2 is most highly enriched on genes that are upregulated in Mecp2-null 
mice and down-regulated in Mecp2-overexpression mice, indicating direct repressive 
activity of MeCP2 at these loci (Lagger, Connelly, Schweikert, et al., 2017). These 
dysregulated genes contained higher levels of CA(C) methylation in their gene 
bodies, providing a link between MeCP2 binding at these methylated sites and 
transcriptional repression (Gabel et al., 2015; Chen et al., 2015; Lagger, Connelly, 
Schweikert, et al., 2017). While MeCP2 has many interaction partners associated 
with gene silencing, strong evidence supports the importance of its role in the 
recruitment of the NCoR/SMRT co-repressor complex to chromatin. This interaction 
is abolished by the RTT-causing missense mutation, R306C, in MeCP2 (Lyst et al., 
2013; Fig. 1.5.1). Strikingly, analysis of gene expression on the cerebellum of knock-
in mice expressing this mutated allele also showed dysregulation of a large number 
of genes, including the upregulation of long genes. (Gabel et al., 2015). 
 
A recent study by Lyu et al. (2016) may provide a link between transcriptional 
repression by MeCP2 and reduced cell size, a common phenotype of RTT patients 
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and models. This study shows that loss of MeCP2 in cultured primary mouse neurons 
results in indirect downregulation of PTEN (a negative regulator of the AKT 
signalling pathway that promotes cell growth). This is mediated by a miRNA, miR-
137, which targets PTEN. These findings are consistent with an earlier report 
showing that MeCP2 directly represses miR-137 transcription by recruiting the 
transcription factor, SOX2, to its promoter (Szulwach et al., 2010). While the 
AKT/mTOR pathway has been shown to be impaired in the absence of MeCP2 
(Ricciardi et al., 2011), further work is needed to determine whether MeCP2-





1.5.2 MeCP2 as a transcriptional activator 
 
As mentioned above, genome-wide studies have found large numbers of genes that 
are dysregulated in the absence of MeCP2 (reviewed by Guy et al., 2011). Contrary 
to a repressive function of MeCP2, these studies identified a greater number of 
downregulated than upregulated genes in tissues from RTT patients and Mecp2-
mutant mice. Furthermore, quantification of the levels of RNA per cell in human 
ESC-derived neurons and specific mouse brain regions, shows that loss of MeCP2 
activity results in a total reduction in both ribosomal and messenger RNA (Li et al., 
2013; Lagger, Connelly, Schweikert, et al., 2017). Improved normalisation 
techniques used to analyse RNA-sequencing data that account for cell number 
instead of total amount of RNA mean that the percentage of dysregulated genes that 
Figure 1.5.1: The Transcriptional Repression Domain and NCoR/SMRT 
Interaction Domain of MeCP2 
Schematic diagram of MeCP2 protein (e2) annotated with the Methyl-CpG 
binding domain (MBD, residues 78-162); the Transcriptional repression domain 
(TRD, residues 207-310); and the NCoR/SMRT Interaction Domain (NID, 
residues 285-309). The RTT-causing missense mutation, R306C, abolishes the 
interaction with the NCoR/SMRT co-repressor complex. References: Nan et al., 
1993; Nan et al., 1998; Lyst et al., 2013. 
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are upregulated in the absence of MeCP2 is likely to be even higher than originally 
predicted. The most recent estimate is ~400 upregulated genes and ~8000 
downregulated genes in mouse hypothalamus (Lagger, Connelly, Schweikert, et al., 
2017). Overall, these genome-wide transcription changes would predict that MeCP2 
can also function as a global transcriptional activator.  
 
MeCP2 has been reported to directly interact with two transcriptional activators (Fig 
S2): CREB1 (Chahrour et al., 2008) and MYCN (Murphy et al., 2011). Whereas 
MYCN only reduces the repressive activity of MeCP2 when they co-localise at 
genomic sites, CREB1 is thought to provide a mechanism for MeCP2-mediated gene 
activation. Sequential ChIP of MeCP2 and CREB1 showed that these proteins 
preferentially co-occupy the promoters of MeCP2 target genes: those which are 
down-regulated in the hypothalamus of Mecp2-null mice and upregulated in Mecp2 
overexpression mice.  
 
In contrast to the high percentage of reciprocally dysregulated genes reported 
(Chahrour et al., 2008; Chen et al., 2015), the global effect on RNA level was not 
reciprocal. Overexpression of a transcriptional activator would predict an increase in 
total RNA, but levels were not significantly different from wild-type controls 
(Lagger, Connelly, Schweikert, et al., 2017). It is therefore possible that 
transcriptional changes could be a result of an upper limit on total transcription, 
complicating their interpretation.  
 
It is likely that there is a strong connection between decreased RNA levels and the 
reduced cell size observed in RTT patients and models (Bauman et al., 1995; Chen et 
al., 2001; Yazdani et al., 2012), but it is unclear whether decreased transcription 
results in reduced cell size or vice versa. Li et al. (2013) reported that Mecp2-null 
cells have reduced transcription of both ribosomal RNA and transcripts encoding 
ribosomal proteins resulting in decreased nascent protein synthesis, which is required 
for cell growth. Alternatively, the transcriptional effect may be secondary: the 
smaller size of sub-optimal RTT neurons could reduce the transcriptional potential of 




Regardless of whether transcriptional changes are a direct or indirect result of the 
absence of MeCP2 activity, they are likely to contribute to RTT pathology. Deletion 
of Mecp2 in adult mice led to shrinkage of the animals’ brains and neuronal nuclei 
with symptom progression (Du et al., 2016; see section 1.4.5). Downregulation of 
individual genes can also have an impact on the RTT phenotype. Several relevant 
genes have been identified, including A2BP1 (encoding ataxin 2 binding protein 1) 
and GAMT (encoding guanidinoacetate methyltransferase), both of which are 
reduced in patients with intellectual disability and seizures (Chahrour et al., 2008). 
The most well studied phenotypically-relevant downregulated gene is brain-derived 
neurotrophic factor (BDNF), a growth factor essential for neuronal differentiation 
and survival. Chang et al. (2006) show that neuronal overexpression of BDNF from a 
human transgene in Mecp2-null mice improves their lifespan and motor function. 
Drugs that increase BDNF levels are now being tested as therapies for RTT 
(reviewed by Katz et al., 2016). BDNF partially rescued the reduced brain size 
phenotype in Mecp2-null mice (Chang et al., 2006) and the reduced cell size 
phenotype in MECP2-null cultured human neurons (Li et al., 2013). In the cultured 
MECP2-null neurons, ectopic BDNF expression resulted in the upregulation of the 
AKT/mTOR pathway, providing a mechanism for cell growth (Li et al., 2013). 
Interestingly, the rescue of cell size was not combined with a rescue of total RNA 
levels (Li et al., 2013), arguing against the hypothesis that cell size imposes a limit 
on total transcription. 
 
A2bp1, Gamt and Bdnf are all reciprocally dysregulated in Mecp2-null and 
overexpression models (Chahrour et al., 2008), but their contribution to the MECP2 
duplication syndrome pathology has not been investigated. Two further relevant 
genes, Crh (encoding corticotrophin-releasing hormone) and Oprm1 (encoding G 
protein-coupled μ-opioid receptor) are down-regulated in Mecp2-null mice and 
upregulated in Mecp2 overexpression mice. Reducing the expression of either gene 
by heterozygous deletion partially rescues the Mecp2 overexpression phenotype in 
mice: reduction of Crh alleviated their anxiety phenotype, and reduction of Oprm1 




1.5.3 MeCP2 as a chromatin remodeller 
 
Several studies have described a role of MeCP2 in remodelling chromatin structure. 
Its ability to compact unmethylated nucleosomal arrays (NAs) in vitro was 
demonstrated by Georgel et al. (2003). Later, this activity was confirmed using 
methylated NAs (Nikitina et al., 2007; Baker et al., 2013). All three papers show that 
the C-terminus of MeCP2 is important for this function, as mutants truncated after 
the methyl-CpG binding domain (MBD) have little or no activity in these assays. In 
addition to the MBD, MeCP2 has three other short basic regions that have been 
shown to interact with non-methylated DNA: two AT hooks and a ‘basic patch’ 
(Baker et al., 2013; Heckman et al., 2014; Lyst, Connelly et al., 2016; Fig. 1.5.3; Fig. 
1.5). AT hook 1 (residues 184-195) was first noted in the initial study describing 
MeCP2 (Lewis et al., 1992), but its ability to preferentially bind AT-rich DNA was 
only demonstrated recently (Lyst, Connelly et al., 2016). Baker et al. (2013) 
identified a second AT hook (residues 265-272), which is also able to bind AT-rich 
DNA, albeit more weakly (Lyst, Connelly et al., 2016). AT hook domains are best 
characterised in the HMGA protein family, which each have two or three of these 
domains. Sequence alignment of MeCP2 with HMGA1 identified a third basic region 
with high homology to the third AT hook in HMGA1. However, it contains an 
insertion that destroys the consensus motif so is unlikely to have AT-hook activity 
(Baker et al., 2013). The highly conserved C-terminus of MeCP2 contains an 
additional DNA-binding domain, referred to as the ‘basic patch’ consisting of 
residues 274-340 (Heckman et al., 2014). Truncated proteins that are missing one 
(G273X) or two (R270X) of these DNA-binding domains (Fig. 1.5.3) have a reduced 
ability to condense methylated NAs in vitro. This impairment is worse in the shorter 
truncation (R270X), indicating a cumulative effect of these DNA-binding domains 








Although MeCP2 alone is sufficient to condense nucleosomal arrays, in vivo this 
activity may also involve its interaction partners. MeCP2 has been shown to bind 
directly to several chromatin remodelling and chromatin modifying proteins (Fig. 
1.5), including ATRX (Nan et al., 2007; Kernohan et al., 2010), HP1γ (Agarwal et 
al., 2007), SMC1/3 (Kernohan et al., 2010), DNMT1 (Kimura et al., 2003), TET1 
(Cartron et al., 2013) and Lamin B (Guarda et al., 2009).  Methylation of H3K9 by 
G9a and HLCS could affect global chromatin structure as well as repress 
transcription locally (Fuks et al., 2003; Subbanna et al., 2014; Xue et al., 2013). The 
HDAC-containing repressor complexes that interact with MeCP2 (described in 
section 1.5.1) can also alter chromatin structure by the removal of acetyl groups from 
histone tails.  
 
The role of the SWI/SNF2 ATPase, ATRX (α-thalassemia/mental retardation, X-
linked), in mouse models of RTT has been the most widely studied. In wild-type 
mice, ATRX co-localises with MeCP2 at heterochromatic foci in neurons; but this 
localisation is reduced in Mecp2-null mice. This delocalisation of ATRX does not 
occur in peripheral tissues (such as kidney and liver) or in the brains of new-born 
mice (Nan et al., 2007; Baker et al., 2013). This indicates that the neuronal-specific 
MeCP2-dependent mechanism for proper ATRX localisation becomes dominant 
upon neuronal maturation as MeCP2 levels increase, with alternative mechanisms of 
localisation present in peripheral tissues and developing brains (Nan et al., 2007; 
Figure 1.5.3: The DNA binding domains of MeCP2 
Schematic diagram of MeCP2 protein (e2) annotated with the Methyl-CpG 
binding domain (MBD, residues 78-162); AT-hook 1 (H1, residues 184-195); AT-
hook 2 (H2, residues 265-272); and the ‘basic patch’ (BP, residues 274-340). 
The first nonsense mutation, R270X, removes both AT-hook 2 and the ‘basic 
patch’. The second nonsense mutation, G273X, removed the ‘basic patch’ only. 
References: Nan et al., 1993; Baker et al., 2013; Heckman et al., 2014; Lyst, 
Connelly et al., 2016). 
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Baker et al., 2013). Indeed, overexpression of ATRX fragments in cultured mouse 
fibroblasts shows that its N-terminus is sufficient for localisation to heterochromatic 
foci. However, overexpression of its C-terminal half, which interacts with residues 
108-169 of MeCP2, requires MeCP2 to recruit it to heterochromatin (Nan et al., 
2007). Surprisingly, mice expressing the two truncated alleles mentioned above, 
R270X and G273X, both show delocalisation of ATRX, despite retaining the ability 
to bind ATRX. Interestingly, the loss of ATRX localisation in the neurons of these 
mice follows symptom progression: occurring earlier in the more severe R270X 
truncation. The authors of this study propose a model where MeCP2 is recruited to 
chromatin via its MBD and manipulates the chromatin structure via multiple DNA 
interactions, promoting a chromatin environment that retains ATRX. The 
progressively weak remodelling activity with the loss of one or two DNA-binding 
domains affects the rate of chromatin de-condensation, leading to ATRX loss, and to 
disease progression (Baker et al., 2013). A further link between ATRX and the 
pathology of MECP2-related disorders is the discovery that the point mutation in the 
MBD, A140V, specifically reduces the affinity of MeCP2 for ATRX without 
affecting DNA binding (Nan et al. 2007). This mutation causes intellectual disability 
in male patients (Neul, 2012). 
 
A role of MeCP2 in chromatin compacting activity in vivo would predict increased 
chromatin density upon its upregulation. This was demonstrated when MeCP2 was 
ectopically overexpressed in mouse myoblasts: chromocentres became larger and 
fewer in number due to clustering (Brero et al., 2005). This activity was weakened by 
RTT-causing missense mutations that disrupt MBD function, showing a requirement 
for this domain (Agarwal et al., 2011). The authors of these studies propose that 
upregulation of MeCP2 during myogenesis is responsible for the clustering of 
pericentromeric heterochromatin that occurs during differentiation (Brero et al., 
2005), and that this process is furthered by the recruitment of HP1γ, resulting in 
increased levels of H3K9me3 (Agarwal et al., 2007). Recently, Linhoff et al. (2015) 
developed a 3D imaging technique called ChromATin to analyse these effects in 
mouse brains. Surprisingly, they show that Mecp2-null neurons in heterozygous 
females have more densely packed chromatin than wild-type neurons in the same 
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tissue. The magnitude of the change varied between neuronal subtypes: the smallest 
change was in cerebellar granule cells, which express the lowest levels of MeCP2. A 
possible explanation for the reverse effects observed in myoblasts and neurons is that 
these different cell types contain different levels of other chromatin architectural 
proteins, such as the linker histone H1. Normally, neurons have one molecule of 
histone H1 every two nucleosomes, half the amount than in other cell types (Pearson 
et al., 1984). Strikingly, in Mecp2-null neurons, histone H1 levels are doubled (Skene 
et al., 2010). MeCP2 has been shown to preferentially displace histone H1 (Nan et 
al., 1997; Ghosh et al., 2010), providing a potential mechanism for reduced histone 
H1 levels in wild-type neurons. Further work is needed to confirm whether mutants 
of MeCP2 that contain an intact MBD (e.g. R270X and G273X) retain the ability to 
displace histone H1, keeping its levels down. If so, it will be important to analyse 
how their presence on chromatin affects its structure given that they lack one or two 
of the additional DNA binding domains. 
 
MeCP2 has also been implicated in chromatin-looping at imprinted gene loci, 
resulting in transcriptional repression of these genes. This was first described at the 
Dlx5/Dlx6 locus by Horike et al. (2005). In wild-type mouse brains, Chromosome 
Conformation Capture (3C) was used to detect two different loop structures: one 
associated with the active maternal allele and one with the silent paternal allele. In 
Mecp2-null brains, Dlx5 and Dlx6 are both upregulated due to loss of repression of 
the paternal alleles. This is combined with increased histone acetylation and reduced 
H3K9 dimethylation at this locus. Furthermore, only the loop structure associated 
with active chromatin could be detected. The authors propose that MeCP2 recruits 
histone modifying enzymes such as HDAC-containing complexes and H3K9 
methyltransferases to this locus to enable the formation of chromatin loops that 
maintain silencing. This is consistent with a loss of HDAC1 recruitment to 
Dlx5/Dlx6 in Mecp2-null brains. Although MeCP2 has also been reported to interact 
with the maintenance DNA methyltransferase, DNMT1, no changes in DNA 
methylation were observed at this locus. Biallelic expression of DLX5 was also 
detected in lymphoblastoid cell lines (LCLs) derived from RTT patients. Two of 
these patients have missense mutations in the MBD (T158M and G161V) indicating 
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the importance of this domain for the function of MeCP2 in regulating chromatin 
loops. Two more recent studies by Kernohan and colleagues (2010 and 2014) 
describe a more direct mechanism for MeCP2 regulation of chromatin looping at 
imprinted genes. They demonstrate that MeCP2 interacts with two subunits of the 
cohesin ring complex (SMC1 and SMC3) as well as ATRX in mouse brains 
(Kernohan et al., 2010) and that MeCP2 is required for ATRX and CTCF recruitment 
at the H19 locus. Together, these proteins regulate proper long-range chromatin 
interactions at this locus, which are disrupted in the absence of MeCP2, resulting in 
upregulation of gene expression (Kernohan et al., 2014). Surprisingly, these proteins 
were found to preferentially bind the unmethylated maternal allele of H19, enabling 
its silencing in postnatal brains (Kernohan et al., 2010). Further work is needed to 
determine whether MeCP2 binding at this locus is methylation independent. This 
mechanism provides an additional link between MeCP2 and ARTX function, further 
connecting the two forms of intellectual disability caused by their mutation.  
 
It is possible that loss of imprinting at the Dlx5/Dlx6 locus could contribute to the 
RTT phenotype as Dlx5 is important for the function of GABAergic neurons. 
Conversely, loss of imprinting was only detected in the LCLs derived from three out 
of four RTT patients tested: the fourth has the common C-terminal nonsense 
mutation, R294X (Horike et al., 2005). 
 
1.5.4 MeCP2 as a regulator of alternative splicing 
 
MeCP2 has been reported to directly interact with a number of splicing factors (Fig. 
1.5), including FBP11, HYPC (Buschdorf and Strätling, 2004), YB-1 (Young et al., 
2005), PRPF3 (Long et al., 2011), LEDGF, DHX9, TDP-43 and FUS (Li et al., 
2016). Aberrantly spliced mRNAs have been detected in RNA-sequencing datasets 
obtained from three different regions of the brains of Mecp2-null mice. A range of 
different aberrant splicing events occurred in these transcripts, including skipped 
exons and retained introns. Interestingly, expression levels were unaffected in most 




The use of Mecp2-null animals for this study gives no indication about which of the 
splicing factors that interact with MeCP2 might be responsible for these changes. 
The binding sites for three of these splicing factors have been mapped to the C-
terminus of MeCP2: the related proteins, FBP11 and HYPC, require residues 311-
486 (Buschdorf and Strätling, 2004) and YB-1 requires residues 195-329 (Young et 
al., 2005). Altered splicing events were also detected in knock-in mice expressing a 
C-terminally truncated allele of MeCP2 (lacking residues 309-CT), highlighting the 
involvement of these three proteins. The presence of YB-1 binding sites (ACE 
elements) near alternatively spliced exons in the top 10 aberrantly spliced genes 
indicates an importance for YB-1. The deletion of an ACE element from a CD44 
splicing reporter minigene abolished MeCP2-mediated inclusion of two alternative 
exons, providing further evidence for a role of YB-1 binding in MeCP2-mediated 
alterative splicing (Young et al., 2005). Another splicing factor, LEDGF, is thought 
to be for required MeCP2-mediated splicing of the Gria2 gene, as knockdown of 
MeCP2 and LEDGF had the same effect on the inclusion ratio of two mutually 
exclusive exons in a Gria2 reporter minigene (Li et al., 2016). 
 
Maunakea et al. (2013) demonstrated a link between high DNA methylation levels 
and inclusion of alternatively spliced exons in two human cell lines: lung fibroblasts 
(IMR90) and colorectal cancer cells (HCT116). Data from these cell lines shows that 
DNA methylation and MeCP2 binding are more highly enriched at included 
alternatively spliced exons than excluded exons. While DNA methylation depletion 
and MeCP2 knockdown both result in both aberrant exclusion and inclusion of exons 
(as seen in Mecp2-null mice, Li et al., 2016), the aberrantly spliced exons that 
normally have the highest levels of both DNA methylation and MeCP2 binding 
tended to be excluded when these were reduced. Overall, this data indicates that 
MeCP2 binding to highly methylated exons promotes their inclusion in transcripts. 
This study does not test whether any of the splicing factors shown to interact with 
MeCP2 are involved in these DNA methylation-dependent splicing events. Instead, 
they show that this activity is HDAC-dependent, with strong overlap between 
aberrant splicing events in MeCP2-depleted and Trichostatin A-treated cells. Their 
data is consistent with a kinetic model of splicing regulation, whereby MeCP2 
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recruits HDAC-containing complexes to highly methylated exons, resulting in slower 
RNA pol II elongation and increased exon inclusion (Maunakea et al., 2013). 
 
Li et al. (2016) show that MeCP2 is also enriched over exons and exon/intron 
boundaries in the mouse cortex. As yet, there is no evidence so far to determine 
whether this regulates MeCP2-mediated splicing in the brain: via its interactions 
either with splicing factors or with HDAC-containing complexes. Surprisingly, a 
RTT-causing mutation that destroys MBD function (R106W) has no effect on the 
ability of MeCP2 to mediate exon inclusion of the CD44 minigene reporter in 
transfected HeLa cells (Young et al., 2005). Instead this activity requires the RNA-
binding ability of MeCP2 as its interaction with YB-1 is RNA-dependent (Jeffery 
and Nakielny, 2004; Young et al., 2005). Conversely, the interactions between 
MeCP2 and several other splicing factors, PRPF3, LEDGF, DHX9, TDP-43 and 
FUS,  have been shown to be RNA-independent (Long et al., 2011; Li et al., 2016), 
so DNA binding may play a role in recruiting these MeCP2-splicing factor 
complexes to their target sites. 
 
Whatever the mechanism for MeCP2 regulation of alternative splicing, the mis-
spliced transcripts are likely to have phenotypic consequences. Alternative splicing is 
thought to be particularly important in the central nervous system since almost all 
neurotransmitter receptors and ion channels have multiple alternatively spliced 
isoforms (reviewed by O'Donovan and Darnell, 2001). Potentially relevant affected 
genes include Gria1/2/3/4, components of the AMPA receptor (Li et al., 2016), and 
Dlx5, which is involved in the function of GABAergic neurons (Young et al., 2005). 
Unlike Dlx5, which has elevated expression in Mecp2-null mice due to altered 
chromatin looping (Horike et al., 2005; see section 1.5.3), the expression levels of 
Gria1/2/3/4 are unaffected in Mecp2-null mice (Li et al., 2016). Therefore, any 






1.5.5 MeCP2 as a regulator of miRNA processing 
 
A recent study has described a role of MeCP2 in promoting miRNA processing 
(Tsujimura et al., 2015). MeCP2 was shown to interact with core components of the 
nuclear miRNA processing complex: DGCR8, Drosha and DDX5. RNA-sequencing 
of miRNAs identified 60 and 75 miRNAs that were downregulated by >1.5 fold in 
Mecp2 KO neurons and neural stem cells (NSCs), respectively. This study goes on to 
focus on miR-199a, the only one of the nine miRNAs downregulated in both cell 
types that affects cell size. They propose a link between MeCP2-mediated processing 
of miR-199a and cell growth: miR-199a targets three inhibitors of the mTOR 
signalling pathway, SIRT1, HIF1a and PDE4D. The model is supported by the 
characterisation of a miR-199a KO mouse, which resembles many of the features of 
Mecp2-null animals, including the development of hypoactivity, gait abnormalities, 
trembling and irregular breathing after a symptom-free period of 3 weeks. These 
symptoms lead to premature death from six weeks of age. These mice also have 
reduced body weight and brain size, consistent with a defect in cell growth. 
Surprisingly, a separate study published the previous year described a suppressive 
role of MeCP2 in regulating miRNA processing (Cheng et al., 2014a). Using the 
same threshold of >1.5 fold, they identified 314 (out of 720) miRNAs that are 
upregulated and only 63 that are downregulated in the hippocampus of Mecp2-null 
mice. Of the 314 upregulated miRNAs, 106 were downregulated in cortical neurons 
overexpressing MeCP2. While this study reports an interaction between the miRNA 
processing component, DGCR8, and the C-terminus of MeCP2 (Fig. 1.5), it does not 
propose that MeCP2 functions as a component of this complex. Instead, they show 
that MeCP2 competes with Drosha for DGCR8 binding, negatively regulating 
miRNA processing complex formation. Tsujimura et al. (2015) state that they cannot 
replicate this result, but suggest that the differences observed in the two studies could 
be a result of different post-translational modifications altering MeCP2 activity in 
different neuronal subtypes. 
 
Importantly, both studies show that MeCP2 affects the processing and not the 
transcription of its target miRNAs as the levels of the primary miRNA transcripts are 
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unaffected. Altered levels of both the precursor and mature miRNAs confirm that 
MeCP2 is involved in the primary (Drosha-mediated) nuclear processing step rather 
than the secondary (DICER-mediated) cytoplasmic processing step, consistent with 
its nuclear localisation (Cheng et al., 2014a; Tsujimura et al., 2015). 
 
1.5.6 MeCP2 as a regulator of proliferation and apoptosis 
 
Loss of MeCP2 has been shown to inhibit growth in a range of normal and cancerous 
cell lines in culture (Balmer et al., 2002; Nagia et al., 2005; Babbio et al., 2012; 
Bergo et al., 2015; Yang et al., 2016a). Bergo et al. (2015) suggest that MeCP2 is 
involved in organisation of the mitotic spindle since depletion of MeCP2 in 
fibroblasts (MRC5 cells) results in a large percentage of cells with abnormal spindle 
morphology, mostly monopolar. They propose that a subpopulation of MeCP2 (<1% 
of molecules) is responsible for this activity. This subpopulation is phosphorylated 
on Tyr120 and localises at the centromeres throughout the cell cycle. This study was 
prompted by the report of an atypical RTT patient with a Y120D mutation, which 
may mimic the phosphorylated state. Overexpression of the wild-type but not this 
mutated protein rescued the proliferation defect in Mecp2-null MEFs, disproving the 
hypothesis that it is constitutively active for this function. The importance of Tyr120 
phosphorylation for cell proliferation was not tested with the phospho-abolishing 
mutation, Y120F. Yang et al. (2016a) propose an alternative explanation for the 
proliferation defect in MeCP2 deficient cells whereby MeCP2 represses H19, leading 
to elevated levels of Insulin-like growth factor (IGF-1) in hepatic stellate cells. 
 
A proliferation defect due to MeCP2 depletion has also been reported in cultured 
non-neuronal cell types derived from embryonic mouse brains, suggesting that 
reduced proliferation of glial cells may contribute to microcephaly in RTT patients 
and mouse models (Nagai et al., 2005). Conversely, it is unlikely that this 
proliferation defect occurs in vivo as RTT patients have no weight or head 
circumference defects at birth (Hagberg et al., 1985). Furthermore, analysis of X 
chromosome inactivation (XCI) ratios in RTT patients’ peripheral blood cells has 
61 
 
shown that the majority of patients do not have skewed ratios of wild-type to mutant 
cells (http://mecp2.chw.edu.au). 
 
Ectopic overexpression of MeCP2 in cancer cells promotes proliferation (Bernard et 
al., 2006) and increased levels of MeCP2 have been reported in gastric tumours 
(Wada et al., 2010; Tong et al., 2016). Conversely, ectopic overexpression of MeCP2 
in normal cell lines results in increased apoptosis (Bracaglia et al., 2009). In Mecp2-
null MEFs, overexpression of wild-type but not MeCP2-R106W resulted in increased 
cell death, suggesting that this role of MeCP2 is dependent on its ability to bind 
DNA. This apoptotic activity was enhanced by co-overexpression with 
homeodomain-interacting protein kinase 2 (HIPK2), which can interact with MeCP2 
and phosphorylate it on Ser80 (Fig. 1.5; Bracaglia et al., 2009) increasing its affinity 
for DNA (Tao et al., 2009). The role of Ser80 phosphorylation is supported by the 
fact that the phospho-defective mutant, S80A, is unable to promote cell death, and 
the phospho-mimetic mutant, S80E, functions independently of HIPK2 
overexpression. This effect was also seen in P19 (mouse embryonic teratocarcinoma) 
cells differentiated into neurons (Bracaglia et al., 2009) and cerebellar granule cells 
(Dastidar et al., 2012). This latter paper shows that this effect is specific to the 
shorter and less abundant e2 isoform; and that e2-mediated apoptosis is normally 
prevented in healthy neurons by a direct interaction with FOXG1 (the protein that is 
mutated in congenital variant RTT; Fig. 1.5). Williams et al. (2016) recently used a 
Drosophila-based system to show that overexpression of human MeCP2e2 with C-
terminal truncations (residues 431-CT or more), as well as the phospho-mimetic 
mutant S80E, have a stronger effect of neurotoxicity than the full-length protein. 
Together, these studies identify two inhibitory processes at the extreme N- and C-
termini of e2 but shed no light on why e2 but not e1 promotes apoptosis. To my 
knowledge, this is the only isoform-specific function of MeCP2 that has been 
reported. 
 
Neurodegeneration has not been described in Mecp2-overexpression mouse models 
but has been reported in patients with MECP2 duplication syndrome (Reardon et al., 
2010). Two groups have characterised mouse models with very high levels of 
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MeCP2e2: one with a CMV-driven human e2 cDNA transgene at 40-140% of wild-
type levels replacing endogenous MeCP2 (Kerr et al., 2012) and one with 2-8 fold 
levels of mouse e2 expressed in neurons from the Tau locus (Luikenhuis et al., 
2004). Although, in both studies, expression of MeCP2e2 rescues RTT-like 
symptoms in null males, the apoptotic activity of these proteins may be disrupted by 
N-terminal fusion with EGFP or the first 31 amino acids of Tau in Kerr et al. (2012) 
and Luikenhuis et al. (2004) respectively.  
 
Williams et al. (2016) hypothesised that this apoptotic activity of MeCP2e2 might 
provide a mechanism for the high incidence of skewed XCI in women who have 
MECP2 duplicated on one X chromosome (van Esch et al., 2005). Loss of 
overexpressing cells in these individuals would result in a higher proportion of wild-
type cells, providing protection against more severe symptoms (see section.1.3.5). 
While Sztainberg et al. (2015) show that male mouse models of Mecp2-duplication 
whose MeCP2 levels have been halved by genetic deletion or ASO-mediated 
knockdown do not display neurological symptoms, it is unclear from the authors’ 
description whether these mice were treated before or after the onset of symptoms. 
Further work is needed to determine the extent that neurotoxicity contributes to 
MECP2 duplication syndrome pathophysiology and how time-dependent a possible 
cure could be. 
 
1.5.7 Regulation of MeCP2 function by post-translational modification 
 
MeCP2 protein has been reported to be post-translationally modified at multiple sites 
by phosphorylation, acetylation, ubiquitination, SUMOylation and poly(ADP-
ribosyl)ation (Table S2). The discovery of neuronal-activity dependent 
phosphorylation and de-phosphorylation of specific residues provides a mechanism 
for the regulation of MeCP2 activities in response to neuronal signalling. Several 
serine and threonine residues have been found to be phosphorylated in seized mouse 
brains and/or depolarised cultured neurons (Fig. 1.5.7): Ser86, Thr148/Ser149, 
Ser164, Ser229, Ser274, Thr308, Ser421 [human residue number 423] and Ser424 
[human residue number 426] (Ebert et al., 2013; Tao et al., 2009; Zhou et al., 2006). 
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The opposite effect was described for Ser80, which is phosphorylated under basal 





The effect of phosphorylation and de-phosphorylation on the ability of MeCP2 to 
bind DNA has been widely studied. Two separate knock-in mouse lines with 
phospho-abolishing alanine mutations at both Ser421 and Ser424 recapitulate some 
of the features of Mecp2-overexpression mice, including improved motor function, 
heightened context-dependent learning and enhanced LTP (Table S1G; Tao et al., 
2009; Li et al., 2011). This phenotype is consistent with the inability to 
phosphorylate these sites having a gain of function effect. Indeed, the mutated 
protein shows increased binding at several selected loci, resulting in similar 
expression changes of these genes to those observed in Mecp2-overexpression mice 
(Li et al., 2011). The first of these phospho-sites, Ser421, has been characterised 
further. It was shown to be phosphorylated by CamKII kinase in response to 
membrane depolarisation or seizure induction (Zhou et al., 2006; Tao et al., 2009). 
Knock-in mice with only the S421A mutation have increased dendritic branching 
similar to pre-symptomatic overexpression models (Cohen et al., 2011; Jiang et al., 
2013), but their mild motor and social behaviour defects are more reminiscent of 
RTT models (Table S1G). This singularly mutated protein did not have increased 
Figure 1.5.7: Post-translational modifications in MeCP2 
Schematic diagram of mouse MeCP2 protein (e2) annotated with the activity-
dependent phosphorylation sites above and other post-translational modifications 
below. All activity-dependent residues are phosphorylated upon neuronal activity 
except Ser80, which is phosphorylated under basal conditions and 
dephosphorylated upon neuronal activity. All residues numbers are the same 
between human and mouse except S421 [S423 in human] and S424 [S426 in 
human]. All modified are conserved between human and mouse except 




chromatin binding at any of the tested loci (Cohen et al., 2011), suggesting that 
S424A may have been responsible for this phenotype in the double-mutant mice. 
 
Phosphorylation of Ser80 by HIPK2 kinase has been reported in both cycling cells 
and neurons (Bracaglia et al., 2009). Dephosphorylation of this site upon neuronal 
activity is thought to reduce chromatin binding, as demonstrated by the S80A mutant 
protein at selected gene promoters in cultured cortical neurons. Mice with the same 
mutation display mild RTT-like symptoms from 2-3 months of age, including 
impaired motor function (Table S1G; Tao et al., 2009). Although this is consistent 
with reduced MeCP2 function through weakened DNA binding, the phenotype of 
these mice is less severe than those carrying RTT-causing MBD mutations (R111G, 
R133C and T158M/A) that partially or completely abolish DNA binding (Goffin et 
al., 2012; Heckman et al., 2014; Brown, Selfridge et al., 2016). 
 
A recent paper proposed that phosphorylation of MeCP2 at Ser164 also reduces its 
affinity for both methylated and unmethylated DNA. This effect is demonstrated 
using the phospho-mimetic mutant S164D. It remains unclear whether a 
phosphorylated serine would have the same consequence, but computational 
modelling using the crystal structure predicts this to be the case (Stefanelli et al., 
2016). 
 
Notably, phosphorylation or dephosphorylation upon neuronal activity at all of these 
sites in MeCP2 was initially proposed to reduce chromatin binding. To support this, 
depolarisation of cultured neurons with KCl led to MeCP2 release from the BDNF 
promoter (Chen et al., 2003). This model was later revised by a study that performed 
genome-wide ChIP-seq analysis on untreated and depolarised cultured neurons and 
failed to identify any regions of the genome with reduced MeCP2 binding (Cohen et 
al., 2011). 
 
The location of Ser80 at the N-terminal end of the MBD suggested that it could 
decrease DNA binding directly by steric hindrance. Recently Cheng et al. (2014a) 
showed that phosphorylation of Ser80 disrupts intramolecular interaction between 
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the N- and C- termini of MeCP2. Therefore, removal of the phosphate from this 
residue upon membrane depolarisation promotes protein folding into a less active 
state. This model is consistent with the requirement of Ser80 phosphorylation for its 
interactions with YB-1 and DGCR8, when C-terminal fragments of MeCP2 are 
sufficient for their binding (Gonzales et al., 2012; Cheng et al., 2014a; Young et al., 
2005). Similarly, it explains why mutating Ser80 to alanine in the context of an N-
terminal fragment of MeCP2 (residues 1-205) displayed no DNA-binding deficit in 
electrophoretic mobility shift assays (Tao et al., 2009). This protein folding model 
was proposed as an explanation for the increased apoptotic activity in both S80E and 
C-terminally truncated mutants, whereby deletion of the extreme C-terminus 
(residues 431-CT) could destroy intramolecular binding, rendering the protein 
constitutively active (Williams et al., 2016). 
 
The phosphorylation of Thr308 was shown to disrupt binding to the NCoR/SMRT 
co-repressor complex (Ebert et al., 2013). This finding fits with its location within 
the region of MeCP2 required for this interaction: residues 285-309 (Lyst et al., 
2013). This finding provides an activity-dependent mechanism of alleviating 
MeCP2-mediated gene repression without disrupting DNA-binding, which could 
have additional consequences by altering global chromatin structure. The importance 
of Thr308 phosphorylation in vivo was demonstrated by the presence of mild RTT-
like symptoms in T308A knock-in mice. These animals have reduced brain weight, 
impaired motor function and a lower pentylenetetrazol-induced seizure threshold 
(Table 1G; Ebert et al., 2013). This phenotype is surprising as this mutation could be 
predicted to have a gain-of-function effect due to the inability to release the 
NCoR/SMRT complex from chromatin-bound MeCP2. 
 
Two studies describe altered cellular localisation due to the phosphorylation state of 
MeCP2. The absence of phosphorylation at Ser30 [residue 13 in e2] was observed in 
a small proportion of MeCP2e1 molecules that reportedly localised to the 
nucleoplasm in wild-type mouse brains (Yasui et al., 2014). This study does not go 
on to identify a specific role for these molecules, nor does it determine whether 
unphosphorylated e2 is localised similarly. As described in section 1.5.6, a small 
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subpopulation of MeCP2 is phosphorylated at Tyr120 in cycling cells and has been 
proposed to have a role in mitotic spindle assembly (Bergo et al., 2015). The 
relevance of this phospho-site for neuronal function was proposed due to its mutation 
to a phospho-mimetic state (Y120D) in a patient with variant RTT. In two separate 
studies, this mutation has been shown to disrupt DNA-binding (Kudo et al., 2003; 
Agarwal et al., 2011), providing a more likely explanation for this patient’s 
condition. It is yet to be determined whether phosphorylation of Tyr120 also affects 
DNA binding. Examining the effect of the phospho-abolishing mutation Y120F on 
mitotic spindle assembly and regulation of DNA binding will help determine the 
importance of this phospho-site. A phenylalanine at this site has not been reported in 
patients with MECP2-related disorders or in the general population 
(http://mecp2.chw.edu.au/; http://exac.broadinstitute.org/), but is present in both the 
Xenopus and zebrafish homologues, indicating that this mutation – and therefore loss 
of Tyr120 phosphorylation - may not have an adverse effect of MeCP2 function in 
vivo. 
 
Two recent papers report that MeCP2 can be SUMOylated, and that this affects its 
function. The first, by Cheng et al. (2014b), showed that MeCP2 can be 
immunoprecipitated from cultured mouse cortical neurons with a SUMO antibody, 
and that SUMOylation was increased when these cells were depolarised with KCl. 
They identify Lys223 as a SUMOylated residue, as mutating this residue to arginine 
(K223R) led to a much lower level of MeCP2 SUMOylation when it is co-
overexpressed in HEK293 cells with SUMO1. They go on to characterise the activity 
of the K223R mutant protein: showing it has reduced HDAC1/2 binding (the 
catalytic components of the SIN3A co-repressor complex) and reduced ability to 
repress a GFP reporter gene. Lastly, they show that expression of wild-type MeCP2 
but not K223R can rescue the reduced synaptic density phenotype in MeCP2-
depleted hippocampal neurons. While these results indicate that Lys223 is important 
for MeCP2-mediated repression via the SIN3A complex and for neuronal growth, it 
is unclear whether this is due to the presence of SUMO at this residue. A separate 
study, by Tai et al., (2016), found that MeCP2 can be SUMOylated by PIAS1 at 
K412R [human residue 414] using an in vitro SUMOylation assay. They showed that 
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SUMOylation at this site is facilitated by phosphorylation of Thr308 and Ser421, and 
so is increased by neuronal stimulation. Finally, they showed that SUMOylation of 
this residue disrupts CREB binding, leading to a model whereby SUMOylation of 
MeCP2 releases CREB allowing it to activate its target genes, e.g. Bdnf. Despite the 
extensive characterisation of this modification using in vitro and cell-based assays, 
there is no evidence presented in this study that it can occur naturally. It is also worth 
noting that neither of these lysine residues (Lys223 or Lys412) is located in a 
consensus SUMO-substrate motif, ψ-K-X-E (where ψ is any hydrophobic amino 
acid). 
 
A recent study reports poly(ADP-ribosyl)ation of MeCP2 in mouse brains (Becker et 
al. 2016). This modification was mapped to two regions, residues 163-206 and 244-
275, by expressing MeCP2 fragments in cultured cells. Poly(ADP-ribose) 
polymerase (PARP) 1 was shown to be responsible for this modification, with lower 
levels of poly(ADP-ribosyl)ation on ectopically expressed MeCP2 in PARP1-/- 
fibroblasts. This study reports a role for poly(ADP-ribosyl)ation of MeCP2 in 
regulating its chromatin condensing activity. As discussed previously, ectopic 
expression of wild-type MeCP2 in myoblasts results in clustering of chromocentres 
(Brero et al., 2005; see section 1.5.3). This activity was increased upon treatment 
with the PARP1 inhibitor 3AB. This effect was also demonstrated in the PARP1-/- 
fibroblasts, where MeCP2 was shown to have increased localisation and longer 
residence time on heterochromatin. Overall, these results suggest a negative effect of 
poly(ADP-ribosyl)ation on the chromatin remodelling activity of MeCP2 (Becker et 
al., 2016). Further work is needed to determine the impact of poly(ADP-ribosyl)ation 
on MeCP2-mediated chromatin remodelling in neurons. 
 
Two of the modifying enzymes mentioned above, HIPK2 kinase and PIAS1 SUMO 
E3 ligase, are reported to directly interact with MeCP2 (Bracaglia et al., 2009; Tai et 
al., 2006). In addition to these, four modifying enzymes have been proposed to 
directly interact with and modify MeCP2: CDKL5 kinase, IKKα kinase, p300 
acetylase and SIRT1 deacetylase (Fig. 1.5; Mari et al., 2005; Knoshman et al., 2012; 
Zocchi and Sassone-Corsi, 2012). Inhibition of SIRT1 in a variety of cell lines 
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resulted in increased acetylation of Lys22, Lys135, Lys171, Lys200, Lys256, 
Lys271, Lys289 and Lys447 [human residue 449] (Pandely et al., 2015; Zocchi and 
Sassone-Corsi, 2012). Of these modifications, Lys171 acetylation could be of 
particular interest as it has been suggested to decrease binding affinity to ATRX and 
HDAC1 (Pandely et al., 2015). The discovery that CDKL5 kinase can interact with 
MeCP2 (residues 202-CT) and phosphorylate it links classical and early seizure onset 
RTT, as the latter is usually caused by mutations in CDKL5 (Mari et al., 2005). 
 
1.6 Analysis of RTT-causing mutations highlights the key function of MeCP2 
 
1.6.1 The RTT mutation spectrum highlights the importance of the MBD and the NID 
 
A common method for predicting the importance of protein regions or specific 
residues is their evolutionary conservation. MeCP2 is highly conserved along its 
entire length, with 95% identity between human and mouse - greater than the average 
of 86.4% (Makałowski and Boguski, 1998). This suggests that all its domains are 
vital for its function. Strikingly, analysis of the missense mutations that cause RTT 
gives a contrasting picture. These are almost entirely located in two clusters: a large 
cluster in the Methyl-CpG Binding Domain (MBD) and a smaller cluster in the more 
recently defined NCoR/SMRT Interaction Domain (NID) (Fig. 1.6.1; Nan et al., 
1993; Lyst et al., 2013). Analysis of the polymorphisms present in the general 
population (recorded in the ExAC database) helps to determine regions of the protein 
that may be dispensable for its function. Evidence for their benign effect is 
particularly strong in males, who are hemizygous for MECP2. Mapping these 
mutations along the length of MeCP2 shows a reciprocal picture to the RTT-causing 
mutations (Fig. 1.6.1). Together, this suggests that the role of MeCP2 in recruiting 
the NCoR/SMRT co-repressor complex to methylated DNA could be its key function 
in vivo. This is referred to in this study as the ‘bridge hypothesis’, with MeCP2 
forming a bridge between chromatin and the NCoR/SMRT complex. It was first 
proposed by Lyst et al. (2013) upon characterisation of the NID where they showed 
that missense mutations within it abolish binding to components of the NCoR/SMRT 
complex. As the majority of RTT-causing missense mutations in the MBD disrupt 
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DNA binding (Table S3), this hypothesis predicts that Rett syndrome occurs if this 
bridge is broken at either end. While the other proposed roles of MeCP2 may be 
important for full neuronal function, their importance is likely to be secondary, with 





1.6.2 The ‘unexplained’ RTT-causing mutations 
 
While the vast majority of RTT-causing missense mutations fit this bridge 
hypothesis, three lie outside these regions: A2V (e1 only), P225R, P322L/A (Fig. 
1.6.1). Another category of mutations that does not fit the hypothesis is those where a 
portion of the C-terminus after the end of the NID is missing. Importantly, these C-
terminal truncating mutations are the cause of ~10% of cases of RTT. How these 
mutations cause RTT is the subject of an ongoing study in the lab by Jacky Guy. To 
date, she has shown that both P225R and P322L are unstable, resulting in low protein 
levels in neurons derived from knock-in ES cells and knock-in mice. Both mutant 
proteins also show reduced ability to recruit a component of the NCoR/SMRT 
Figure 1.6.1: RTT-causing mutations highlight the importance of the MBD 
and the NID 
Schematic diagram of human MeCP2 protein (e1) annotated with the Methyl-
CpG binding domain (MBD, residues 78-162) and NCoR/SMRT interaction 
domain (NID, residues 285-309). Above: polymorphisms found in hemizygous 
males in the general population (shown in black) and RTT-causing missense 
mutations (shown in red). Below: alignments showing identical amino acids 
conserved between the human protein and homologs in other species 
(chimpanzee, mouse, rat, Xenopus, zebrafish).  References: Nan et al., 1993; 
Lyst et al., 2013; http://exac.broadinstitute.org/; http://mecp2.chw.edu.au/ (last 
updated September 2016). 
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complex (TBL1X) to heterochromatin foci in a cell-based assay. Hemizygous male 
mice expressing these mutant proteins have undergone phenotypic characterisation, 
and both resemble other RTT mouse models (Table S1H). Currently, there is also no 
experimental evidence for the pathogenicity of the e1 missense mutation, A2V, 





1.7 Aims of this project 
The key functional importance of only the Methyl-CpG Binding Domain (MBD) and 
the NCoR/SMRT Interaction Domain (NID) as indicated by the locations of the 
RTT-causing missense mutations is in stark contrast to the common view of MeCP2 
as a multifunctional protein.  The aim of my PhD project was to test the much 
simpler model that MeCP2 functions as a ‘bridge’ between methylated DNA and the 
NCoR/SMRT co-repressor complex. This activity should only require these two 
domains: MBD and the NID. To determine whether the two domains are sufficient 
for MeCP2 function, I made a truncated form of the protein consisting solely of the 
MBD and the NID. This protein lacks three potential dispensable regions of MeCP2: 
the N-terminus before the MBD, the Intervening Region between the MBD and the 
NID, and the C-terminus after the NID. To test the functionality of this protein in 
vivo, I produced a mouse line expressing it from the endogenous Mecp2 locus. Given 
that this was a high-risk strategy and mouse production takes a long time, I 
simultaneously made two other knock-in mouse lines expressing less severe 
truncations of MeCP2. The first is missing only the N-terminus, and the second is 
missing both the N- and the C-termini. Together, these proteins form a stepwise 
series of MeCP2 deletions, enabling any RTT-like symptoms displayed by the 
knock-in mice expressing the most severe truncation to be attributed to one or more 
of the deleted regions. This project ran alongside the characterisation of the 
‘unexplained’ RTT-causing mutants by Jacky Guy, which addresses the same 
hypothesis. 
 
In 2007, Guy et al. showed that the RTT-like symptoms displayed by Mecp2-null 
mice are reversible upon reintroduction of wild-type MeCP2. This was done by 
alleviating transcriptional silencing of the endogenous Mecp2 allele using genetic 
manipulation techniques. This study showed that MeCP2 is not required during 
development and is instead essential for the maintenance of proper function in 
mature neurons. In this study, I set out to determine whether the ‘bridge function’ of 
MeCP2 was sufficient to restore neuronal function after the onset of symptoms in 
MeCP2-deficient mice by activating a gene expressing the most severely deleted 










2.1.1 Standard Buffers 
 
Name Recipe 
L broth 1% (w/v) Bacto tryptone, 0.5% (w/v) Bacto yeast extract, 
1% (w/v) NaCl (Fisher Scientific 5/3160/63) (adjusted to 
pH 7.0 with 5M NaOH) 
Terrific broth 1.2% (w/v) Bacto tryptone, 2.4% (w/v) Bacto yeast 
extract, 2.4% (w/v) glycerol. Add 17 mM KH2PO4 and 72 
mM K2HPO4 before use. 
Ampicillin Stock 50 mg/ml in water (Fisher Scientific T-22943) 
Kanamycin Stock 20 mg/ml in water (Gibco 11815-024) 
TE 10 mM Tris HCl (from 1M pH 7.5 stock; Invitrogen 15504-
020), 1mM EDTA (VMR 20302.236; from 0.5M pH 8.0 
stock) 
6x Orange G 12% (w/v) ficoll (Sigma G8790), 1% (w/v) Orange G 
(Sigma O3756-25G) in TE 
1X TAE 40 mM Tris (Invitrogen 15504-020), 1.142% (v/v) glacial 
acetic acid (Fisher Scientific A/0400/PB17),  1 mM EDTA 
(VMR 20302.236; from 0.5M pH 8.0 stock) 
1X SDS running buffer 24.8 mM Tris (Invitrogen 15504-020), 192 mM glycine 
(Sigma G8790), 1% (w/v) SDS (Sigma L4509) 
1X Transfer buffer 25 mM Tris (Invitrogen 15504-020), 190 mM glycine 
(Sigma G8790) 
TBS (Tris buffered saline) Dissolve 0.5 M Tris (Invitrogen 15504-020) and pH to 8.0 
with HCl (Fisher Scientific H/1200/PB17), add 1.5 M NaCl 
(Fisher Scientific 5/3160/63).  
PBS 1 tablet (Fisher BR14a) per 100ml 
NaPi (1 M pH7.2) 1  M Di-sodium hydrogen phosphate (Fisher Scientific 
S/4440/60), pH to 7.2 using orthophosphoric acid (Fluka 
79617) 
20X SSC 300 mM Trisodium citrate (Fisher Scientific S/3320/60), 3 
M NaCl (Fisher Scientific 5/3160/63), pH to 7.0 with HCl 
Church buffer 0.5 M NaPi  (from 1 M stock) (pH 7.2), 1mM EDTA (VMR 
20302.236), 7% (w/v) SDS (Sigma L4509), 1% (w/v) BSA 
(Sigma A9418) 
PBS-gelatine 1 tablet (Fisher BR14a) per 100ml, 0.1% (w/v) gelatin 
IPTG Stock 100mM in water (Melford MB1008) 
Ponceau 0.1% (w/v) ponceau (Sigma P 7767) in 5% acetic acid 
(Fisher Scientific A/0400/PB17) in water 











GFP Mouse (monoclonal) CRUK WB (1:2,000-
4,000) 
GFP Rabbit (monoclonal) NEB (#2956) WB (1:1,000) 
MeCP2  
(C-term) 
Mouse (monoclonal) Sigma (M6818) WB (1:1,000) 
HDAC3 Mouse (monoclonal) Sigma (3E11) WB (1:1,000) 
TBL1XR1 Rabbit (polyclonal) Bethyl (A300-408A) WB (1:1,000) 
NCoR Rabbit (polyclonal) Bethyl (A301-146A) WB (1:1,000) 
H3 Rabbit (polyclonal) Abcam (ab1791) WB (1:10,000) 
NeuN A60 Mouse (monoclonal) Millipore (MAB377) FC (after 
conjugation to 
Alexa Fluor 647) 
Mouse (800) Donkey LI-COR (926-32212) WB secondary 
(1:10,000) 
Rabbit (800) Donkey LI-COR (926-32313) WB secondary 
(1:10,000) 
Rabbit (680) Donkey LI-COR (926-32223) WB secondary 
(1:10,000) 
Table 2.1.2: List of antibodies 
WB = western blot, FC = flow cytometry 
 
2.1.3 Cell lines 
 
NIH3T3 and HeLa cells were used for cell culture assays. The wild type ES cells 




All mice used in this study were bred and maintained at the University of Edinburgh 
animal facilities under standard conditions and procedures were carried out by staff 
licensed by the UK Home Office and according to the Animal and Scientific 
Procedures Act 1986. Brains were harvested at 6-8 weeks of age (unless stated 
otherwise). Two existing mouse lines were used in addition to the novel lines 
produced in this study: WT-EGFP and R306C-EGFP mice (Brown, Selfridge et al. 














pEGFPN1seq For AAATGTCGTAACAACTCCGC Sequencing 
MBD seq For AGCTTAAACAAAGGAAGTCTGG Sequencing 
NID seq For AAGGAGTCTTCCATACGGTC Sequencing 
EGFP seq Rev GGCTGTTGTAGTTGTACTCC Sequencing 
pEGFPN1seq Rev ACAAACCACAACTAGAATGCAG Sequencing 
NID seq Rev GACCGTATGGAAGACTCCTT Sequencing 
pBS seq For1 CAGCCATACCACATTTGTAGAG Sequencing 
pBS seq For2 TCTGTATGTTAAGAAGCCAACC Sequencing 
intron3 seq For TAGAAGAAAGCTTGTCAGCA Sequencing 
pBS seq Rev2 CCCTACCCATAAGGAGAAGAG Sequencing 
pBS seq Rev1 AGAGTCCCATAGTTTCTCCTG Sequencing 
exon4 For CAGCATCAGAAGGTGTTCAG Sequencing 
MBD seq Rev CCAGTTACCGTGAAGTCAAA Sequencing 
CTD seq Rev ACCATAGGCTGAGTCTTAGC Sequencing 
5LoxP_seq_F GAATTGGAAAGTCAGGAGGCTGGAAC Sequencing 
NeoSTOP seq F1 GACGTGACAAATGGAAGTAGC Sequencing 
NeoSTOP seq F2 TTTGTCAAGACCGACCTGTC Sequencing 
NeoSTOP seq F3 CTGCTTGCCGAATATCATGG Sequencing 
NeoSTOP seq F4 GGAGGATTGGGAAGACAATAGC Sequencing 
NeoSTOP seq F5 CTTGTTGTTCTTACGGAATACC Sequencing 







R306C For CTCCCGGGTCTTGCACTTCTTGATGGGGA Mutagenesis 
R306C Rev TCCCCATCAAGAAGTGCAAGACCCGGGAG Mutagenesis 
5’ screen F4 TCACCATAACCAGCCTGCTCGC 5’ PCR screen 
5’ screen R5 TGCTAAAGCGCATGCTCCAGACT 5’ PCR screen 
5’ screen R3 ATTCGATGACCTCGAGGATCCG 5’ PCR screen 
3’ screen F1 AGTTCTGGAATGGTGAGCAAGG 3’ PCR screen 
3’ screen F2 GACGTAAACGGCCACAAGTTCA 3’ PCR screen 
3’ screen R2 TCAAAAGCAGAGCAGGCAAAAG 3’ PCR screen 
Dock5 For AGTAAAGTAGATTTGTGGGTTCCG Dock5 seq 
Dock5 Rev GTAGAATGTGGAGATTTCCTCTAGC Dock5 seq 
Gen P5 TGGTAAAGACCCATGTGACCCAAG Genotyping 
Gen P7 GGCTTGCCACATGACAAGAC Genotyping 
Gen Cre For GACCGTACACCAAAATTTGCCTGC Genotyping 
Gen Cre Rev TTACGTATATCCTGGCAGCGATC Genotyping 
qPCR MeCP2 For ACCTTGCCTGAAGGTTGGAC qPCR 
qPCR MeCP2 Rev GCAATCAATTCTACTTTAGAGCGAAAA qPCR 
qPCR CycA For TCGAGCTCTGAGCACTGGAG qPCR 
qPCR CycA Rev CATTATGGCGTGTAAAGTCACCA qPCR 





2.2 Methods  
 




For the cell culture-based assays, cDNA encoding the wild-type and truncated 
MeCP2 proteins used in this study (ΔN-EGFP, ΔNC-EGFP and ΔNIC-EGFP) was 
cloned into the pEGFPN1 expression vector (Kanamycin resistant). The shorter 
isoform (e2) was used for this and all sequences were mouse (producing exactly the 
same proteins as the knock-in mice). Full length MeCP2e2 was amplified by PCR 
using primers containing XhoI (5’ end) and BamHI (3’ end), enabling it to be cloned 
into the multiple cloning site (MCS) of pEGFPN1 using these enzymes. This results 
in the desired linker sequence (CKDPPVAT) between MeCP2 and the C-terminal 
EGFP tag - consistent with the pre-existing WT-EGFP mice (and later the novel ΔN-
EGFP mice). cDNA encoding ΔNC-EGFP protein was synthesised (GeneArt, Life 
Technologies) with a 5’ XhoI site and a 3’ NotI site. This enabled it to be cloned into 
the pEGFPN1 vector using these enzymes, with the synthesised EGFP sequence 
replacing the one originally in the vector. This is required to obtain the desired linker 
sequence (GSSGSSG) between MeCP2 and the C-terminal EGFP tag. These two 
plasmids (pEGFPN1_WT-EGFP and pEGFPN1_ΔNC-EGFP) were used to make the 
other two expression plasmids (pEGFPN1_ΔN-EGFP and pEGFPN1_ΔNIC-EGFP). 
To make pEGFPN1_ΔN-EGFP, the N-terminal region on the pEGFPN1_WT-EGFP 
plasmid was replaced with that of pEGFPN1_ΔNC-EGFP using XhoI and BbvCI 
restriction enzymes. To make pEGFPN1_ΔNIC-EGFP, the Intervening region in the 
pEGFPN1_ΔNC-EGFP plasmid was replaced by a synthesised fragment (GeneArt, 
Life Technologies) using HindIII and SacI restriction enzymes. Point mutations 
(R111G and R306) were inserted into the pEGFPN1_WT-EGFP plasmid using the 
QuikChange II XL Site-Directed Mutagenesis Kit (ThermoFisher). 
 
For ES cell targeting, genomic sequences encoding exons 3 and 4 of the truncated 
MeCP2 proteins (ΔN-EGFP, ΔNC-EGFP and ΔNIC-EGFP) were cloned into the 
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pBS_NeoSTOP_MeCP2 vector (Guy et al., 2007; Ampicillin resistant). This vector 
contained flanking sequences homologous to the Mecp2 locus and a Neomycin 
resistance gene and transcriptional STOP cassette flanked by loxP sites in intron 2. 
Genomic sequence encoding ΔNC-EGFP up to the MfeI sites in the 
pBS_NeoSTOP_MeCP2 was synthesised (GeneArt, Life Technologies) and cloned 
into the vector using MfeI restriction digestion. This vector is referred to as 
pBS_NeoSTOP_ ΔNC-EGFP. This vector was used to make the 
pBS_NeoSTOP_ΔNIC-EGFP vector by replacing the Intervening region (all encoded 
in exon 4) with the same synthesised fragment used to make pEGFPN1_ ΔNIC-
EGFP, using BstXI and BbvCI restriction enzymes. To make pBS_NeoSTOP_ΔN-
EGFP, a fragment with the C-terminal sequence and almost all of EGFP (from the 
targeting vector used by Brown, Selfridge et al., 2016) was used to replace the 
deleted C-terminus and EGFP in the pBS_NeoSTOP_ΔNC-EGFP vector using 
BbvCI and AflII restriction enzymes (after sub-cloning the ΔNC-EGFP genomic 
sequence into the pEGFPN1 vector using MfeI so all restriction sites used were 
unique).  
 
All enzymes used were from NEB (used with the recommended buffers): XhoI 
(R0146S); BamHI-HF (R3136S); NotI-HF (R3189S); BbvCI (R0601S); HindIII-HF 
(R3104S); SacI-HF (R3156S); MfeI-HF (R3589S); BstXI (R0113S); AflII (R0520S). 
Digested fragments were run on agarose gels and purified using the QIAGEN gel 
extraction kit. Fragments were ligated using T4 ligase (M0202S) at a ratio of 3:1 
insert to vector for 15 min at room temperature or overnight at 16°C. All plasmid 
sequences were verified by Sanger sequencing using BigDye (ThermoFisher 
Scientific). PCR conditions: 96°C 1 min, followed by 25 cycles of: 96°C 1 min, 50°C 
5 s, 60°C 4 min. Sequencing was performed by Edinburgh Genomics. Plasmids were 
purified using QIAGEN Miniprep (Cat #27106) and Maxiprep (Cat #12262) kits. 
 
Targeting vectors were linearised with NotI, and purified by adding an equal volume 
of PCI (phenol:chloroform:isoamyl alcohol, Sigma 77617-500ML), centrifuged at 
4,500 rpm 10 min, 4°C. The (top) aqueous layer was transferred to new tubes and an 
equal volume of chloroform (Fisher Scientific C/4960/17) was added. Samples were 
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centrifuged again at 4,500 rpm 10 min, 4°C. The (top) aqueous layer was transferred 
to new tubes and DNA was precipitated with 0.1 volume 3M NaOAc (Sigma S7899-
100ML) and 1 volume isopropanol. Precipitated DNA was pelleted at 13,000 rpm 30 
min, 4°C. Pellets were washed in 80% ethanol and resuspended in sterile TE. 
 
2.2.2 Cell culture (HeLa and NIH-3T3) 
 
Both HeLa and NIH-3T3 cells were grown in DMEM (Gibo 41966-029) 
supplemented with 10% foetal bovine serum (Gibco) and 1% Pen Strep (Gibco 
15140-122). Cultures were maintained in T75 or T175 flasks and split regularly 
using TrypLE Express (Gibco 12604-013) and DPBS (Gibco 14190-094). 
 
2.2.3 Immunoprecipitation and western blotting 
 
HeLa cells were seeded into 15 cm dishes (split 1 in 8 from a T175 flask). The 
following day, cells were transfected with 30 μg pEGFPN1-MeCP2 plasmids using 
JetPEI (Polyplus Transfection). Briefly, DNA was vortexed in 0.5 ml 150 mM NaCl 
and 60 μl of JetPEI was vortexed in a separate 0.5 ml 150mM NaCl, before the two 
were combined. After incubating for 15-30 min at room temperature, this solution 
was added drop-wise to cells and left overnight before the media was replaced. 24-48 
hours after transfection, cells were harvested by trypsinisation (TrypLE Express) into 
15 ml falcon tubes. Cell pellets were washed with DPBS and stored at -80°C. 
 
Cells were thawed and resuspended in 1.5 ml cold NE1 (20mM HEPES pH 7.5; 10 
mM NaCl; 1mM MgCl2; 0.1% Triton X-100; 10mM β-mercaptoethanol; protease 
inhibitor tablets (Roche)). Resuspended pellets were Dounce homogenised and 
nuclei were pelleted at 3,000 rpm (5 min, 4°C). The supernatant (cytoplasmic 
fraction) was discarded and nuclei were suspended in 200 μl NE1. Nucleic acids 
were digested with 1 μl (250 units) Benzonase (Sigma E1014-25KU) for 5 min at 
room temperature. An equal volume of NE300 (NE1 plus 300 mM NaCl) was added, 
bringing the NaCl concentration to 150 mM. Samples were incubated under rotation 
for 20 min at 4°C, and then centrifuged at 13,000 rpm (20 min, 4°C). The 
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supernatant was used as the nuclear extract, from which 20-30 μl was saved as 
‘inputs’. The rest of the nuclear extract was incubated with GFP-TRAP_A beads 
(Chromotek gta-20) that had been pre-washed in NE150 (NE1 plus 150 mM NaCl). 
Samples were rotated at 4°C for 30-60 min. Beads were centrifuged and washed four 
times with 1 ml NE150. Proteins were dissociated from the beads by the addition of 
2x Laemmli Sample Buffer (Sigma S3401-1VL) and boiled for 5 min at 100°C. 
Sample buffer was also added to ‘input’ samples, which were also boiled. 
 
Samples were run on 4-15% SDS gels (BioRad Mini-PROTEAN TGX) at 150-200V, 
and transferred onto nitrocellulose membranes (BioRad) at 100V for 1 hour. Good 
quality transfer was verified using Ponceau staining. Membranes were blocked with 
4-5% (w/v) milk in TBST (TBS with 0.05% Tween-20), and incubated with primary 
antibodies added to blocking solution at 4°C overnight. Membranes were then 
washed three times with PBS+0.05% Tween-20, blocked again for 30 min at room 
temperature, incubated with LI-COR secondary antibodies in blocking solution for 2-
3 hours at room temperature, and washed a further three times with PBS+0.05% 
Tween-20. Primary antibodies used: GFP (NEB #2956) or GFP (CRUK), NCoR 
(Bethyl A301-146A), HDAC3 (Sigma 3E11), TBL1XR1 (Bethyl A300-408A). LI-
COR secondary antibodies used: Mouse 800 (926-32212) and Rabbit 680 (926-
32223). Conditions are listed in section 2.1.2. Membranes were scanned using an 
Odyssey Infrared Imager with Image Studio Lite Ver 4.0 software. 
 
2.2.4 Microscopy and TBL1X recruitment assay (NIH-3T3) 
 
NIH-3T3 were seeded in 6-well plates containing HCl-treated and sterilised 
coverslips (~25,000 cells per well). The following day they were transfected with 2 
μg pEGFPN1-MeCP2 plasmids using 6 μl JetPEI per well. Transfections were 
performed as described in section 2.2.3 (using 2x 100 μl 150 mM NaCl). The 
transfection mixture was left on cells overnight before the media was changed. 48 
hours after transfection, cells were washed twice with DPBS and fixed with 4% 
paraformaldehyde (w/v in PBS, pH 7.4) for 15 min at room temperature. Fixed cells 
were washed three times with PBS and then incubated with 1 μg/ml DAPI in PBS (in 
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the dark) for 5 min. Cells were washed a final two times and then the coverslips were 
mounted onto glass slides using ProLong Diamond (Life Technologies P36961). For 
the TBL1X recruitment assay, cells were transfected with 1 μg pEGFPN1-MeCP2 
plasmids and 1 μg pmCherryN1-TBL1X. The cells were then visualised and 
photographed using confocal microscopy (Leica SP5). DAPI was visualised with the 
405 nm laser (15% power) and detected between 420-470 nm; EGFP with the 488 
nm laser (3% power) and detected between 510-550 nm; and mCherry with the 594 
nm laser (12% power) and detected between 610-700 nm. 
 
2.2.5 ES cell culture and gene targeting (CRISPR). PCR strategy for screening ES 
cell clones 
 
ES cells (wild-type line 129/Ola E14 TG2a) were grown in Glasgow MEM (Gibco 
21710-025) supplemented with foetal bovine serum (FBS; Gibco- batch tested), 1% 
Non-essential amino acids (Gibco 11140-035), 1% Sodium Pyruvate (Gibco 11360-
039), 0.1% β-mercaptoethanol (Gibco 31350-010) and 1000 units/ml LIF (ESGRO 
#ESG1107). ES cells were grown in 10 cm dishes coated in PBS-gelatin (coated for 
at least 20 min before adding media and cells). Cells were routinely split 1/8 using 
Trypsin (Gibco 15090-046) every two days with media changed on intermediate 
days. Very low passage cells were used for gene editing. These cells were grown for 
one week before electroporation with 15 μg linearised targeting vector (and 15 μg 
pX300 CRISPR plasmid). 20x10
6
 cells were trypsinised, spun down and resuspended 
in 600ul HBS (1.4 M NaCl, 50 mM KCl, 10 mM Na2HPO4[dihydrate], 55 mM D-
glucose, 20 mM HEPES) containing the plasmids and transferred to a 0.4 cm cuvette 
(BioRad #1652088) for electroporation using a GenePulser X cell machine (240V 
500μF ∞ resistance). After 10 min, cells were diluted in growth medium and plated 
at clonal density: 0.5-2.5x10
6
 cells per 10 cm dish. The following day, the media was 
replaced with G418 selection media (normal growth media with 350 μg/ml G418 
(Gibco 108321-42-2)). The G418 concentration was reduced to 150 μg/ml after a 
further 48 hours and kept at this concentration. Clones were grown up until visible by 
eye (~1 week), before being picked in DPBS using a P20 pipette into wells of a 
round-bottomed 96-well plate. These colonies were then trypsinised (20μl) to break 
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up clumps, before (selection) media was added and they were transferred to a 
gelatinised flat-bottomed 96-well plate. The colonies were grown up with regular 
media changes until the majority of colonies fill the wells, turning the media yellow 
overnight. At this point, colonies were given fresh media and then split 1/2 after 3-4 
hours for cryopreservation. For this, trypsinised (30 μl trypsin) colonies were 
‘quenched’ with 70 μl Quench medium (1:1 selection medium and FBS). Half of this 
volume was transferred to a new 96-well plate with an additional 150 μl selection 
media for continued growth (for genomic DNA purification). Cold 2x Freeze 
medium (25% DMSO (v/v) in selection medium) was added to the other half, and the 
plate was then sealed and stored at -80°C. 
 
Colonies were thawed by placing the 96-well plate into a 37°C water bath. Positive 
clones were then transferred to 24-well plates. These were grown up until they filled 
two T25 flasks, from which one was cryopreserved (1xFreezing medium: growth 
medium supplemented with 12% FBS and 10% DMSO) and the other was used for 
genomic DNA purification. 
 
2.2.6 Genomic DNA purification and Southern blotting (and sequencing Mecp2 and 
Dock5) 
 
After splitting the colonies 1/2 (see section 2.2.5), the half that was grown on was 
used for genomic DNA purification. First, these cells were lysed in 100 μl lysis 
buffer (100 mM Tris pH8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, 100 μg/ml 
Proteinase K, 50 μg/ml RNase A (Thermo Scientific #EN0531)) overnight at 37°C. 
Lysates were transferred to V-bottomed 96-well plates using wide-bore tips. DNA 
was precipitated with 100 μl isopropanol (Fisher Scientific P/7500/17) and plates 
were centrifuged at 3,000 rpm, 15 min. Pellets were washed with 75% ethanol and 
plates were centrifuged at 3,000 rpm, 15 min. Pellets were air-dried and then 




Genomic DNA was purified from ES cell pellets harvested from T25 flasks using 
Puregene Core Kit A (Qiagen 1042601) according to manufacturer’s instructions for 
cultured cells. DNA pellets were dissolved in 400 μl DNA hydration solution. 
 
Colonies were screened by PCR at the 5’ end (primer pairs F4/R3 and F4/R5) and at 
the 3’ end (primer pairs F1/R2 and F2/R2). This was done using Phusion polymerase 
(NEB #M0530L) with the HF buffer. PCR conditions: 98°C (hot start) for 30 s, 
followed by 35 cycles of: 98°C 10 s, annealing temperature 15 s, 72°C 1 min 45 s; 
and then 10 min elongation at 72°C. Annealing temperatures: 72°C for F4/R3 and 
F4/R5, 71°C for F1/F2 and 70°C for F2/F2. PCR reactions were run on 2% agarose 
gels. Positive clones give products of 3.16 kb for both F4/R3 and F4/R5, and 3.18 kb 
and 3.11 kb for F2/R2 and F1/R2, respectively. 
 
For Southern blot analysis, 10 μg of genomic DNA was digested with 3 μl restriction 
enzyme (Bsu36I, BsrGI or BamHI-HF) in a total volume of 40 μl containing the 
recommended NEB buffer for >3 hours at 37°C. 8 μl 6x Orange G was added and the 
digested fragments were separated on 0.8% agarose gels run at 36V overnight. The 
next day, gels were incubated in 0.25M HCl (Fisher Scientific H/1200/PB17) for 15 
min and then 0.4 M NaOH (Fisher Scientific S/4880/53) for 45 min. DNA fragments 
were transferred to ZetaProbe membranes (BioRad) that had been pre-wetted with 
0.4 M NaOH. DNA probes homologous to either exon 4 or the end of the 3’ 
homology arm were radioactively labelled using the Promega Prime-a-Gene 
Labeling System. For each blot, 25 ng probe DNA was boiled at 100°C for 2 min in 
a total volume of 30 μl water. The boiled probe was rapidly chilled on ice before 
adding 10 μl 5x reaction buffer, 2 μl dNTPs (dATP, dGTP and dTTP) and 2 μl BSA 
[all reagents are included in this kit]. Next, 5 μl [α
32
]dCTP (Perkin Elmer) and 1 μl (5 
units) DNA polymerase (Klenow) Fragment were added and the reaction mixture 
was incubated for 1 hour at room temperature. The reaction was stopped with 20 mM 
EDTA and the probe was purified using a G50 column (GE Healthcare). The probe 
was then boiled at 100°C for 5 min, cooled rapidly on ice and added to membranes 
that had been blocked in 25 ml Church buffer containing 125 μl Herring Sperm DNA 
(Sigma D7290-1ML) at 65°C for >30 min. Probes were left to hybridise at 65°C 
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overnight. The next day, membranes were washed three times with 3xSSC/0.2% 
SDS that had been preheated to 65°C. Radioactivity was monitored during this 
process. If further washing was needed, 1xSSC/0.2% SDS was used. The blots were 
left to expose for 1-5 days in Phosphorimager cassettes (GE Healthcare) and then 
scanned using a Typhoon FLA 7000. Bands were quantified using ImageQuant 
software. 
 
The Mecp2 locus (exons 3 and 4) was sequenced in the positive clones. This region 
was amplified with Phusion polymerase (primers pBS seq For2 and pBS seq Rev2) 
and the PCR product was then sequenced by Sanger Sequencing. The top-intragenic 
predicted off-target site (Dock5) was also PCR amplified (using DreamTaq, Thermo 




To determine the karyotype of the ES cell clones, they were grown normally and 
then treated for 3 hours with 0.1 μg/ml colemid (KARYOMAX, Gibco 1512-012) to 
cause metaphase arrest. Cells were then trypsinised and pelleted and resuspended in 
300 μl of growth media and 5 ml of 0.4% (w/v) KCl and incubated at 37°C for 10 
min. Next, 100 μl of freshly prepared fixative (3:1 methanol and acetic acid) was 
added and mixed gently. Cells were pelleted at 300xg, 5 min and the supernatant was 
discarded. The cell pellet was resuspended in 5 ml fixative and incubated at room 
temperature for 20 min. Cells were pelleted again at 300xg, 5 min, and then 
resuspended in 200-500 μl fixative. This suspension was dropped onto pre-chilled 
glass slides from a height of ~30 cm to spread out the cells. Slides were left to dry 
overnight before covering with coverslips using Vectashield containing DAPI (H-
1200). Cells were photographed under the microscope and chromosomes were 





2.2.8 The production of knock-in mouse lines 
 
One positive ES cell clone was used to make each knock-in mice line. These cells 
were injected into blastocysts (embryonic day 3.4) obtained from C57BL/6J females 
after natural mating. Typically, 15 ES cells were injected into each blastocyst and 12 
injected blastocysts were transferred to pseudo-pregnant recipient females (either 
C57BL/6J or F1). Blastocyst injections were performed by Jim Selfridge and Martha 
Koerner. Chimaeric pups were recognised by varied coat colour as the ES cells were 
129/Ola (chinchilla) and the injected blastocysts were C57BL/6J (black). The 
majority of chimaeras were males, consistent with the ES cells being male. Male 
chimaeras were bred with homozygous CMV-Cre (ubiquitous deleter) mice 
(C57BL/6J). The resulting germline female pups were recognisable by their agouti 
(brown) coat colour. They were heterozygous for the knocked-in truncated allele, 
which was expressed due to Cre-mediated recombination (excising the Neomycin 
resistance gene and STOP cassette). These heterozygous females were bred with 
wild-type C57BL/6J males to produce the first hemizygous males expressing the 
truncated proteins. Some pups in this generation had both the truncated Mecp2 allele 
and the (X-linked) CMV-Cre transgene due to crossing over during meiosis. Cre-
negative heterozygous females from this generation were used for further breeding 
onto the C57BL/6J background. Mice were backcrossed for four generations to a 




Mice were genotyped using ear punches. 25 μl ‘ear biopsy buffer’ (50 mM KCl, 1.5 
mM MgCl2, 10mM Tris HCl pH8.5, 0.01% PBS-gelatine, 0.45% NP-40, 0.45% 
Tween 20, 0.45% Triton X-100, 100 μg/ml Proteinase K) was added to each. These 
were then heated using the following programme: 65°C 15 min, 96°C 2 min, 65°C 4 
min, 96°C 1 min, 65°C 1 min, 96°C 2 30 s. Genotypes were determined by PCR 
using DreamTaq polymerase. Mecp2 genotypes were determined using P5/P7 
primers, which are located in intron 2 spanning the site from which the NeoSTOP 
cassette was excised. Excision of this cassette leaves a loxP site and polylinker 
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sequence so mutant animals have a larger PCR product. Cre genotypes were 
determined using primers located in this region so can only produce a PCR product 
when the transgene is present. Genotyping was performed by Dina De Sousa. 
 
2.2.10 Genomic DNA purification from brains 
 
Brains were harvested and snap-frozen in liquid nitrogen and stored at -80°C. Frozen 
half-brains were thawed and Dounce homogenised in 3 ml lysis buffer (50 mM Tris 
HCl pH7.5, 100 mM NaCl, 5mM EDTA). Proteinase K was added to a final 
concentration of 0.4 mg/ml and SDS to 1%. Samples were incubated overnight at 
55°C. The next day, RNase A was added to a final concentration of 0.1 mg/ml and 
incubated at 37°C for 1-2 hours. An equal volume of PCI (phenol:chloroform: 
isoamyl alcohol, Sigma 77617-500ML) was added and samples were centrifuged at 
3,000 rpm, 15 min. The supernatant (aqueous phase) was transferred to new tubes 
and DNA was precipitated with 0.1 volume 3M NaOAc and 2.5 volumes of ethanol. 
Precipitated DNA was extracted with a heat-sealed glass Pasteur pipette, washed in 
80% ethanol, and dissolved in 400 μl TE. Genomic DNA was analysed by Southern 
blotting, as described in section 2.2.6. 
 
2.2.11 Western blot analysis of protein levels in whole brain crude extracts 
 
Frozen half-brains were Dounce homogenised in 750 μl cold NE1 (20 mM HEPES 
pH7.9, 10 mM KCl, 1 mM MgCl2, 0.1% Triton X-100, 20% glycerol, 0.5 mM DTT 
or 14.3 mM β-mercaptoethanol (Sigma M6250-250ML), and protease inhibitors 
(Roche)). Nucleic acids were digested with 3 μl (750 units) Benzonase (Sigma 
E1014-25KU) for 15 min at room temperature. Next, 750 μl of 2x Laemmli Sample 
Buffer (Sigma S3401-1VL) was added and samples were boiled for 3 min at 100°C, 
snap-frozen on dry ice, and boiled again for 5 min. Aliquots were stored at -80°C. 
Samples were diluted 1/6 with 1x sample buffer before protein levels were analysed 
by western blotting (method as described in section 2.2.3, except 4-20% gels were 
used, and transfer onto nitrocellulose membranes was done overnight at 30V). 
Antibodies used: GFP (NEB #2956), MeCP2 C-terminal (Sigma M6818), H3 
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(Abcam ab1791) and Rabbit 800 (LI-COR 926-32313). Western blots were 
quantified using Image Studio Lite Ver 4.0 and genotypes were compared using t-
tests. Novel knock-in lines were compared to WT-EGFP controls (Brown, Selfridge 
et al., 2016). 
 
2.2.12 Flow cytometry analysis of protein levels in whole brain nuclei 
 
 Fresh brains were used for Flow Cytometry analysis, harvested from animals aged 
12 weeks. WT-EGFP mice (Brown, Selfridge et al., 2016) were used as controls. 
Brains were Dounce homogenised in 2 ml cold homogenisation buffer (320 mM 
sucrose, 5 mM CaCl2, 3 mM Mg(Ac)2, 10 mM Tris HCl pH.7.8, 0.1 mM EDTA, 
0.1% NP40, 0.1 mM PMSF, 14.3mM β-mercaptoethanol, protease inhibitors 
(Roche)). A further 3 ml homogenisation buffer was added, followed by 5 ml of 50% 
OptiPrep gradient centrifugation medium (50% Optiprep (Sigma D1556-250ML), 5 
mM CaCl2, 3mM Mg(Ac)2, 10 mM Tris HCl pH7.8, 0.1M PMSF, 14.3mM β-
mercaptoethanol). First, 10 ml of 29% OptiPrep solution (diluted in water) was 
added to Ultra clear Beckman Coulter centrifuge tubes, and then the brain lysate was 
layered on top. Samples were centrifuged at 7,500 rpm (equivalent to 10,100xg) for 
30 min, 4°C. Pelleted nuclei were resuspended in Resuspension buffer (20% glycerol 
in DPBS with protease inhibitors (Roche)). Aliquots (four per brain) were snap-
frozen in liquid nitrogen and stored at -80°C.  
 
For flow cytometry analysis, frozen nuclei were thawed on ice and pelleted at 600xg 
(5 min, 4°C). Nuclei were resuspended in 1 ml PBTB (5% (w/v) BSA, 0.1% Triton 
X-100 in DPBS with protease inhibitors (Roche)). Nuclei were pelleted again and 
resuspended in 250 μl PBTB. To stain for NeuN, 10 μl of NeuN-A60 antibody 
(Millipore MAB377) was conjugated to Alexa Fluor 647 using the APEX Antibody 
Labelling Kit (Invitrogen A10475). The final eluate from this reaction, which 
contained the conjugated antibody, had a volume of ~50 μl. 2ul of this eluate was 
added to the nuclei and incubated under rotation for 45 min at 4°C. These samples 
were analysed by flow cytometry using a BD LSRFortessa SORP: 50,000 nuclei 
(events) for each sample. Nuclei were gated by size (to remove debris and clumps) 
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and NeuN levels. The mean EGFP expression was obtained for the total nuclei and 
the high NeuN (neuronal) subpopulation (n>8,000). Fluorescence was measured in 
arbitrary units (au). Background EGFP fluorescence (94 arbitrary units) was 
determined by analysing nuclei obtained from an untagged wild-type mouse, and this 
value was subtracted from the other samples. Genotypes were compared using t-tests. 
 
2.2.13 RNA purification from brains and qPCR 
 
Frozen half brains were homogenised in 3 ml TRI Reagent (Sigma T9424) by 
Polytron and incubated at room temperature for 10 min. Next, 300 μl 1-Bromo-3-
chloropropane (Sigma B9673-200ML) was added and samples were vortexed and 
then transferred to 15 ml PhaseLock tubes (5Prime). Sampled were then centrifuged 
at 3,500 rpm for 15 min and the supernatant was transferred into new tubes. RNA 
was precipitated by adding 1.5 ml isopropanol (incubated for 10 min at room 
temperature). RNA was then pelleted at 3,500 rpm for 15 min. Pellets were washed 
with 3 ml 70% ethanol and centrifuged for another 5 min. RNA pellets were then air-
dried and dissolved in 300 μl nuclease-free water. RNA samples were stored at -
80°C. 
 
DNA was removed from 10 μg of these RNA preps using the DNA-free kit 
(Ambion). Next, 0.5 μg of this DNA-free RNA was reversed transcribed using the 
iScript cDNA Synthesis Kit (BioRad). cDNA samples were made up to 200 μl and 
stored at -20°C. Mecp2 RNA levels were analysed by qPCR, normalised to 
Cyclophilin A. 2.5 μl of cDNA was added to the qPCR reaction mixture with 1X 
SYBR+Fluorescein (from 2X stock = Sensimix, Bioline) and 500 nM each of 
forward and reverse primers in a total volume of 12.5 μl in 384-well plates. Samples 
were run on a LightCycler 480WS1.5. PCR conditions: 95°C 10 min, followed by 45 
cycles of: 95°C 15 s, 60°C 15 s, 72°C 20 s (during which DNA levels were 
recorded). Melting curves of the final PCR products were obtained with continuous 
measurement from 60°C to 95°C (ramp 0.11, 5 acquisitions per °C). Standard curves 
for each primer pair were calculated using serial dilutions of cDNA samples. The 




were pipetted in triplicate, and the mean Cp values for each sample were used. 
Primer efficiencies (E) were 1.995 and 1.879 for Mecp2 and Cyclophilin A, 
respectively (average of all experiments). Mecp2/Cyclophilin A ratios were 
calculated for each sample using the formula: EcycA^(CpcycA) / EMecp2^(CpMecp2). 
These ratios were averaged between replicate experiments for each animal. Graphs 
show the mean (and standard deviation) values between three biological replicates, 
normalised to the wild-type littermates for each line. Genotypes were compared 
using t-tests. 
 
2.2.14 Immunoprecipitation from brain nuclear extracts 
 
Immunoprecipitations were performed using nuclear extracts from the brains of the 
knock-in mice. WT-EGFP and R306C-EGFP mice (Brown, Selfridge et al., 2016) 
were used as controls. Frozen brains were Dounce homogenised in 1 ml NE1 (20 
mM HEPES pH7.9, 10 mM KCl, 1 mM MgCl2, 0.1% Triton X-100, 20% glycerol, 
14.3 mM β-mercaptoethanol, and protease inhibitors (Roche)). Nuclei were pelleted 
at 3,000 rpm, 5 min, 4°C and the supernatant (cytoplasmic fraction) was discarded. 
Nuclei were washed in 500 μl NE1 and pelleted again before being resuspended in 
500 μl NE1. Nucleic acids were digested with 1.5 μl (375 units) Benzonase (Sigma 
E1014-25KU) for 10 min at room temperature. An equal volume of NE300 (NE1 
plus 300 mM NaCl) was added bringing the NaCl concentration to 150 mM. Samples 
were incubated under rotation for 20 min at 4°C, and then centrifuged at 13,000 rpm 
(20 min, 4°C). The supernatant was used as the nuclear extract and its protein 
concentration was determined using BioRad Protein Assay Dye Reagent (#500-0006) 
according to manufacturer’s instructions. Samples were adjusted to the same protein 
concentration with NE150 (NE1 plus 150 mM NaCl) and 30 μl was saved as 
‘inputs’. Equal volumes of the remaining nuclear extract (using the maximum 
volume possible) were incubated with GFP-TRAP_A beads (Chromotek gta-20) that 
had been pre-washed in NE150 (NE1 plus 150 mM NaCl). Samples were rotated at 
4°C for 1 hour. Beads were centrifuged and washed four times with 1 ml NE150. 
Proteins were dissociated from the beads by the addition of 2x Laemmli Sample 
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Buffer (Sigma S3401-1VL) and boiled for 5 min at 100°C. Sample buffer was also 
added to ‘input’ samples, which were also boiled. Samples were analysed by western 
blotting (described in section 2.2.3). Primary antibodies used: GFP (CRUK), 
HDAC3 (Sigma 3E11). LI-COR secondary antibody used: Mouse 800 (926-32212). 
Conditions are listed in section 2.1.2. Membranes were scanned using an Odyssey 
Infrared Imager with Image Studio Lite Ver 4.0 software. 
 
2.2.15 Scoring of mouse phenotypic severity 
 
Backcrossed (94% C57BL/6J) scoring cohorts each consisted of 10 mutant animals 
and 10 wild-type littermates. Animals were housed with genotypes intermixed in two 
large cages per cohort (10 animals per cage). Preliminary outbred (75% C57BL/6J) 
cohorts were also scored for the ΔNC-EGFP and ΔNIC-EGFP lines. The ΔNC-EGFP 
outbred cohort consisted of 7 mutants and 9 wild-types, and the ΔNIC-EGFP outbred 
cohort consisted of 10 mutants and 1 wild-type. (Note: some animals in these outbred 
cohorts also carried the CMV-Cre transgene.) Animals were scored from 4 weeks up 
to a maximum of a year using a scoring system developed by Guy et al. (2007). Mice 
were scored in six categories: spontaneous activity, gait, hind-limb clasping, tremor, 
abnormal breathing and general appearance. Mice receive a score between 0 and 2 
for each category, where 0 = as wild-type, 1 = present, and 2 = severe. Intermediate 
scores of 0.5 and 1.5 were also used in all categories except hind-limb clasping 
(Cheval, Guy et al., 2012). The scores in each category are added together to give the 
aggregate symptomatic score for each animal. The mean scores for all animals are 
plotted over time. 
 
Animals were also weighed during scoring sessions. Animals were culled if they lost 
more than 20% of their maximum body weight (unless they had been obese). Growth 
curves were compared by Repeated Measures ANOVA (the animals that died within 
the experimental period – one wild-type in each ΔNC cohort and one ΔNIC in their 





2.2.16 Behavioural tests 
 
A second backcrossed (94% C57BL/6J) cohort for each mouse line underwent a 
series of behavioural tests. These cohorts also consist of 10 mutant animals and 10 
wild-type littermates. Tests were performed over a two week period when the 
animals were 20-21 weeks of age. 
 
On day 1, anxiety levels were tested using the Elevated Plus Maze. This is a cross-
shaped maze 65cm above the floor with two open arms (20 x 8cm), two closed arms 
(20 x 8 x 25cm) and a central area (8 x 8cm). It is set up in a dimly lit room with 
uniform lighting between each of the closed arms and each of the open arms. 
Animals were placed in the central area and left to explore for 15 min (during which 
the experimenter left the room). Mice were tracked using ANYmaze software 
(Stoelting). Mice were determined to be in a particular area of the maze if ≥70% of 
their body was inside this region. Several parameters for this test were analysed: time 
spent in areas, total distance travelled, distance ratios (each area: total distance), and 
number of arm entries. Genotypes were compared using t-tests if both datasets fitted 
a normal distribution (determined using D’Agostino-Pearson omnibus and Shapiro-
Wilk normality tests). Otherwise, Kolmogorov-Smirnov tests were used. 
 
On day 2, activity and anxiety levels were tested using the Open Field test. The 
apparatus used consists of a square arena measuring 50 by 50 cm, which is evenly lit 
(in a dimly lit room) and littered with fresh wood chippings. The animals were 
placed in the centre of the area and left to explore for 20 minutes each (during which 
the experimenter left the room). Mice were tracked using ANYmaze software 
(Stoelting), which divided the area into nine squares of equal size. Mice were 
determined to be in a particular area of the maze if ≥70% of their body was inside 
this region. Activity was assessed by total distance travelled and time immobile. An 
immobile episode is defined as lack of movement for a minimum of 10 seconds. 
Anxiety was assessed by the time spent in the central square time or Centre:Total 
ratio of distance travelled. Data was analysed for the full test period and also after 
division into two 10 min segments. Genotypes were compared using t-tests if both 
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datasets fitted a normal distribution (determined using D’Agostino-Pearson omnibus 
and Shapiro-Wilk normality tests). Otherwise, Kolmogorov-Smirnov tests were used. 
 
On day 3, muscle strength was analysed using the Hanging Wire test. The apparatus 
consists of a 1.5mm diameter wire, 35 cm above the bench. Animals are placed on a 
horizontal wire with their forepaws by the experimenter, and the time taken to bring 
a hind paw to the wire is recorded. Animals are given a maximum of 30 seconds to 
complete this task. Animals that take longer or fall off the wire are given the 
maximum score of 30. The test was performed three times for each animal (with an 
inter-test interval of 30 min) and the mean of the three tests was calculated. 
Genotypes were compared using t-tests if both datasets fitted a normal distribution 
(determined using D’Agostino-Pearson omnibus and Shapiro-Wilk normality tests). 
Otherwise, Kolmogorov-Smirnov tests were used. 
 
On days 6-9, motor coordination and learning was analysed using the Accelerating 
Rotarod. This consists of a 3 cm diameter rod that can rotate between 4 and 40 
revolutions per minute (rpm). On the first day, the animals are accustomed to the 
apparatus in a short training session where they must stay on the track for 30 seconds 
at its lowest speed (4 rpm). On the subsequent three days, each animal undergoes 
four trials (with an inter-trial interval of 90 min) where the speed is slowly increased 
from 4 rpm to 40 rpm over 5 min. The time taken to fall (latency) is recorded and the 
average time for each day is calculated. Genotypes were compared using t-tests if 
both datasets fitted a normal distribution (determined using D’Agostino-Pearson 
omnibus and Shapiro-Wilk normality tests). Otherwise, Kolmogorov-Smirnov tests 
were used. Learning (and worsening) were analysed by comparing the datasets for 
each genotype over time. As several datasets did not fit a normal distribution, the 
non-parametric Friedman test was used for all experiments. 
 
2.2.17 Genetic reversal experiment  
 
The knock-in ES cells for all lines contained a Neomycin resistance gene and 
transcriptional STOP cassette in intron 2. This cassette was not deleted before any of 
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the ES cell lines were used in blastocyst injections. ‘STOP’ mice unable to express 
the ΔNIC-EGFP allele were produced simply by breeding ΔNIC-EGFP (NeoSTOP) 
chimaeras with wild-type C57BL/6J females. STOP mice were scored and weighed 
(see section 2.2.15). Survival was graphed using Kaplan Meier plots and genotypes 
were compared using the using Mantel-Cox test. 
 
Mice with the potential to activate the silenced ΔNIC-EGFP gene (STOP CreER) 
were produced by crossing heterozygous STOP females with males that were 
heterozygous for the CreER
T
 transgene (C57BL/6J background). Male STOP 
animals that did not carry the transgene and wild-types with and without the 
transgene were also produced in this cross. 
 
Male mice of all four genotypes (STOP CreER
T
; STOP; WT CreER
T
; WT) were 
used in the reversal experiment. All animals were scored and weighed weekly from 4 
weeks (see section 2.2.15). From 6 weeks of age, they were all given a series of 
Tamoxifen (Sigma T5648-1G) injections. The regime consisted of two weekly 
injections followed by five daily injections, each at a dose of 100 μg Tamoxifen/g 
weight. Tamoxifen was solubilised by sonication in corn oil by sonication. The 
experiment was continued until 2 weeks after all the STOP controls had died, when 
the animals were 28 weeks of ages. At this point their brains were harvested for 
DNA and protein analysis (methods described above). 
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Chapter 3 – Designing truncations of MeCP2 lacking the potentially dispensable 
domains and verifying that these proteins retain ‘bridge’ function 
  
3.1 Introduction and aims 
 
The Rett syndrome (RTT) missense mutation spectrum highlights the Methyl-CpG 
Binding Domain (MBD) and the NCoR/SMRT Interaction Domain (NID) as the key 
functional domains of MeCP2. This suggests that MeCP2 forms a bridge between 
chromatin and the NCoR/SMRT co-repressor complex. My PhD project was to test 
this ‘bridge’ hypothesis by determining whether these two domains are necessary and 
sufficient for MeCP2 function in vivo. The strategy used was to make a stepwise 
series of truncated MeCP2 alleles where the regions outside the MBD and NID have 
been deleted and then test their function in vivo by producing mouse lines expressing 
the truncated alleles from the endogenous Mecp2 locus. Three truncated proteins of 
decreasing length were designed and tested in this study (Fig. 3.1): the first (ΔN) is 
missing the N-terminal region before the MBD; the second (ΔNC) is missing both 
this N-terminal region and the long C-terminal region after the NID; and the third 
(ΔNIC) is missing both the N- and C-termini, and the Intervening region between the 
MBD and the NID has been replaced by an exogenous linker sequence and a nuclear 
localisation signal (NLS). This chapter outlines the initial stages of this project: the 
design of the truncated alleles and the assays that I carried out to determine that these 
two domains had retained their ability to interact with both methylated DNA and the 
NCoR/SMRT complex. The truncated proteins were designed to remove as many as 
possible of the other annotated domains in MeCP2 whilst retaining bridge function. It 
is important to note that these considerations were based on the functions of the 
various regions of MeCP2 known at the time (October 2013). I will discuss how 







3.2 Considerations when designing truncated proteins 
 
3.2.1 Complications at the N-terminus due to the Mecp2 gene structure 
 
The Mecp2 gene consists of four exons, and mRNA transcripts undergo alternative 
splicing resulting in the production of two protein isoforms: e1 and e2. The more 
abundant isoform, e1, is translated from mRNA consisting of exons 1,3 and 4, with 
its start codon in exon 1. The mRNA encoding the shorter and less abundant isoform, 
e2, contains all four exons and is translated from a downstream start codon in exon 2. 
These two isoforms are almost identical since the vast majority of the coding 
sequence for both is in exons 3 and 4. They differ only by the short extreme N-
termini encoded in exons 1 and 2 for isoform e1 and e2, respectively (Kriaucionis 
and Bird, 2004; Mnatzakanian et al., 2004). The use of two translational start codons, 
one for each isoform (Fig. 3.2.1) makes deletion of the N-terminal sequence at the 
endogenous locus in the knock-in mice very complicated. I therefore considered the 
consequences of retaining the extreme N-terminal sequences in the truncated 
proteins. These are 26 amino acids and 9 amino acids long in e1 and e2, respectively 
(Fig. S2). No role has been attributed to the longer (e1) terminus, consistent with its 
poor evolutionary conservation (Fig. S2). The e2 isoform has, however, been 
Figure 3.1: Stepwise truncations of MeCP2 protein 
Schematic diagram of the truncated proteins designed in this study, compared to 
the full length protein (WT-EGFP). Several features shown here are described 
below: retention of the extreme N-terminus; the boundaries of the MBD and the 
NID; the use of the exogenous NLS from SV40; the presence of the EGFP tag; 
and the design of linker sequences. Drawn to scale (e2 isoforms). Linker 
sequences are shown as dark grey bars. Dotted lines denote corresponding 
regions between the proteins. 
95 
 
reported to promote apoptosis, a function that is negatively regulated by its 
interaction with FOXG1. Although the mechanism for how this isoform promotes 
apoptosis has not been identified, it is unlikely that this 9 amino acid sequence is 
sufficient for this activity. Furthermore, the e1 isoform can interact weakly with 
FOXG1, suggesting that the e2 N-terminal sequence is not sufficient for this 
interaction (Dastidar et al., 2012). I therefore decided to retain these extreme N-
terminal sequences, leaving exon 1 and 2 of the endogenous gene unedited in the 
knock-in mice. To facilitate proper splicing into exon 3, the first 10 base pairs of this 
exon encoding Glu10-Glu11-Lys12 were also included in the truncated proteins (Fig. 
3.2.1). Therefore, in the truncated proteins, the retained region contains a total of 29 





3.2.2 Deciding the boundaries of the MBD 
 
It is well established that the Methyl-CpG Binding Domain (MBD) of MeCP2 binds 
to DNA in a methylation-specific manner (Nan et al., 1993). However, the residues 
that define the MBD vary between different studies. Deletion analysis identified 
residues 78-162 to be the minimal region that could bind methylated DNA (Nan et 
al., 1993). A slightly longer sequence, residues 77-167, was used to determine the X-
Figure 3.2.1: The short extreme N-termini of both isoforms were retained 
due to the MeCP2 gene structure 
Schematic of the wild-type MeCP2 gene structure, encoded by four exons 
(upper); and how the N-terminus was deleted in the truncated proteins (lower). 
The 5’UTRs of e1 and e2 isoforms, located in exons 1 and 2, respectively, are 
shown in white. The retained extreme N-terminal sequences in exons 1, 2 and 
the very beginning of exon 3 are shown in black. The MBD is shown in blue and 
the NID is shown in pink. The deleted N-terminal, intermediate and C-terminal 
sequences are shown in grey. 
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ray structure, co-crystallised with a methylated DNA oligonucleotide (Ho et al., 
2008).  
 
The ‘bridge’ hypothesis predicts that loss of function mutations in MeCP2 must 
disrupt its ability to form the bridge. If this hypothesis is correct, all RTT-causing 
missense mutations located in the MBD must affect DNA binding – a consequence 
that has been reported for many of them (Table S3). Therefore, in this study it is 
important to include the entire cluster of missense mutations in the region defined as 
the MBD. This cluster extends from residue 100 to 161 (Fig 3.2.2), so is entirely 
within the minimal DNA-binding region identified in deletion analysis (Nan et al., 
1993). 
 
A large number of post-translational modifications (PTMs) have been identified 
along the length of MeCP2, many of which lie within the MBD. This includes four 
activity-dependent phosphorylation sites: pSer80, pSer86, Thr148/Ser149, and 
Ser164 (Fig. 3.2.2; Zhou et al., 2006; Tao et al., 2009; Ebert et al., 2013). At the time 
of designing these proteins, only phosphorylation of Ser80 had been implicated in the 
regulation of DNA binding (Tao et al., 2009). In neurons, Ser80 is phosphorylated 
under basal conditions and dephosphorylated upon membrane depolarisation. De-
phosphorylation of this site has been reported to reduce DNA binding affinity, 
suggesting that this activity is regulated by neuronal signalling (Tao et al., 2009). At 
the time, the most likely mechanism for its effect on DNA binding affinity was steric 
hindrance due to the location of Ser80 at the N-terminal end of the MBD. It therefore 
seemed essential to include this residue in the defined MBD. The kinase responsible 
for its phosphorylation, HIPK2, recognises the motif S/T-P (Bracaglia et al., 2009), 
so further N-terminal extension was not required to ensure that this residue could be 
phosphorylated. Regardless of its functional importance, the location of Ser80 within 
the minimal region required for DNA binding (Nan et al., 1993) ensured its 
inclusion. Very little was known about the other modified residues around this region 





When designing these truncated proteins, particularly the most severe (ΔNIC), it was 
tempting to remove as much of the potentially dispensable sequence as possible, 
leaving the minimal length required to form a bridge between chromatin and the 
NCoR/SMRT complex. Whilst the MBD has undergone precise deletion analysis 
(Nan et al., 1993), it is impossible to predict whether this minimal sequence would 
retain its function when fused to the sequences that end up adjacent to it as a result of 
deletions in these truncated proteins. The MBD in this study is preceded by the 
extreme N-terminal residues in all three truncated proteins, and followed by a 
sequence that links to an exogenous NLS in ΔNIC.  To increase the chance that these 
neighbouring sequences would not interfere with DNA binding and that the protein 
would be properly folded, a larger region consisting of residues Pro72-Pro173 was 
used. This encompasses the peptide used to determine the crystal structure (Ho et al., 
2008). As proline residues introduce flexibility to protein structure, they serve as 
good boundaries either side of the MBD. This region is very highly conserved 
throughout evolution, with reduced conservation either side (Fig. 3.2.2). 
 
3.2.3 Deciding the boundaries of the NID 
 
The region of MeCP2 required for binding to the NCoR/SMRT co-repressor complex 
has been identified using deletion analysis. It consists of residues 285-309, and is 
located at the C-terminus of the historical Transcriptional Repression Domain (Nan 
et al., 1998; Lyst et al., 2013). All RTT-causing missense mutations in this cluster are 
located within this region (Fig. 3.2.3) and several have been shown to abolish 
binding to members of the NCoR/SMRT co-repressor complex (Lyst et al., 2013). 
The binding region also contains the phospho-site Thr308 (Fig. 3.2.3), which is 
important for activity-dependent regulation of NCoR/SMRT complex binding (Ebert 
et al., 2013). 
 
The structure of MeCP2 outside the MBD is unknown, and has been suggested to be 
largely disordered (Ghosh et al., 2011). I therefore had to rely on secondary structure 
prediction programmes to help with the design of this region of the truncated 
proteins. PHD software (https://npsa-prabi.ibcp.fr/NPSA/npsa_phd.html) predicted 
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the presence of two alpha helices around the NID: consisting of residues 274-287 and 
300-307 (Fig. 3.2.3; Fig S4). The region defined as the NID in this study is extended 
at the N-terminus until Pro272 to include the first of these helices. Unfortunately, the 
inclusion of these extra amino acids results in the retention of an uncharacterised 
activity-dependent phosphorylated residue, Ser274 (Ebert et al., 2013). It may be, 
however, that this residue cannot be phosphorylated in ΔNIC due to the loss of the 
upstream residues that could be required for the kinase responsible for its 
phosphorylation to recognise this site. 
 
The C-terminus of the NID was easier to define as the deletion analysis was more 
precise at this end, with the removal of a single amino acid (peptides ending with 
residue 308) resulting in reduced binding (Lyst et al., 2013). This is particularly 
interesting as a well characterised knock-in mouse expressing MeCP2 1-308 exhibits 
mild RTT-like symptoms (Shahbazian et al., 2002b). The NID used in this study was 
only extended by three amino acids beyond the identified binding domain to Val312, 
taking it to the end of an evolutionarily conserved region (Fig. 3.2.3). This is 
consistent with another knock-in mouse expressing MeCP2 residues 1-312, which 
was already being characterised in the lab when I began this project (Lagger and 
Selfridge, unpublished). 
 
3.2.4 Exogenous NLS 
 
The endogenous bipartite nuclear localisation signal (NLS) of MeCP2 is located in 
the Intervening domain, directly upstream of the boundary of the NID used in this 
study (Fig. 3.2.3). Its functionality and ability to bind nuclear import machinery have 
been confirmed (Nan et al., 1996; Baker et al., 2015; Lyst, unpublished), yet its 
requirement for MeCP2 protein function remains controversial. This is because the 
MBD is sufficient for MeCP2 localisation to heterochromatin (Nan et al., 1996). 
Despite the attraction of reducing MeCP2 to just the MBD and the NID, it seemed 
safer to include an NLS as it may be necessary for function in vivo. As the second 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(Baker et al., 2013; Lyst, Connelly et al., 2016), I chose to delete the endogenous 
NLS and replace it with an exogenous one from SV40. This is a commonly used 
strong monopartite NLS (sequence PKKKRKV) that lacks the AT hook motif 
(Kalderon et al., 1984). 
 
3.2.5 The inclusion of the EGFP tag 
 
There are several good quality antibodies that recognise MeCP2, but they all detect 
epitopes that are located in either the N- or C-termini. Therefore, the two smaller 
truncated proteins, ΔNC and ΔNIC, would be undetectable. This was solved by the 
inclusion of an exogenous tag. The structure of the Mecp2 gene (as described in 
section 3.2.1) means that the tag must be added to the C-terminus. In the case of the 
C-terminally truncated proteins, ΔNC and ΔNIC, it would be directly after the NID 
(joined by a short linker, described below). Whereas several short tags such as HA or 
an in vivo biotinylated peptide (de Boer et al., 2003) have been shown to work 
efficiently for western blotting, immunofluorescence and ChIP, they are unstructured 
and therefore might interfere with NCoR/SMRT complex binding. EGFP was chosen 
as it is globular (Royant and Noirclerc-Savoye, 2011) and therefore less likely to 
interfere with the structure of the truncated MeCP2 proteins. Additionally, knock-in 
mice expressing wild-type MeCP2 tagged with EGFP show no RTT-like symptoms 
(Brown, Selfridge et al., 2016). These mice and the R306C-EGFP mice provided 
vital controls in the biochemical characterisation of the mice presented in this study. 
 
3.2.6 Linker sequences 
 
To increase the chance that the MBD and NID retained their function in the truncated 
proteins, flexible linker sequences were included between these two domains. As the 
N-terminal extension of the NID to Pro272 reached the endogenous NLS (Fig. 3.2.3), 
I decided not to insert additional amino acids between the SV40 NLS and the NID. 
The first three amino acids of the NID, Pro272-Gly273-Ser274, provide flexibility 
between the SV40 NLS and the functional portion of the NID. As the existing WT-
EGFP knock-in mice contain a short linker (CKDPPVAT) between the C-terminus of 
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MeCP2 and the EGFP tag (Brown, Selfridge et al., 2016), I chose to use the same 
sequence in the design of the ΔN-EGFP protein for consistency. However, a more 
flexible linker was preferred to connect the NID and the EGFP tag for the two C-
terminally truncated alleles. Gly-Ser linkers are commonly used as they are both 
flexible and polar, so do not introduce hydrophobicity (e.g. Jørgensen et al., 2006). 
The sequence GSSGSSG was inserted between the NID and EGFP tag, and also 
between the MBD and the SV40 NLS in ΔNIC-EGFP. Codons were varied to avoid 
repetitive sequence, taking mouse codon usage into account. Sequence alignments of 
the truncated proteins and cDNA sequences are included in the Appendix (Fig. S5-
6). 
 
3.3 Verification of bridge function in the truncated proteins 
 
Before making knock-in mice with the series of truncated Mecp2 alleles, it was 
important to test whether the proteins I designed retained the ability to form the 
bridge between methylated DNA and the NCoR/SMRT co-repressor complex. This 
was done with established transient transfection assays using cultured mammalian 
cells. For this, cDNA sequences encoding e2 isoforms of the MeCP2 truncated 
proteins were cloned into the commercial overexpression vector, pEGFPN1. 
 
3.3.1 All truncated proteins are successfully expressed in HeLa cells where they are 
able to bind endogenous NCoR/SMRT complex components 
 
HeLa cells have successfully been used to determine the ability of FLAG-tagged 
fragments and mutants of MeCP2 to bind endogenous NCoR/SMRT complex 
components, mirroring the results from mouse brain (Lyst et al., 2013). Briefly, 
MeCP2 constructs are overexpressed transiently in HeLa cells and harvested after 
24-48 hours. The MeCP2 variants are pulled down from nuclear extracts and the 
presence of NCoR/SMRT complex components in the immunoprecipitate is 
determined by western blotting. I performed this assay with the truncated proteins 
that I had designed, using GFP-TRAP beads. Western blotting using a GFP antibody 
shows that all proteins were successfully expressed and immunoprecipitated, with 
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bands at the expected sizes (Fig. 3.3.1; Table S4). Furthermore, all three truncated 
proteins were able to bind members of the NCoR/SMRT complex: NCoR, HDAC3 
and TBL1XR1. As previously reported (Lyst et al., 2013), this interaction was 
abolished in the NID mutant, R306C, which was used as a negative control. This 




3.3.2 Verification of binding to methylated DNA in mouse fibroblasts 
 
In mouse cells, around 40% of mCpG marks are present in pericentromeric 
heterochromatin, which appears as DAPI bright spots (Lewis et al., 1992; Nan et al., 
1996). Co-localisation of proteins such as MeCP2 with these foci is a well-
established assay for determining whether they can bind to DNA in a methyl-specific 
Figure 3.3.1: Truncated MeCP2 proteins can bind NCoR/SMRT complex 
components 
Immunoprecipitation of EGFP-tagged MeCP2 proteins: full length (WT), with the 
R306C mutation (R306C), and the three truncations (ΔN, ΔNC, ΔNIC), from 
HeLa nuclear extracts using GFP-TRAP beads. Western blots are shown to 
indicate successful expression and immunoprecipitation of the MeCP2 proteins 
(probed using a GFP antibody), and to assess binding to NCoR/SMRT complex 
components (NCoR, HDAC3 and TBL1XR1 antibodies). ‘In’ = input, ‘IP’ = 
immunoprecipitate, m = size marker. Representative blot of eight experiments 




manner (Nan et al., 1996). All three truncations of MeCP2 co-localised with the 
DAPI bright spots when they were over-expressed in NIH-3T3 cells (mouse 
fibroblasts). The MBD mutant, R111G, which abolishes binding to methylated DNA 
(Kudo et al., 2003), was used as a negative control and shows diffuse nuclear 




3.3.3 Simultaneous binding to methylated DNA and a component of the NCoR/SMRT 
complex, TBL1X  
 
The ‘bridge hypothesis’ predicts that MeCP2 recruits the NCoR/SMRT co-repressor 
complex to chromatin. It is therefore vital that the truncated proteins retain the ability 
to bind DNA and NCoR/SMRT components simultaneously. This can be determined 
using an assay developed in our lab (Lyst et al., 2013). The NCoR/SMRT complex 
Figure 3.3.2: Truncated MeCP2 proteins can bind methylated DNA 
EGFP-tagged MeCP2 proteins were overexpressed in NIH-3T3 cells and the 
EGFP tag was visualised using confocal microscopy. DAPI staining shows 
pericentromeric heterochromatin as bright spots. All three truncated proteins (ΔN, 
ΔNC, ΔNIC) co-localise with these foci in all cells, resembling the wild-type 




member TBL1X lacks an NLS and, when overexpressed alone in NIH-3T3 cells, it 
remains in the cytoplasm. Co-overexpression with MeCP2 results in its translocation 
to heterochromatic foci. This is dependent on NID binding activity as it is abolished 
by the R306C mutation (Lyst et al., 2013; Fig. 3.3.3). I performed this assay using 
the truncated MeCP2-EGFP proteins. All three were able to bring TBL1X-mCherry 




Figure 3.3.3: Truncated MeCP2 proteins can bind methylated DNA and the 
NCoR/SMRT complex member, TBL1X, simultaneously 
MeCP2-EGFP proteins were co-overexpressed with TBL1X-mCherry in NIH-3T3 
cells, and the fluorescent tags were visualised by confocal microscopy. DAPI 
staining shows pericentromeric heterochromatin as DAPI bright spots. All three 
truncated proteins (ΔN, ΔNC, ΔNIC) recruit TBL1X-mCherry to heterochromatic 
foci, resembling the wild-type protein (WT). The NID mutant, 306C, is unable to 






In order to test the ‘bridge’ hypothesis, I have designed a truncated MeCP2 protein 
that retains only the Methyl-CpG Binding Domain (MBD) and NCoR/SMRT 
interaction domain (NID) of the wild-type sequence. This protein also contains an 
exogenous NLS (from SV40) between the two domains to facilitate nuclear import 
and a C-terminal EGFP tag to enable its detection and purification. These domains 
are connected with short flexible linker sequences in case their direct fusion affected 
their activity. The protein is referred to as ΔNIC-EGFP, because it lacks all three 
other regions of full-length MeCP2: the N-terminus before the MBD, the Intervening 
region between the MBD and the NID, and the C-terminus after the NID. ΔNIC-
EGFP retains only 34% of the full-length MeCP2 amino acid sequence (Table S4). In 
this chapter, I have explained how I designed this truncated protein and demonstrated 
that it retains the ability to bind methylated heterochromatin and the NCoR/SMRT 
co-repressor complex simultaneously. 
 
If the ‘bridge’ hypothesis is correct, replacement of endogenous Mecp2 with the 
genomic DNA sequence encoding ΔNIC-EGFP will not have any phenotypic 
consequences. If, however, these mice display RTT-like symptoms, I would want to 
determine which of the deleted regions is responsible for this protein’s reduced 
function. To enable this distinction (if required), I also designed two less severely 
truncated MeCP2 proteins: ΔN-EGFP, which only lacks the N-terminus; and ΔNC-
EGFP, which lacks both the N- and C-termini. Together, these three truncated 
proteins form a step-wise deletion series, retaining 88%, 54% and 34% of the full-
length MeCP2 protein sequence. The pre-existing knock-in line expressing C-
terminally truncated MeCP2 (residues 1-312), which retains 66% of the protein 
sequence, can also be considered to be a member of this series (Lagger and Selfridge, 
unpublished). Unlike the three novel truncations, the 1-312 protein does not have an 
exogenous tag. The ability to bind methylated heterochromatin and the NCoR/SMRT 
co-repressor complex simultaneously was also confirmed for all three of these less 




3.4.1 Impact of the Mecp2 gene structure of protein design 
 
All three of the truncated alleles designed in this study lack the N-terminus before 
the MBD. Deletion of this region was designed in such a way that genomic DNA 
sequences encoding the truncated protein can be inserted into the endogenous Mecp2 
locus in mice, i.e. exons 1 and 2 (containing the start codons for isoforms e1 and e2, 
respectively) were retained as well as the first 10 base pairs of exon 3 to enable 
proper splicing. This results in the retention of 29 or 12 amino acids in the e1 or e2 
isoforms, respectively.  
 
3.4.2 Deletion of the N- and C-termini and Intervening region is likely to abolish 
almost all other reported functions, including those discovered since designing these 
proteins 
 
The main aim when designing the most severely truncated protein (ΔNIC-EGFP) 
was to retain enough of the Methyl-CpG Binding Domain (MBD) and NCoR/SMRT 
interaction domain (NID) sequences to preserve the interactions with methylated 
DNA and the NCoR/SMRT complex, whilst abolishing the other proposed functional 
domains of MeCP2. The sequences defined as the MBD (resides 72-173) and the 
NID (272-312) are extended by several amino acids either side of each of the 
minimal binding domains to increase the chance that they retain their functionality 
within the context of the truncated proteins. Although the vast majority of the 
mapped interaction sites reported in the literature are wholly or partially deleted in 
ΔNIC-EGFP, more precise mapping is needed to predict whether some interactions 
are likely to be lost, for example with FOXG1 and SIN3A (Fig. S7; Dastidar et al., 
2012; Nan et al., 1998; Lyst et al., 2013). Due to overlap with the MBD, it was 
impossible to delete the sequences required for either ATRX or DNMT1 binding 
(Nan et al., 2007; Kimura et al., 2003).  
 
Several novel MeCP2 interaction partners have been reported since I finalised the 
design of these proteins. Three of these have been mapped, all to the deleted regions: 
LEDGF and DHX9 to the Intervening region (Li et al., 2016) and DGCR8 to the C-
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terminus (Cheng et al., 2014a). Heckman et al. (2014) also reported a novel DNA-
binding domain termed the ‘basic patch’ which overlaps with the NID. Although a 
longer peptide was used to demonstrate its DNA-binding activity (Fig. S7), the basic 
residues required for DNA binding are all located in the NID. Therefore, of these 
recent findings, only the function of ‘Basic Patch’ is likely to be retained in ΔNIC-
EGFP, and this would have been unavoidable anyway due to its overlap with the 
NID. Another novel finding is that activity-dependent phosphorylation of Ser164 
(located just after the minimal MBD) has been reported to disrupt DNA binding 
(Stefanelli et al., 2016). Since I wanted to retain activity-dependent regulation of 
MBD activity, it is fortunate that the slightly extended MBD used in this study 
(residues 72-173) includes this phospho-site and any nearby residues that might be 
needed for recognition by the kinase responsible for its phosphorylation. 
 
3.4.3 Deletion of these regions may have structural consequences that affect its 
activity 
 
It has long been discussed in the literature that MeCP2 is highly disordered outside 
the MBD (Ghosh et al., 2011), making it seem a perfect candidate for deletion 
analysis. Increasing evidence now indicates the presence of intramolecular 
interactions within its length (Cheng et al., 2014a; Connelly and Belsom, 
unpublished). Cheng et al. (2014a) demonstrate that the two halves of the protein can 
directly interact, and that this is disrupted by Ser80 phosphorylation. Ser80 is 
normally phosphorylated at high levels in neurons and is dephosphorylated upon 
membrane depolarisation (Bracaglia et al., 2009; Tao et al., 2009). Phosphorylation 
of this site has been shown to be promote DNA binding (Tao et al., 2009) and be 
essential for binding to YB-1 (Gonzales et al., 2012) and DGCR8 (Cheng et al., 
2014a). Together, these findings fit a model whereby neuronal signalling promotes 
intramolecular interactions by dephosphorylation of Ser80, reducing its affinity for 
DNA, YB-1 and DGCR8. The N- and C- terminal fragments used by Cheng et al. 
(2014a) to show intramolecular binding in MeCP2 consisted of residues 1-305 and 
306-CT.  It is therefore highly likely that this interaction is lost by deletion of the C-
terminus in this study (residues 313-CT). Consequentially, characterisation of  
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knock-in mice expressing the C-terminally truncated proteins (ΔNC-EGFP, ΔNIC-
EGFP and 1-312) will help determine the functional importance of the intramolecular 
interaction in vivo.  
 
3.4.5 Concluding remarks 
 
I have successfully designed three truncations of MeCP2 where the regions outside 
the MBD and NID have been progressively deleted. The shortest of these proteins, 
ΔNIC-EGFP, retains only the MBD and NID of MeCP2. All other reported 
functional domains are wholly or partially deleted in this protein except for a small 
number that are unavoidable. Using cell culture-based assays, I have proved that all 
three of these proteins retain the ability to bind methylated heterochromatin and the 
NCoR/SMRT complex simultaneously. Therefore, these designs meet all the 
necessary criteria required to be used in the production of knock-in mice. 
Characterisation of the resulting mouse lines will determine the importance of each 
of the three potentially dispensable regions. If the ΔNIC-EGFP mice display no 
RTT-like symptoms, this will provide a strong indication that ‘bridge’ function is 
sufficient for proper MeCP2 activity in vivo. 
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Chapter 4 – Generation of knock-in mouse lines from targeted ES cells 
 
4.1 Introduction and aims 
 
In order to test the functionality of the three truncated MeCP2 proteins (see Chapter 
3), I had to produce a knock-in mouse line for each. Mecp2-null and loss-of-function 
mouse models recapitulate many of the features of Rett syndrome, including 
hypoactivity, tremors, abnormal gait, and breathing problems (e.g. Guy et al., 2001; 
Chen et al., 2001; Baker et al., 2013; Brown, Selfridge et al., 2016). Although the 
most appropriate model of Rett syndrome is the heterozygous female, the symptoms 
exhibited by the mice are relatively mild and only develop at 3-12 months of age 
(Guy et al., 2001). Hemizygous male Mecp2-null mice develop symptoms around 4 
weeks of age, resulting in premature death at 6-12 weeks (Guy et al., 2001; Chen et 
al., 2001). The use of hemizygous males also simplifies biochemical characterisation 
of Mecp2 knock-in lines as heterozygous females are mosaic due to X chromosome 
inactivation (XCI). In this chapter, I will outline the production process of the knock-
in mice lines carrying truncated alleles of MeCP2. I will also present the biochemical 
characterisation of these mice: determining the expression levels of the truncated 
MeCP2 proteins and mRNA transcripts and the ability of these proteins to interact 
with NCoR/SMRT complex components in the brain. 
 
4.2 ES cell targeting strategies and screening processes 
 
All mouse lines were produced from targeted male ES cells in which the truncated 
alleles had been knocked into the endogenous Mecp2 locus. This was the 
predominant method at the time, and avoids the complications of sterility that may 
occur in hemizygous male or homozygous female Mecp2 mutants produced by 
CRISPR/Cas9 injection protocols using zygotes. CRISPR/Cas9 technology was used 
instead to increase gene editing efficiency in the production of ΔN-EGFP and ΔNIC-




4.2.1 Generation of one positive ΔNC-EGFP ES cell line using the traditional 
method 
 
The first truncated allele of MeCP2 used for ES cell targeting was ΔNC-EGFP: the 
intermediate of the three, missing both the N- and C-termini (Fig. 3.1). Prior to ES 
cell targeting, a synthesised DNA fragment encoding the ΔNC-EGFP genomic 
sequence was cloned into the pBS_NeoSTOP_MeCP2 targeting vector using MfeI 
restriction sites (Fig. 4.2.1A). This fragment contained exons 3 and 4 and the 
intervening intron, the EGFP tag, and flanking regions up to the restriction sites. 
Exons 1 and 2 are located upstream of the 5’ homology arm in this vector and remain 





The targeting vector was linearised using the NotI restriction site (Fig. 4.2.1A) and 
introduced into male ES cells via electroporation. G418 resistance was used to select 
Figure 4.2.1A: pBS_NeoSTOP_MeCP2 targeting vector 
Diagram of the targeting vector cloned by Jacky Guy (Guy et al., 2007). It has a 
pBluescript II vector backbone and contains the wild-type mouse MeCP2 
genomic DNA sequence of exons 3 and 4 flanked by parts of intron 2 and the 3’ 
UTR. A Neomycin resistance gene, ‘Neo’, (conferring resistance to G418) and a 
transcription stop cassette, ‘STOP’, flanked by loxP sites (black arrows) has been 
inserted into intron 2. MfeI sites were used in this study to clone in the fragments 
encoding the EGFP-tagged truncated MeCP2 alleles. NotI was used for 
linearisation of the plasmid. 
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for cells that had integrated the vector. In total, 192 clones were picked and grown up 
in 96 well plates, from which cells were frozen and genomic DNA was extracted. 
Potential positive clones were identified by PCR screening (Fig. 4.2.1B). Only clones 
that have integrated the vector at the correct locus will produce a PCR product as 
primers span the end of the 5’ homology arm. Eight positive clones were identified in 
an initial screen using F4/R3 PCR primers, all of which were confirmed with a 





All eight clones were successfully grown up to fill T25 flasks, from which they were 
cryopreserved or used for genomic DNA extraction. Four clones that had a different 
sized band in the initial PCR screen were also grown up as negative controls. The 
higher quality genomic DNA prepared from the cells grown up in T25 flasks was 
further screened using Southern blotting (Fig 4.2.1C). Since the PCR screen had 
spanned the 5’ end, I ensured that Southern analysis would be able to distinguish 
between partial and full integration of the ΔNC-EGFP genomic sequence. An 
internal probe located within the 3’ homology arm was used to detect both the 
correctly targeted locus and random integrants. Analysis with Bsu36I digestion 
shows that only one clone, 2G7, had been correctly targeted, as the other seven 
clones all contain the 4.7 kb wild-type band. Two clones (1D7 and 1E12) contain 
additional bands of different sizes, which are likely to be due to random integration 
of the vector. The second blot, using BsrGI digestion, confirms that 2G7 has been 
correctly targeted. In this blot, the seven clones that appeared positive in the PCR 
have a band that is larger than the 9.7 kb wild-type band present in the negative 
Figure 4.2.1B: 5’ PCR screen 
Diagram of the ΔNC-EGFP locus showing the location of PCR primers used for 
screening ES cell clones. The solid black line represents the sequence encoded 
in the targeted vector and the dotted lines indicate the flanking regions present in 
mouse genomic DNA. The ΔNC-EGFP locus is drawn to scale, but the primer 
arrows are enlarged for visibility. Clones were screened using F4/R3 and 




control clones. This is likely to be due to recombination within the length of the 
donor sequence, resulting in integration of the NeoSTOP cassette and N-terminal 
deletion but not of the C-terminal deletion and EGFP tag. This may have occurred 
due to the length of the DNA sequence to be integrated (5.5 kb); and the fact that the 
sequence of the ΔNC-EGFP donor molecule only differs from the wild-type genomic 
sequence at the ends (the NeoSTOP cassette and N-terminal deletion at the 5’ end 
and the C-terminal deletions and EGFP tag at the 3’ EGFP). In between, there is a 
long region (1.7 kb) of DNA encoding the truncated protein that is homologous to 
the wild-type sequence where recombination could occur. Sequencing of clone 1A2 
confirmed that this is indeed was had happened, and these clones contain an 
untagged ΔN allele. The presence of both bands in clone 2C2 suggests that it is a 
mixed clone. 
 





The single positive clone, 2G7, was verified further before it was used to make 
knock-in mice. Sequencing of the Mecp2 locus in genomic DNA confirmed that the 
ΔNC-EGFP allele had been incorporated successfully without mutations. I also 
checked that these cells had the normal karyotype of 40 chromosomes (Fig. 4.2.1D). 
This clone passed all requirements so could be used in blastocyst injections to 




4.2.2 Increased efficiency and extra considerations with the addition of 
CRISPR/Cas9 technology  
 
The gene editing method described above was used successfully to produce a knock-
in ΔNC-EGFP ES cell line. Nevertheless, the frequency of correct targeting was very 
low: the donor plasmid was integrated at the correct locus in 4.2% (8/192) G418 
resistance clones and the entire desired sequence was integrated in only one of these. 
Figure 4.2.1C: Southern blot analysis shows one successfully targeted 
ΔNC-EGFP clone 
Screening of potential positive clones by Southern blotting. The upper portion 
shows the ΔNC-EGFP targeting strategy with maps of the restriction sites of the 
two enzymes used in Southern analysis, Bsu36I and BsrGI. An internal probe, 
recognising the 3’ homology arm was used, drawn as a black line. The positive 
clone, 2G7, is highlighted in orange. 
Figure 4.2.1D: Clone 2G7 has a normal 
karyotype 
Cells were arrested in metaphase with 
colcemid and stained with DAPI. 
Chromosomes were counted manually in 31 
cells. Median = 40, shown by black bar. 40 




To increase the gene editing frequency of the two remaining constructs to generate 
ΔN-EGFP and ΔNIC-EGFP knock-in ES cells, I took advantage of CRISPR/Cas9 
technology. Cas9 is a bacterial DNA endonuclease from Streptococcus pyogenes that 
makes a double-stranded cut in DNA at a site determined by the sequence of a guide 
RNA (gRNA). The gRNA sequence must be followed by the Protospacer adjacent 
motif (PAM), which has the consensus ‘NGG’. A gDNA targeting the wild-type 
sequence at the site in intron 2 where the NeoSTOP cassette had been inserted was 
designed and tested by Jacky Guy (Fig. 4.2.2A). The absence of this sequence in the 
donor molecule prevents its excision by Cas9. It also prevents subsequent cutting of 





The pX330 plasmid expressing both the gRNA and Cas9 was introduced into ES 
cells with the linearised targeting vector via electroporation. A higher level of 
plasmid integration was evident by the density of G418 resistant clones: single 
clones were most easily picked from plates seeded at one fifth of the density used 
previously. Ninety-six clones were picked for each allele, and genomic DNA was 
screened by PCR using F4/R3 primers as before (Fig. 4.2.1B). Of these, 67% (58/86, 
Figure 4.2.2A: CRISPR/Cas9 targeting strategy 
(Upper) Sequence in intron 2 of the wild-type locus showing the location of the 
guide RNA (gRNA), the PAM, and the Cas9 double-stranded cut site. The guide 
RNA spans the NcoI site that was used to insert the NeoSTOP cassette into 
intron 2 in the targeting vector. (Lower) The same region of the intron 2 
sequence after integration of the targeting vector. The inserted NeoSTOP 
cassette (labelled ‘insertion’, shown in grey) in this sequence disrupts the guide 
RNA sequence, preventing further cleavage by Cas9. 
CRISPR strategy designed and tested by Jacky Guy 
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excluding clones that did not grow up) and 66% (61/92) of clones gave PCR 
products of the correct size for ΔN-EGFP and ΔNIC-EGFP, respectively. Therefore, 
the introduction of CRISPR/Cas9 has greatly enhanced the targeting frequency at the 
correct locus. 
 
The low editing frequency in the production of a ΔNC-EGFP clone was due to two 
reasons: low insertion rate at the correct locus and only partial insertion of the donor 
molecule at this site. It is clear from the 5’ PCR screen that CRISPR/Cas9 mediated 
cleavage of the endogenous Mecp2 locus overcame the first of these problems. The 
problem of partial insertion of the donor molecule due to recombination within its 
length was likely to occur in the production of ΔN-EGFP and ΔNIC-EGFP knock-in 
ES cells since both of these vectors have long stretches of wild-type sequence within 
their length. To distinguish between full and partial insertion of the desired sequence 
in these clones, I developed a 3’ PCR screen (Fig. 4.2.2B). Only a small proportion 
of clones that were positive in the 5’ PCR screen (F4/R3 primers) were also positive 
in the 3’ screen using F2/R2 primers: 22% (13/58) and 36% (22/61) of ΔN-EGFP 
and ΔNIC-EGFP clones, respectively. Positive clones were confirmed with both the 
5’ F4/R5 primers and the 3’ R1/R2 primers (suitable for ΔNIC-EGFP clones only). 
These results show that the high level of partial recombination persists in the clones 
targeted using CRISPR/Cas9. This is notably lower in the ΔNIC-EGFP clones, which 
have a shorter region of internal homology due to the deletion of the Intervening 
region and C-terminus.  
 
 
Figure 4.2.2B: 5’ and 3’ PCR screens 
Diagram of the ΔNIC-EGFP locus showing the location of PCR primers used for 
screening ES cell clones. The solid black line represents the sequence encoded 
in the targeted vector and the dotted line indicates the flanking regions present in 
mouse genomic DNA. The ΔNIC-EGFP locus is drawn to scale, but the primer 
arrows are enlarged for visibility. Clones were screened using F2/R2 and ΔNIC-
EGFP positives were confirmed using F1/R2. The reaction products are 3.18 kb 
and 3.11 kb for F2/R2 and F1/R2, respectively. F1 is not suitable for screening 




Clones that were positive in the PCR screens were then screened by Southern 
blotting. Firstly, this was done using the genomic DNA purified from the 96-well 
plates that had been used for the PCR screening (Fig. S8A). While all the clones 
contained a 6.0 kb band, suggesting correct targeting, a few contained one or more 
(often multiple) additional bands representing random integration. For this reason, 
four ΔN-EGFP clones and six ΔNIC-EGFP clones were excluded at this stage (not 
highlighted in Fig. S8A). The remaining nine ΔN-EGFP clones and sixteen ΔNIC-
EGFP clones were thawed and grown up in T25 flasks for cryopreservation and high 
quality genomic DNA purification. 
 
Genomic DNA purified from the nine potential positive ΔN-EGFP clones was 
analysed by Southern screening with a second enzyme, BamHI. This experiment 
identified two correctly targeted clones, 4E1 and 4G9 (Fig S6B). Clone 4H12 was 
excluded due to the extra band on the preliminary BsrGI blot. Other clones contain 
additional random integrants (e.g. 3A11), or are mixed clones consisting of both ΔN-
EGFP and untagged ΔN cells (e.g. 4F3). The sixteen potentially positive ΔNIC-
EGFP clones were also screened with a second enzyme, Bsu36I. This identified five 
positive clones: 3E1, 3F1, 3F5, 3H10 and 4D7, which all only contained a band of 
the correct size in both blots (Fig S6C, highlighted in pink). Several clones (e.g. 3E3) 
were excluded due to the presence of a band 4.7 kb in size. This is likely to be due to 
the presence of untagged ΔN rather than wild-type cells (which give the same sized 
band) in these clones as the cells underwent G418 selection. Other clones (e.g. 4C7) 
were rejected due to the presence of additional random intergrants.  
 
The ΔN-EGFP and ΔNIC-EGFP positive clones underwent the same checks as 
described above. Sequencing of genomic DNA showed that the Mecp2 locus had 
been correctly edited. The CRISPR design tool (http://crispr.mit.edu/) that was used 
to design the gRNA predicts the top off-target sites. The highest scoring intragenic 
locus, Dock5, was also sequenced. None of the clones obtained off-target 
mutagenesis at this site. Although all clones appeared to have a normal karyotype 
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(Fig. 4.2.2C), I chose ΔN-EGFP clone 4G9 and ΔNIC-EGFP clone 3F1 for the 




4.3 Generation of knock-in mice using positive ES cell clones 
 
4.3.1 Successful generation of germline transmitting chimeras from blastocyst 
injections 
 
The knock-in ES cells were used for blastocyst injections to produce chimaeras. This 
procedure was performed by Jim Selfridge and Martha Koerner. Each line underwent 
3-5 rounds of injection resulting in 6, 7 and 16 chimeras for ΔN-EGFP, ΔNC-EGFP 
and ΔNIC-EGFP lines, respectively (Table 4.3.1). Chimaeras are recognisable by 
coat colour as they are made up of a mixture of C57BL/6J (black) cells from the 
blastocyst and injected 129/Ola (chinchilla) ES cells (Fig. 4.3.1). Breeding the 
chimaeras resulted in germline transmission for all three lines.  
 
Figure 4.2.2C: All ΔN-EGFP and ΔNIC-EGFP clones have a normal karyotype 
Cells were arrested in metaphase with colcemid and stained with DAPI. 
Chromosomes were counted manually. Median = 40 in all, shown by black bar. 
Percentage of cells with 40 chromosomes: 4E1 27% (n=22), 4G9 75% (n=12), 




 ΔN-EGFP ΔNC-EGFP ΔNIC-EGFP 
ES cell clone 4G9 2G7 3F1 
Blastocysts 100 115 130 
Transfers into 
recipient ♀s 
9 15 10 
Pregnancies 4 12 6 
Pups born 14 51 28 




2 ♂/3 ♂ 3 ♂/ 7 (6 ♂, 1 ♀) 2 ♂/2 ♂ 
STOP line (xC57BL/6J): 2 
♂/8 (3 ♂, 5 ♀) – see 
Chapter 6 
Table 4.3.1: Production of knock-in mice. Notes from blastocyst injections (totals 




4.3.2 Breeding program to generate hemizygous males for phenotypic and 
biochemical analysis 
  
To reduce the number of ES cell passages, the floxed NeoSTOP cassette in intron 2 
was retained in the cells used for blastocyst injections, and was instead deleted by 
crossing with mice that ubiquitously express Cre recombinase. This was done at the 
first stage: breeding chimaeric males to homozygous CMV-Cre females (Fig 4.3.2A; 
Table 4.3.1). Only female pups produced in this cross will carry the truncated Mecp2 
allele, located on their chimaeric father’s X chromosome. These females will also 
inherit the CMV-Cre gene (which is also X-linked) from their mother. Ubiquitous 
expression of CMV-Cre in early development will result in the excision of the floxed 
NeoSTOP cassette. These heterozygous females will therefore express the truncated 
Mecp2 alleles. Not all female pups produced in this cross will carry the desired 
allele: the germline transmitting chimaeras produce sperm from both their C57BL/6J 
and introduced 129/Ola cells (Fig. 4.3.2A). Germline transmitted female pups are 
Figure 4.3.1 Chimaeras 
Two of the ΔNC-EGFP 
chimaeras 
Photograph by Jim Selfridge 
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recognisable by their brown coat colour, as they inherit chinchilla coat colour genes 






These heterozygous females were backcrossed with C57BL/6J males to produce the 
first hemizygous males carrying the truncated alleles. Some animals also carried the 
CMV-Cre transgene, due to crossing over in meiosis in their mothers (Fig. 4.3.2A). 
Both CMV-Cre negative and CMV-Cre positive knock-in and wild-type males were 
used in preliminary scoring cohorts for the two more severe mutations: ΔNC-EGFP 
and ΔNIC-EGFP. Heterozygous female pups that didn’t carry the CMV-Cre 
transgene were used for further backcrossing with C57BL/6J males. Generation N=4 
(94% C57BL/6J) was used for extensive phenotypic analysis: animals were divided 
into two cohorts, one for scoring and one for behavioural testing. This is consistent 
with previous studies in the lab (Brown, Selfridge et al., 2016). 
Figure 4.3.2A: Knock-in mouse breeding programme 
Diagram of crosses and genotypes of offspring produced at each stage. The 
knocked-in truncated allele is denoted by *, the NeoSTOP cassette by ‘S’, and 
CMV-Cre by ‘Cre’. Breeding pairs are indicated by black rectangles. Each 
generation is labelled by the number of times is has been backcrossed (N) and 
the resulting percentage of C57BL/6J background. 
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Southern blot analysis of genomic DNA purified from the brains of these knock-in 
mice show that these lines carry the desired allele after successful Cre-mediated 




Figure 4.3.2C: legend on next page 
Figure 4.3.2B: ΔN-EGFP knock-in mice carry the Cre-recombined allele 
(Left) Genomic DNA sequences of the WT locus, the targeted NeoSTOP ΔN-
EGFP allele, and the Cre-recombined allele. Diagrams show maps of the 
restriction sites of the enzyme used in Southern analysis, BsrGI. An internal 
probe, recognising exon 4 was used, drawn as a black line. (Right) Southern blot 









4.4 Expression levels of truncated alleles in knock-in mice 
 
The first step in the biochemical characterisation of these mouse lines was to look at 
the expression levels of the truncated MeCP2 proteins. The level of MeCP2 is very 
important, as lower levels (~50%) result in mild RTT-like symptoms (Kerr et al., 
2008; Samaco et al., 2008). Approximately equivalent expression levels of the 
different truncated proteins is required for proper comparison of their function in 
vivo. 
 
Figure 4.3.2C: ΔNC-EGFP knock-in mice carry the Cre-recombined allele 
(Left) Genomic DNA sequences of the WT locus, the targeted NeoSTOP ΔNC-
EGFP allele, and the Cre-recombined allele. Diagrams show maps of the 
restriction sites of the enzyme used in Southern analysis, Bsu36I. An internal 
probe, recognising the 3’ homology arm was used, drawn as a black line. (Right) 
Southern blot of genomic DNA purified from ES cells and mouse brains. 
 
Figure 4.3.2D: ΔNIC-EGFP knock-in mice carry the Cre-recombined allele 
(Left) Genomic DNA sequences of the WT locus, the targeted NeoSTOP ΔNIC-
EGFP allele, and the Cre-recombined allele. Diagrams show maps of the 
restriction sites of the enzyme used in Southern analysis, Bsu36I. An internal 
probe, recognising the 3’ homology arm was used, drawn as a black line. (Right) 
Southern blot of genomic DNA purified from ES cells and mouse brains. STOP 




4.4.1 Analysis of protein levels by western blotting and flow cytometry 
 
The protein level in the brains of the knock-in mice was determined using two 
independent assays: western blot analysis and flow cytometry. Due to the location of 
the epitopes detected by antibodies, only the ΔN-EGFP mice could be compared 
directly to their untagged littermates, using an antibody that recognises the C-
terminus of MeCP2. Western blot analysis on whole brain crude extract shows that 





All three proteins were quantified with a GFP antibody, using WT-EGFP mice as a 
comparator. The levels of ΔN-EGFP were found to be ~74% of WT-EGFP controls 
(Fig. 4.4.1B).  Taking account of the slightly elevated levels of WT-EGFP protein in 
these mice (159% as much protein as untagged controls) (Brown, Selfridge et al. 
2016), ΔN-EGFP is close to wild-type levels (~118%), which is consistent with the 
result obtained with the MeCP2 antibody. The levels of ΔNC-EGFP quantified from 
western analysis are slightly lower: ~45% of WT-EGFP, equivalent to ~72% of 
untagged wild-type. The most severe truncation, ΔNIC-EGFP, has dramatically low 
Figure 4.4.1A: Quantification of ΔN-
EGFP protein levels using western 
blotting 
(Upper) Western blot of crude whole 
brain extract derived from hemizygous 
male ΔN-EGFP and wild-type controls 
mice (three biological replicates of 
each). MeCP2 was detected with a C-
terminal antibody (Sigma 6818). 
Histone H3 was used as a loading 
control. ‘m’ = size marker. 
(Lower) Quantification of protein levels 
by western blotting. The samples were 
run on two blots and the values were 
combined (protein levels were 
calculated relative to WT controls). 
Graph shows mean and standard 
deviation. Protein levels were not 
significantly different: p=0.215, t-test. 
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protein levels when analysed in this way: ~18% of WT-EGFP, equivalent to ~29% of 
untagged wild-type. 
 
Although MeCP2 mutations frequently affect protein levels in knock-in mice (Goffin 
et al., 2012; Brown, Selfridge et al., 2016), it is surprising that the levels correlate 
with protein size. To overcome inaccuracies of quantifying proteins of different sizes 
by western blotting, I exploited the endogenous fluorescent EGFP tag for flow 
cytometry analysis. Nuclei were purified from whole brains and EGFP fluorescence 
was used to measure protein levels. Using this method, all three truncated proteins 
have higher levels relative to WT-EGFP than in the western blot analysis, and 
protein levels do not correlate with protein size (Fig. 4.4.1C). The protein level in 
ΔN-EGFP mice is not significantly different from WT-EGFP controls and the ΔNC 
mice have slightly higher protein levels: 127% of WT-EGFP mice (** p=0.003, t-
test). Although the levels of ΔNIC-EGFP are still lower than the other lines, the 
difference is less dramatic: 48% of WT-EGFP mice (*** p=0.0002, t-test) instead of 
~18%.  
 
It has previously been shown that MeCP2 is most highly expressed in neurons 
(Skene et al., 2010), and neuronal-only expression of Mecp2 can rescue the null 
phenotype (Luikenhuis et al., 2004).  Additionally, deletion of Mecp2 in various 
neuronal subtypes (e.g. GABAergic neurons) results in RTT-like symptoms (Chao et 
al., 2010; reviewed by Guy et al., 2011). Altered protein levels in neurons are 
therefore most likely to have the greatest effect on the phenotype of the knock-in 
mice presented in this study.  Flow cytometry analysis enables the separation of 
neuronal nuclei by staining with an Alexa Fluor 647-conjugated antibody that 
recognises the neuronal marker, NeuN. As expected, nuclei in the neuronal 
subpopulation have higher levels of MeCP2 than the whole brain average (Fig. 
4.4.1C). As with the total nuclei, protein levels in ΔN-EGFP mice are not 
significantly different from WT-EGFP controls, and ΔNC-EGFP mice have very 
slightly elevated protein levels: 117% of WT-EGFP controls (* p=0.014). The 






Figure 4.4.1B: Quantification of protein levels using western blotting 
(Upper) Western blots of crude whole brain extract derived from hemizygous 
male WT-EGFP, ΔN-EGFP, ΔNC-EGFP and ΔNIC-EGFP mice (three biological 
replicates of each). MeCP2 was detected with a GFP antibody. Histone H3 was 
used as a loading control. ‘m’ =size marker, * = non-specific band. 
(Lower) Quantification of protein levels by western blotting. The samples were 
run on two blots and the values were combined (protein levels were calculated 
relative to WT-EGFP controls). Graphs show mean and standard deviation. 
Statistical analysis was performed using t-tests: ΔN-EGFP 74% not significant 





4.4.2 Analysis of mRNA levels by quantitative PCR 
 
To determine whether the low level of protein in the ΔNIC-EGFP mice was due to 
reduced gene expression or protein instability, I performed quantitative PCR (qPCR) 
on cDNA prepared from RNA purified from the brains of these mice. Here, I was 
able to compare the knock-in mice directly to their wild-type littermates, using 
primers located within the MBD, spanning exon 3. qPCR analysis shows that RNA 
levels are actually elevated by almost 2-fold in these mice (Fig. 4.4.2). The low 
protein level is therefore likely to be due to protein instability. The high level of 
RNA observed may indicate the presence of a negative feedback loop regulating 
MeCP2 expression. 
 
ΔN-EGFP mice also have elevated levels of RNA, compared to their wild-type 
littermates: ~1.5 fold (Fig. 4.4.2). This is consistent with other EGFP-tagged Mecp2 
knock-in mice (Brown, Selfridge et al., 2016). However, the levels of RNA in ΔNC-
Figure 4.4.1C: Quantification of protein levels using flow cytometry 
(Left) Example histogram of NeuN-Alexa Fluor 647 fluorescence, used to obtain 
the ‘neuronal’ population (high NeuN). (Right) Quantification of protein levels by 
flow cytometry. Nuclei were purified from the brains of knock-in mice (three 
biological replicates of each genotype) and stained with anti-NeuN-Alexa Fluor 
647. Protein level was determined by EGFP fluorescence in all nuclei 
(n=50,000), and the neuronal (high NeuN) subpopulation (n>8,000). Graph 
shows mean and standard deviation (au = arbitrary units). Statistical analysis 
was performed using t-tests to compare each line to WT-EGFP controls. All 
nuclei: ΔN-EGFP not significant p=0.338, ΔNC-EGFP 127% ** p=0.003, ΔNIC-
EGFP 48% *** p=0.0002. Neuronal nuclei: ΔN-EGFP not significant p=0.672, 




EGFP mice are not significantly different from their wild-type littermates (Fig. 
4.4.2). This is surprising given the higher levels of ΔNC-EGFP protein measured 




In summary, at the RNA level, ΔN-EGFP and ΔNC-EGFP alleles are both expressed 
in the brain at the same level or slightly higher than the wild-type controls. This 
results in slightly higher levels of protein for both ΔN-EGFP and ΔNC-EGFP lines - 
at a level comparable to the WT-EGFP mice. The use of flow cytometry analysis in 
this study overcame the problem of comparing the levels of proteins of different sizes 
by western blotting. This technique also facilitated easy quantification of the levels 
of each truncated protein in the neuronal nuclei. The levels of ΔN-EGFP and ΔNC-
EGFP were comparable to WT-EGFP in the neuronal subpopulation. The most 
severely truncated allele, ΔNIC-EGFP, is present at a lower level than the others. It is 
likely that its level is underestimated by western blot analysis and that is it closer to 
Figure 4.4.2: Quantification of RNA levels by qPCR 
RNA was purified from whole brains and converted to cDNA. This was analysed 
by qPCR using primers located within the MBD that spanned exon 3. This 
allowed direct comparison of each line to their wild-type littermates (three 
biological replicates of each). Graphs show the mean and standard deviation,  
(combined quantifications of ≥3 experiments, each pipetted in triplicate). 
Statistical analysis was performed using t-tests. ΔN-EGFP: 152% of wild-type * 
p=0.021 (four experiments), ΔNC-EGFP: n.s. p=0.791 (three experiments), ΔNIC-




the quantification obtained by flow cytometry: 48% of WT-EGFP in whole brain. 
Taking the elevated expression of WT-EGFP into account (159% of wild-type 
controls using western blotting; Brown, Selfridge, et al., 2016), its levels could be as 
high as 76% of wild-type. Its relative expression level in the neuronal nuclei is only 
slightly lower: 40% of WT-EGFP. Finally, quantification of ΔNIC-EGFP mRNA 
levels by qPCR shows that it is overexpressed to around 2-fold compared to wild-
type controls. This rules out transcriptional silencing as the cause of low ΔNIC-
EGFP protein levels and suggests that this protein may have reduced stability. 
 
4.4.3 All three truncated proteins can interact with HDAC3, the catalytic component 
of the NCoR/SMRT complex, in the brain 
 
I have previously shown that all three truncated proteins can interact with 
endogenous NCoR/SMRT co-repressor complex components when over-expressed 
in HeLa cells (section 3.3.1). To determine whether these proteins retained this 
activity when expressed in the brains of knock-in mice, I performed 
immunoprecipitation experiments on brain nuclear extracts obtained from the novel 
knock-in mouse lines. The two pre-existing knock-in mouse lines, WT-EGFP and 
R306C-EGFP (Brown, Selfridge et al., 2016), were used as positive and negative 
controls, respectively. All MeCP2 proteins were successfully immunoprecipitated 
with GFP-TRAP beads from the nuclear extracts, shown by western blot probed with 
a GFP antibody (Fig. 4.4.3). The catalytic component of the NCoR/SMRT complex, 
HDAC3, was co-immunoprecipitated with all proteins except the negative control, 
R306C-EGFP. The level of binding, however, varied between proteins: ΔN-EGFP 
appears to bind HDAC3 at WT levels, ΔNC-EGFP pulls down slightly less HDAC3, 
and ΔNIC-EGFP pulls down very little (Fig. 4.4.3). This result is in contrast to 
observations in HeLa cells (Fig. 3.3.1). 
 
To investigate this result further, I followed the levels of the MeCP2 proteins 
throughout the steps of this experiment to determine whether they had been equally 
extracted and immunoprecipitated. It seemed surprising that the amount of 
immunoprecipitated protein was very even between samples, contrasting with the 
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level of these proteins quantified by western blotting using crude brain extract (Fig. 
4.4.1B). Although I had calculated a volume of GFP-TRAP beads that should have 
been in excess, it was a possibility that the beads were saturated. To determine if this 
was the case, I analysed the unbound fraction by western blotting after incubation 
with the beads. Only very little MeCP2 remained in the nuclear extracts, indicating 
complete immunoprecipitation of these proteins (Fig. S9). An alternative explanation 
was a difference in extraction efficiency between these proteins. Nuclei were treated 
with benzonase and then incubated in 150 mM NaCl before centrifugation to obtain 
soluble nuclear extracts that were used as inputs. Insufficient extraction of MeCP2 
would result in it being discarded in the pellet at this stage. Western blot analysis of 
the pellets shows higher levels of WT-EGFP, Δ-EGFP and ΔNC-EGFP than of 
ΔNIC-EGFP, indicating that this may be the cause of the differences (Fig. S9). 
Unfortunately, equal protein extraction of these proteins may be impossible to obtain 
as increasing the salt concentration disrupts the interaction between MeCP2 and the 
NCoR/SMRT complex. Further work is needed to determine whether ΔNIC-EGFP 
has reduced ‘bridge’ function in vivo. 
 
 
Figure 4.4.3: Truncated MeCP2 proteins can bind HDAC3, the catalytic 
component of the NCoR/SMRT complex, in the brain 
Immunoprecipitation of EGFP-tagged MeCP2 proteins: full length (WT), with the 
R306C mutation (R306C), and the three truncations (ΔN, ΔNC, ΔNIC), from brain 
nuclear extracts using GFP-TRAP beads. Western blots show successful 
immunoprecipitation of the MeCP2 proteins (probed using a GFP antibody), and 
co-immunoprecipitation with HDAC3. ‘In’ = input, ‘IP’ = immunoprecipitate, * 
denotes the presence of IgG from small amounts of blood in these samples, 
detected by the anti-mouse secondary antibody. (Representative blots from one 






I have successfully produced knock-in mouse lines expressing each of the three 
truncated alleles: ΔN-EGFP, ΔNC-EGFP and ΔNIC-EGFP. First, I cloned genomic 
DNA sequences encoding these proteins into a targeting vector that contained a 
Neomycin resistance cassette and Mecp2 homology arms. I then used these vectors to 
target the endogenous Mecp2 locus on the single X chromosome in male mouse ES 
cells. Positive ES cell clones were identified by PCR and Southern blot screening. Of 
the 192 ΔNC-EGFP clones screened, only one was correctly edited. For the other 
two alleles, I took advantage of CRISPR/Cas9 technology, increasing the editing 
efficiency to 2/86 (2.3%) for ΔN-EGFP and 5/92 (5.4%) for ΔNIC-EGFP. One ES 
cell clone for each line was injected into blastocysts to produce chimaeras. 
Chimaeras from all three lines produced heterozygous female pups carrying the 
truncated allele. These were backcrossed onto a C57BL/6J background to produce 
hemizygous males for biochemical and phenotypic analysis. The two less severe 
truncations, ΔN-EGFP and ΔNC-EGFP, contain slightly elevated levels of MeCP2 in 
the brain, comparable with the levels previously quantified in WT-EGFP mice 
(Brown, Selfridge et al., 2016). The ΔNIC-EGFP protein, which lacks the 
Intervening region as well as both the N- and C-termini, is present at lower levels in 
the brains of the knock-in mice: 40-48% of WT-EGFP controls. High levels of 
ΔNIC-EGFP mRNA suggest that deletion of this region results in reduced protein 
stability. Lastly, I performed GFP-pulldowns using whole brain nuclear extracts and 
showed that all three truncated proteins are able to bind the NCoR/SMRT co-
repressor complex in the brains of these mice but with varying affinities.  
 
4.5.1 CRISPR/Cas9 technology increased the gene editing efficiency at the Mecp2 
locus in ES cells 
 
The conventional targeting method used to produce the ΔNC-EGFP knock-in ES 
cells resulted in a low frequency of insertion at the Mecp2 locus (8/192 clones). 
Furthermore, the entire ΔNC-EGFP sequence was correctly incorporated in only one 
of these eight clones. I made use of CRISPR/Cas9 technology to boost the targeting 
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efficiency during subsequent production of ΔN-EGFP and ΔNIC-EGFP knock in ES 
cell lines. CRISPR/Cas9-mediated cleavage of the Mecp2 locus dramatically 
increased the frequency of donor molecule insertion. It did not, however, promote 
full over partial insertion of the desired sequence. One possible reason for this is that 
the Cas9 cut site and the Neomycin resistance gene are both located at the 5’ end of 
the donor molecule. Therefore, the selection cassette will be readily inserted upon 
DNA cleavage, but the resulting G418-resistant clones may not contain the entire 
desired sequence. Relocation of either the CRISPR target site or the selection 
cassette to the 3’ end of the gene could result in a higher percentage of correctly 
targeted G418-resistant clones. 
 
An alternative method for selecting positively targeted clones with fluorescent tags 
was recently developed in the lab (Shah et al., 2016). This study used Fluorescence-
Activated Cell Sorting (FACS) to isolate human neuronal progenitor cells that have 
incorporated an mCherry tag at the C-terminus of MECP2. Fluorescent cells were 
sorted into 96 well plates, and grown up as clonal populations. As neuronal 
progenitor cells express higher levels of MeCP2 than ES cells, it must first be 
established whether the EGFP-tagged MeCP2 proteins expressed in ES cells are 
detectable by FACS before using this method for future ES cell targeting. If possible, 
this method would bypass the need for the insertion of the floxed selectable marker, 
which had to be subsequently deleted in the knock-in mice. 
 
Unfortunately, the use of CRISPR/Cas9 for gene editing increases the frequency of 
random integration or multi-copy insertion of the donor molecules (this study and 
Schick et al., 2016). Recent studies have used circular rather than linearised donor 
plasmids to reduce this. Another possible consequence is integration of the CRISPR 
pX330 plasmid. I performed Southern blot analysis using a probe that is homologous 
to the Bluescript vector backbone to check whether this had occurred in any of the 
chosen clones. All three clones used to make the knock-in mice (2G7, 4G9 and 3F1) 




4.5.2 Flow cytometry analysis provides accurate quantification of the levels of the 
truncated proteins in the brains of knock-in mice 
 
A crucial part of the characterisation of knock-in mouse lines is quantifying the 
expression level of the mutant proteins. This is usually done using western blot 
analysis. Brown, Selfridge et al. (2016) used flow cytometry to measure the levels of 
EGFP-tagged MeCP2 alleles with missense mutations in four knock-in mouse lines, 
confirming the results they had obtained using western blotting. Unlike the truncated 
MeCP2 mutants produced in this study, those characterised by Brown, Selfridge et 
al. (2016) are all the same size. Surprisingly, in this study, estimations of the MeCP2 
protein levels in the truncated knock-in mouse lines varied greatly between these two 
analysis methods, and the values obtained by western blot analysis correlated with 
protein size. The most likely explanation for this effect is that proteins of different 
sizes behave differently in the western blot procedure, i.e. they are transferred with 
difference efficiencies from SDS gels to nitrocellulose membranes. The use of 
gradient gels (4-20%) and slow low-voltage transfer conditions did not alter this 
result. I therefore conclude that the levels estimated by flow cytometry are more 
reliable. To confirm this, western blot analysis could be performed using the nuclei 
purified for flow cytometry analysis to ensure that the difference between the 
techniques due to a bias in the western blotting procedure and is not a result of the 
nuclei-purification method used for flow cytometry. 
 
4.5.3 The Intervening region of MeCP2 between the MBD and the NID may be 
required to maintain protein stability 
 
The low protein levels but high mRNA levels in mice expressing ΔNIC-EGFP, the 
smallest truncation missing all three potentially dispensable domains, suggests that 
this protein is unstable. As protein levels are not reduced in mice expressing ΔNC-
EGFP, missing only the N- and C-terminal regions, it is likely that the Intervening 
region of MeCP2 is required for protein stability. This region contains one of the 
three ‘unexplained’ RTT-causing missense mutations that lie outside the MBD or 
NID, P225R. Knock-in mice expressing MeCP2-P225R also have lower levels of 
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protein: 22% compared to wild-type controls (and wild-type levels of mRNA). 
Further analysis using a cell culture-based stability assay has confirmed that P225R 
is unstable (Guy and Alexander-Howden, unpublished). Further work is needed to 
determine whether ΔNIC-EGFP is unstable or inefficiently translated. The elevated 
levels of ΔNIC-EGFP mRNA detected in these mice indicated the presence of a 
possible negative feedback loop increasing its expression. This, however, is not 
observed in the P225R knock-in mice (Guy, unpublished) or R168X knock-in mice, 
which also have very low protein levels (Lawson-Yuen et al., 2007). An alternative 
explanation for the higher ΔNIC-EGFP mRNA levels is increased stability of one or 
more of the alternatively spliced/polyadenylated transcripts. 
 
4.5.4 ΔNIC-EGFP may have reduced ‘bridge’ activity 
 
Immunoprecipitation of the truncated proteins from brain nuclear extracts was 
performed to determine HDAC3 (the catalytic component of the NCoR/SMRT 
complex) binding. The results suggest the ΔNC-EGFP has a slightly reduced affinity 
for HDAC3, and additional deletion of the Intervening region in ΔNIC-EGFP results 
in very weak binding. This result contrasts with those obtained using HeLa cells (see 
Chapter 3). Further investigation of this is required to enable proper quantification of 
binding affinity. Additionally, the binding of other members of the NCoR/SMRT 
complex needs to be assessed - particularly TBL1XR1/TBL1X, which binds directly 
to MeCP2 (Lyst et al., 2013). Experimental approaches to determine ‘bridge’ 
function of these proteins are discussed in Chapter 7. 
 
4.5.5 Concluding remarks 
 
In conclusion, I have successfully produced knock-in mouse lines from targeted ES 
cells for all three of the truncated Mecp2 alleles. The two less severe alleles: ΔN-
EGFP (missing only the N-terminus) and ΔNC-EGFP (missing both the N- and C-
termini) are expressed at slightly elevated levels in the brain, comparable to the 
expression of WT-EGFP protein. As the WT-EGFP mice are essentially 
phenotypically normal, the slightly elevated levels of these proteins should not affect 
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the phenotype of these mice. My results suggest that additional deletion of the 
Intervening region in the ΔNIC-EGFP protein results in instability and reduced 
binding to HDAC3. Unfortunately, the lower ΔNIC-EGFP protein levels and reduced 
‘bridge’ function could make it harder to address the bridge hypothesis as it will be 
impossible to determine whether any RTT-like symptoms detected in these mice are 
the result of the loss of additional functions that require the Intervening region or due 







Chapter 5 – Phenotypic analysis of mice expressing truncations of MeCP2 
 
5.1 Introduction and aims 
 
In this chapter, I will describe the phenotypes of all three truncated Mecp2 knock-in 
mouse lines. Hemizygous males were used for all phenotypic analysis as they 
provide a more sensitive assay for protein function. Hemizygous male mouse models 
lacking Mecp2 or expressing mutant versions that cause RTT in patients have been 
widely studied (e.g. Guy et al., 2001; Goffin et al., 2012; Baker et al., 2013; Brown, 
Selfridge et al., 2016). They display a severe phenotype, with rapid symptom 
progression from 4 weeks of age, resulting in premature death. The mouse models 
expressing RTT-causing MeCP2 mutant proteins mirror the severity spectrum in 
patients (Baker et al., 2013; Brown, Selfridge et al., 2016). Hemizygous males have 
also been studied to detect more subtle phenotypes caused by milder mutations in 
MeCP2, including A140V (which causes intellectual disability in patients) and 
phospho-abolishing mutants (e.g. Jentarra et al., 2010; Tao et al., 2009; Cohen et al., 
2011). This means that characterisation of knock-in mouse models expressing 
MeCP2 mutants is a semi-quantitative assay of these proteins’ function. Here, I 
present the phenotypic analysis of the truncated MeCP2 mouse lines using an 
established scoring system and commonly used behavioural tests. Overall, this 
analysis gives a robust assessment of the phenotypes of these lines. Mice were 
backcrossed onto a 94% C57BL/6J background for phenotypic analysis to allow 
comparison between the novel lines and to other Mecp2-mutant mice in previous 
studies (Brown, Selfridge et al., 2016). Preliminary outbred cohorts of the two more 
severe truncations, ΔNC-EGFP and ΔNIC-EGFP, were scored in addition. Both 
backcrossed and preliminary cohorts consist of mutant mice and wild-type 
littermates, which serve as controls. These wild-type controls express the 





5.2 Phenotypic scoring using a well-established system 
 
The phenotype of the mice was assessed over a period of one year using a well-
established scoring system developed in the lab to record the presence and 
progression of RTT-like symptoms in mouse models. This system was based on 
SHIRPA screening of Mecp2-nulll mice and was first published by Guy et al. (2007). 
Mice were scored in six categories: spontaneous activity, gait, hind-limb clasping, 
tremor, abnormal breathing and general appearance. Mice received a score between 0 
and 2 for each category, where 0 = as wild-type, 1 = present, and 2 = severe. 
Intermediate scores of 0.5 and 1.5 were also used in all categories except hind-limb 
clasping (Cheval, Guy et al., 2012). The scores in each category were added together 
to give the aggregate symptomatic score for each animal. Loss of MeCP2 function 
results in reduced spontaneous activity; abnormal gait where hind legs are splayed; 
hind limb clasping of one (score = 1) or both (score = 2, or 1 if partial) legs towards 
the body; development of a tremor; development of breathing problems; and 
degradation of general condition including dull coat, hunched posture, and dull or 
crusty eyes. This system is quick (2-3 minutes per animal), non-invasive, and can be 
repeated multiple times with the same animals. Aggregate scores for each animal 
were averaged to show symptom progression over time for each mouse line. Animals 
were culled if they reached a score of 2 in any of the last three categories: tremor, 
breathing problems or general condition. The mice in the scoring cohorts were also 
weighed as several Mecp2-mutant lines have altered body weight (Guy et al., 2001; 
Brown, Selfridge et al., 2016). Additionally, symptom progression is often combined 
with weight loss (Guy et al., 2001). Mice were culled if they lost >20% of their 
maximum body weight (unless they had been obese). Animals were caged together 
with their wild-type littermates and scored blind. Scoring began soon after weaning, 
at 4 weeks of age, when symptoms begin to develop in Mecp2-null animals. 
 
5.2.1 ΔN-EGFP mice are indistinguishable from their wild-type littermates 
 
The ΔN-EGFP mice, expressing the least severe of all the three truncations - missing 
only the N-terminal region (Fig. 3.1) - are viable, healthy and fertile. A backcrossed 
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(94% C57BL/6J) cohort of ten ΔN-EGFP animals and ten wild-type littermates was 
scored every four weeks for 52 weeks. Over this period, all ten ΔN-EGFP animals 
survived and were indistinguishable from their wild-type littermates. Overall, all 
animals of both genotypes received very low total scores: up to a maximum of 2.5 
(except at 52 weeks when three ΔN animals scored more) (Fig. 5.2.1i). This was 
mainly due to mild gait defects or reduced activity from 4-12 weeks. Very rarely, 
both wild-type and ΔN-EGFP animals were given a low score (0.5) for general 
appearance due to piloerection or irregular breathing, but these symptoms did not 
persist when these individuals were scored over subsequent months. No tremor or 
hind-limb clasping was detected in any individuals until the final time point (but 
these were detected in both mutant and wild-type animals). ΔN-EGFP mice 
displayed no weight difference from their wild-type littermates (Fig. 5.2.1ii, repeated 





5.2.2 ΔNC-EGFP mice are asymptomatic but have a mild weight phenotype 
 
Mice expressing the second truncated protein, ΔNC-EGFP, missing both the N- and 
C-termini (Fig. 3.1) are also viable, healthy and fertile. Outbred and backcrossed 
cohorts of mice were scored over one year and were indistinguishable from their 
Figure 5.2.1: ΔN-EGFP mice are phenotypically normal 
Scoring (i) and growth (ii) curves for hemizygous male ΔN-EGFP mice and their 
wild-type (WT) littermates. Graphs show mean values (scores) or mean and 
standard deviation (weights). Mice were scored every 4 weeks from 4-52 weeks. 
WT n=10, ΔN-EGFP n=10.  (Backcrossed) null scores and weight data was 
obtained by Jacky Guy (Brown, Selfridge et al., 2016). Null animals: scoring 
n=12, weights n=20. WT and ΔN growth curves were compared using repeated 
measures ANOVA: not significant p=0.362. 
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wild-type littermates throughout this period (Fig. 5.2.2Ai). As described above for 
the ΔN-EGFP line, some mice received low scores, rarely exceeding a score of 2. 
The maximum score obtained by ΔNC-EGFP individuals in the backcrossed cohort 
was 4.5. However, this was also the case for the wild-type littermates, and two wild-
types were given scores of 6 and 7.5 - the latter of which was culled due to intestinal 
blockage at 10 weeks of age. As with the ΔN-EGFP line, these scores were mostly 
due to mild gait defects or reduced activity from 4-5 weeks. Mild breathing problems 
(score of 0.5 or 1) were recorded for both wild-type and ΔN-EGFP individuals, but 
they did not persist over subsequent weeks. Only the animal that developed an 
intestinal blockage had more severe breathing problems (on the day that it was 
culled). Mild tremors (score of 0.5 or 1) were more rare: recorded occasionally in 
animals of both genotypes, and only persisting in two wild-type mice. Hind-limb 
clasping was absent for the majority of the scoring period, but partial clasping (score 
of 1) was recorded for a few animals of both genotypes from 40 weeks. One ΔNC-
EGFP animal was an exception to this: it began partial clasping at 24 weeks and 
persisted until the end of the experiment. Some wild-type and ΔNC-EGFP animals 
received low scores (0.5) for general condition due to slight piloerection, which 
became more common with increased age (>32 weeks). Again, only the culled wild-
type received a higher score (of 2) in this category. 
 
The results for the outbred cohort were very similar, with animals of both genotypes 
mostly receiving maximum scores of 2 (Fig. 5.2.2Aii). These scores were almost 
entirely recorded for activity and gait, plus general appearance as the animals got 
older. Breathing problems and tremors were even less frequent than in the 
backcrossed cohort, and no hind-limb clasping was observed. All seven ΔNC-EGFP 
mice survived for the duration of the experiment (one year), but one wild-type 
littermate was culled due to weight loss at 44 weeks of age. Although some 
individuals of both genotypes in this cohort carried the CMV-Cre transgene, this did 
not affect their scores (Fig. S10i). 
 
The backcrossed ΔNC-EGFP mice displayed a mild weight phenotype: they were 
heavier than their wild-type littermates (Fig. 5.2.2Bi). This is not significant at any 
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individual time point (analysed using t-tests) but is significant overall (repeated 
measures ANOVA, **** p<0.0001). Importantly, the weakness of this phenotype 
meant that the animals were not distinguishable by size, so the scoring was truly 
blind. The biological significance of weight phenotypes in Mecp2-mutant mice is 
unclear as it has previously shown to be linked to genetic background (Guy et al., 
2001). To support this, no weight phenotype was observed between ΔNC-EGFP 
mice and their wild type littermates in the outbred (75% C57BL/6J) cohort (Fig. 
5.2.2Bii). This was not affected by the presence of the CMV-Cre transgene in some 




Figure 5.2.2A: ΔNC-EGFP mice are asymptomatic over one year 
Scoring of backcrossed (i) and outbred (ii) hemizygous male ΔNC-EGFP mice 
and their wild-type (WT) littermates. Graphs show mean values. Backcrossed 
(94% C57BL/6J) mice were scored weekly from 4-16 weeks, and every 4 weeks 
thereafter up to one year. WT n=10, ΔNC-EGFP n=10. Outbred (75% C57BL/6J) 
mice were scored weekly from 5-16 weeks (excluding weeks 12 and 15) and 
every 4 weeks thereafter up to one year.  WT n=9, ΔNC-EGFP n=7.  † denotes 
the time points where one wild-type was culled due to weight loss: aged 10 
weeks in the backcrossed cohort and aged 44 weeks in the outbred cohort. 
Backcrossed null scoring data was obtained by Jacky Guy (Brown, Selfridge et 







5.2.3 ΔNIC-EGFP mice exhibit mild RTT-like symptoms 
 
Mice expressing ΔNIC-EGFP, the third and most severely truncated protein retaining 
only the MBD and the NID, are also viable and fertile, but exhibit mild RTT-like 
symptoms from around 7 weeks (Fig. 5.2.3Ai). Unlike Mecp2-nulls or mice carrying 
RTT-causing mutations, these symptoms do not progress and survival is not affected. 
The backcrossed cohort was scored weekly or biweekly for one year. The average 
score of these animals rose slowly to 2.4 at 8 weeks of age, but plateaued at this level 
(fluctuating around ~2.5). Individual scores throughout this scoring period are mostly 
below 4.5. The wild-type littermates in this cohort were comparable to those in the 
ΔN-EGFP and ΔNC-EGFP cohorts described above, mostly only receiving low 
scores for activity and gait. The higher scores obtained by the ΔNIC-EGFP mice are 
due to more severe gait defects and partial hind-limb clasping. Several animals 
Figure 5.2.2B: ΔNC-EGFP mice have a slight weight phenotype after 
backcrossing 
Growth curves of backcrossed (i) and outbred (ii) hemizygous male ΔNC-EGFP 
mice and their wild-type (WT) littermates. Graphs show mean and standard 
deviation. Backcrossed (94% C57BL/6J) mice were weighed weekly from 4-16 
weeks, and every 4 weeks thereafter up to one year. WT n=10, ΔNC-EGFP 
n=10. Outbred (75% C57BL/6J) mice were weighed weekly from 4-16 weeks 
(excluding week 15) and every 4 weeks thereafter up to one year.  WT n=9, 
ΔNC-EGFP n=7.  † denotes the time points where one wild-type was culled due 
to weight loss: aged 10 weeks in the backcrossed cohort and aged 44 weeks in 
the outbred cohort. WT and ΔNC growth curves were compared using repeated 
measures ANOVA: backcrossed cohort **** p<0.0001, outbred cohort not 
significant p=0.739. Backcrossed null weight data was obtained by Jacky Guy 




regularly obtained gait scores of 1.5 or 2 from ~8 weeks. Partial clasping (score of 1) 
was detected from 7 weeks of age; and in four out of ten animals, this progressed to 
more severe hind-limb clasping (score of 2) from 15, 24, 32 and 44 weeks. One 
ΔNIC-EGFP animal in this cohort was found dead at 43 weeks of age. The cause of 
its death is unknown as its symptoms were very mild (never exceeding a score of 
2.5), but it had lost 15% of its bodyweight (not quite reaching the 20% threshold 
where the animal must be culled). 
 
An outbred cohort of ten ΔNIC-EGFP mice and one wild-type littermate was also 
scored. In this cohort, all ten ΔNIC-EGFP animals survived until one year of age. 
Their scores increased very slowly over the first 36 weeks, then plateaued around an 
average of 3.5-4 (Fig. 5.2.3Aii). The slower progression of symptoms in this cohort 
was due to the later onset of hind-limp clasping: ~18 weeks compared to ~7 weeks. 
Later, their scores were slightly elevated compared to the backcrossed cohort, due to 
higher activity and gait scores from 28 weeks of age and higher general condition 
scores from 34 weeks. It is difficult to say whether this is due to more severe defects 
in these categories or a drift in the scoring criteria over the course of this study. 
Activity and general condition (mostly age-related piloerection) are particularly 
prone to subjectivity. The presence of the CMV-Cre transgene in some individuals 
had no effect on the scores in this cohort (Fig. S10iii). 
 
Both scoring cohorts were weighed over the same period. Backcrossed ΔNIC-EGFP 
mice were ~40% lighter than their wild-type littermates - significant at all time points 
from 5 weeks of age, analysed using t-tests (Fig. 5.2.3Bi). The two growth curves 
were compared using repeated measures ANOVA, giving high significance (**** 
p<0.0001). The weight phenotype was also observed on the outbred background 
(Fig. 5.2.3Bii), but as there was only one wild-type littermate in this cohort, 
statistical analysis is not possible. It is important to note that the growth curve of this 
wild-type animal is comparable to the other wild-types on this background (i.e. wild-
types in the ΔNC-EGFP outbred cohort). The weights of the outbred cohort were not 











Figure 5.2.3A: ΔNIC-EGFP mice display mild RTT-like symptoms 
Scoring of backcrossed (i) and outbred (ii) hemizygous male ΔNIC-EGFP mice 
and their wild-type (WT) littermates. Graphs show mean values. Backcrossed 
(94% C57BL/6J) mice were scored weekly from 4-26 weeks, and every 2 weeks 
thereafter up to one year. WT n=10, ΔNIC-EGFP n=10. Outbred (75% C57BL/6J) 
mice were scored weekly from 4-52 weeks (excluding week 41).  WT n=1, ΔNIC-
EGFP n=10. † denotes the time point where one ΔNIC-EGFP mouse from the 
backcrossed cohort was found dead, aged 43 weeks. Backcrossed null scoring 
data was obtained by Jacky Guy (Brown, Selfridge et al., 2016). Null animals: 
n=12. (Deaths of null animals are not shown.) 
Figure 5.2.3B: ΔNIC-EGFP mice are lighter than their wild-type littermates 
Growth curves of backcrossed (i) and outbred (ii) hemizygous male ΔNIC-EGFP 
mice and their wild-type (WT) littermates. Graphs show mean and standard 
deviation. Backcrossed (94% C57BL/6J) mice were weighed weekly from 4-26 
weeks, and every 2 weeks thereafter up to one year. WT n=10, ΔNIC-EGFP 
n=10. Outbred (75% C57BL/6J) mice were weighed weekly from 4-52 weeks 
(excluding week 41).  WT n=1, ΔNIC-EGFP n=10. † denotes the time point 
where one ΔNIC-EGFP mouse from the backcrossed cohort was found dead, 
aged 43 weeks. WT and ΔNIC growth curves were compared using repeated 
measures ANOVA: backcrossed cohort **** p<0.0001, outbred cohort N/A. 
Backcrossed null weight data was obtained by Jacky Guy (Brown, Selfridge et 
al., 2016). Null animals: n=20. (Deaths of null animals are not shown.) 
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5.3 Behavioural analysis using a series of standard tests 
 
A second cohort of backcrossed mice for each line underwent a series of behavioural 
tests. The chosen tests are commonly used for mouse models of Rett syndrome, 
detecting differences in activity, anxiety and motor skills (Goffin et al., 2012; Pitcher 
et al., 2015; Brown, Selfridge et al., 2016). All three mouse lines underwent the same 
behavioural analysis: Elevated Plus Maze on day 1; Open Field test on day 2; 
Hanging Wire test on day 3; and Accelerating Rotarod on days 6-9 (one day of 
training followed by three days of trials). Prior to the tests, the animals had not been 
handled except for husbandry. This is particularly important for the Elevated Plus 
Maze and Open Field test, which monitor exploratory behaviour. These tests are 
therefore done at the beginning of the experimental regime as the Hanging Wire and 
Accelerating Rotarod tests involve handing by the experimenter. The Accelerating 
Rotarod is a very tiring task, so is carried out at the end of the series of behavioural 
characterisation assays. This analysis was performed when the animals were 20-21 
weeks of age. 
 
5.3.1 ΔN-EGFP mice show no phenotype in any test 
 
The Open Field test is used to measure activity and anxiety. It consists of a square 
arena measuring 50 by 50 cm, which is evenly lit and littered with fresh wood 
chippings. The animals are left to explore this area for 20 minutes each. Activity is 
assessed by total distance travelled and time immobile. An immobile episode is 
defined as lack of movement for a minimum of 10 seconds. ΔN-EGFP mice show no 
phenotype compared to their wild-type littermates using either of these measures 
(Fig. 5.3.1A). To assess anxiety, the arena is divided into nine equal squares and the 
time spent in the middle square is calculated. Wild-type mice tend to explore the 
perimeter of their enclosure and avoid this middle section (Fig. 5.3.1B). RTT models 
tend have decreased anxiety, which can be measured by the increase in time spent in 
this middle region. An alternative measurement for anxiety is Centre:Total ratio of 
distance travelled, used by Shahbazian et al. (2002b), McGill et al. (2006) and 
Samaco et al. (2008). The ΔN-EGFP mice show no anxiety phenotype in this test 
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using either method of measurement (Fig. 5.3.1C). The way that animals behave in 
the arena can change over the course of the test, with differences between genotypes 
only apparent in some segments (Shahbazian et al., 2002b; Samaco et al., 2008). For 
this experiment, reanalysis of the data divided into two segments of 10 minutes gives 





Figure 5.3.1A: ΔN-EGFP mice have no activity phenotype in the Open Field 
test 
(i-iv) Results of the Open Field test performed on ΔN-EGFP mice and their wild-
type (WT) littermates. The data was analysed using AnyMaze software. WT 
n=10; ΔN-EGFP n=10. (i) Total distance travelled. Graph shows individual values 
and the group mean and standard deviation.  Not significant p=0.691 (t-test). (ii) 
Distance travelled in the two 10 minute segments of the test. Graph shows group 
mean and SD. Not significant: segment 1 p=0.587, segment 2 p=0.870 (t-tests). 
(iii) Time spent immobile. Graph shows individual values and the group median. 
Not significant: p=0.988 (KS test). (iv) Time spent immobile in the two 10 minute 
segments of the test. Graph shows group median and range. Not significant: 
segment 1 p=0.988, segment 2 p=0.988 (KS tests). Note: one immobile episode 








Figure 5.3.1B: Open Field plot 
Example track of a wild-type mouse 
from the Open Field test 
Figure 5.3.1C: ΔN-EGFP mice have no anxiety phenotype in the Open Field 
Test 
(i-iv) Results of the Open Field test performed on ΔN-EGFP mice and their wild-
type (WT) littermates. The data was analysed using AnyMaze software. WT 
n=10; ΔN-EGFP n=10. (i) Centre time: total time spent in the central region. 
Graph shows individual values and the group mean and standard deviation.  Not 
significant: p=0.822 (t-test). (ii) Time spent in the centre in the two 10 minute 
segments of the test. Graph shows group median and range. Not significant: 
segment 1 p=0.759, segment 2 p=0.759 (KS tests). (iii) Centre:Total distance 
ratio. Graph shows individual values and the group mean and standard deviation. 
Not significant: p=0.891 (t-test). (iv) Centre:Total distance ratio in the two 10 
minute segments of the test. Graph shows group mean and SD. Not significant: 
segment 1 p=0.634, segment 2 p=0.790 (t-tests).  
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The Elevated Plus maze is a more commonly used test for anxiety. It consists of a 
cross-shaped maze with two open well-lit arms, two closed darker arms and a small 
central region between them. The animals are left to explore this maze for 15 minutes 
each. Wild-type mice tend to spend the vast majority of time in the darker arms and 
avoid the anxiety-provoking open arms (Fig. 5.3.1D). RTT mouse models display a 
decreased anxiety phenotype in the test by spending more time in the open arms than 
their wild-type littermates. Interestingly, several RTT models show significantly 
decreased anxiety is this test but not the Open Field test (Brown, Selfridge et al., 
2016 and unpublished data), suggesting that this test is more stringent. The ΔN-




The Hanging Wire test measures muscle strength and motor coordination. Animals 
are placed on a horizontal wire with their forepaws, and the time taken to bring a 
hind paw to the wire is recorded. Animals are given a maximum of 30 seconds to 
complete this task. Animals that take longer or fall off the wire are given the 
maximum score of 30. The test was performed three times for each animal and the 
mean of the three tests was calculated. RTT mouse models show a reduced 
performance in this test (Brown, Selfridge et al., 2016). The ΔN-EGFP mice show no 
phenotype in this test (Fig. 5.3.1E). As seen with other lines (presented below), there 
Figure 5.3.1D: ΔN-EGFP mice have no anxiety 
phenotype in the Elevated Plus Maze 
Upper: Example track of a wild-type mouse, 
which spends more time in the closed arms 
(shaded). 
Lower: Results of the Elevated Plus Maze 
performed on ΔN-EGFP mice and their wild-type 
(WT) littermates. The times spent in the open and 
closed arms were determined for each genotype 
using AnyMaze software. The graph shows 
individual values and group medians. WT n=10; 
ΔN-EGFP n=10. No difference was found 
between the ΔN-EGFP mice and their WT 
littermates using Kolmogorov-Smirnov tests: 
closed arms p=0.988, open arms p=0.759. 
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is considerable variation between individuals when this test is performed on older 




Accelerating Rotarod is a test of motor coordination and learning. This test is 
performed over four days. On the first day, the animals are accustomed to the 
apparatus in a short training session where they must stay on the track for 30 seconds 
at its lowest speed (4 rpm). On the subsequent three days, each animal undergoes 
four trials where the speed is gradually increased from 4 rpm to 40 rpm over 5 
minutes. The time taken to fall (latency) is recorded and the average time for each 
day is calculated. Wild-type mice tend to display motor learning in this test, with 
increasing latency to fall over the three day period. RTT models show a reduced 
performance in this test, which becomes significant on day 2 or 3 (Brown, Selfridge 
et al., 2016). The ΔN-EGFP mice did not perform significantly differently from their 
wild-type littermates on any of the three days of this test (Fig. 5.3.1F, analysed by 
KS tests). They do, however, have a trend towards reduced performance by day 3 
and did not display learning in this test, unlike their wild-type littermates (analysed 







Figure 5.3.1E: ΔN-EGFP mice have no muscle 
strength phenotype in the Hanging Wire test 
Results of the Hanging Wire test performed on ΔN-EGFP 
mice and their wild-type (WT) littermates. The time taken 
to bring their hind paw to a horizontal wire was recorded, 
up to a maximum score of 30 seconds. The graph shows 
the mean of three tests for each animal and the group 
mean and standard deviation. WT n=10; ΔN-EGFP n=10. 
No difference was found between the ΔN-EGFP mice and 






5.3.2 ΔNC-EGFP mice may have a weak anxiety phenotype 
 
Behavioural analysis of the ΔNC-EGFP backcrossed cohort using the Open Field test 
showed that these mice have no activity phenotype compared to their wild-type 
littermates (Fig. 5.3.2A). However, these mice displayed a weak anxiety phenotype, 
spending more time in the central region of the arena (Fig. 5.3.2B; * p=0.020, t-test). 
This difference occurred during the first 10 minute segment (* p=0.036, t-test). This 
phenotype was below the threshold of significance using the alternative measure of 
anxiety, the Centre:Total distance ratio over the whole test (p=0.089, t-test) and in 
the two 10 minute segments (segment 1: p=0.137, segment 2: p=0.460, t-tests). 
 
The weak decreased anxiety phenotype illustrated in the Open Field test, was not 
found in the potentially more stringent Elevated Plus Maze. In this test, ΔNC-EGFP 
mice resemble their wild-type littermates, both spending very little time in the 
anxiety-provoking open arms of the maze (Fig. 5.3.2C). 
 
Figure 5.3.1F: ΔN-EGFP mice have no motor deficit on the Accelerating 
Rotarod 
Results of the Accelerating Rotarod performed on ΔN-EGFP mice and their wild-
type (WT) littermates. The time taken to fall off the rotating track was recorded, 
and the mean was taken for four trials for each day. The graph shows mean 
values for each individual animal and the group medians. WT n=10; ΔN-EGFP 
n=10. No difference was found between the ΔN-EGFP mice and their WT 
littermates for any day using Kolmogorov-Smirnov tests: day 1 p=0.759, day 2 
p=0.401, day 3 p=0.055. Learning was determined using Friedman tests to 






Figure 5.3.2A: ΔNC-EGFP mice have no activity phenotype in the Open 
Field Test 
(i-iv) Results of the Open Field test performed on ΔNC-EGFP mice and their wild-
type (WT) littermates. The data was analysed using AnyMaze software. WT 
n=10; ΔNC-EGFP n=10. (i) Total distance travelled. Graph shows individual 
values and the group mean and standard deviation.  Not significant p=0.791 (t-
test). (ii) Distance travelled in the two 10 minute segments of the test. Graph 
shows group mean and SD. Not significant: segment 1 p=0.724, segment 2 
p=0.320 (t-tests). (iii) Time spent immobile (immobile episodes are >10s). Graph 
shows individual values and the group median. Not significant: p=0.401 (KS test). 
(iv) Time spent immobile in the two 10 minute segments of the test. Graph shows 
group median and range. Not significant: segment 1 p=>0.999, segment 2 







Figure 5.3.2B: ΔNC-EGFP mice may have a mild anxiety phenotype in the 
Open Field Test 
(i-iv) Results of the Open Field test performed on ΔNC-EGFP mice and their wild-
type (WT) littermates. The data was analysed using AnyMaze software. WT 
n=10; ΔNC-EGFP n=10. (i) Centre time: total time spent in the central region. 
Graph shows individual values and the group mean and standard deviation.  
* p=0.020 (t-test). (ii) Time spent in the centre in the two 10 minute segments of 
the test. Graph shows group mean and SD. Only segment 1 is significantly 
different: * p=0.036, segment 2: n.s. p=0.208 (t-tests). (iii) Centre:Total distance 
ratio. Graph shows individual values and the group mean and standard deviation. 
Not significant: p=0.089 (t-test). (iv) Centre:Total distance ratio in the two 10 
minute segments of the test. Graph shows group mean and SD. Not significant: 









Muscle strength and motor co-ordination were analysed using the Hanging Wire test 
and Accelerating Rotarod, respectively. The ΔNC-EGFP mice did not perform 
significantly differently from their wild-type littermates in either test (Fig. 5.3.2D-E). 
However, there is a trend to reduced performance in the Hanging Wire test that could 
be caused by their increased weight compared to their wild-type siblings (Fig. 
5.3.2Dii). Notably, in this cohort, neither the wild-type nor the ΔNC-EGFP mice 
displayed learning on the Accelerating Rotarod (analysed by Freidman test: p=0.353 
for wild-type, p=0.549 for ΔNC-EGFP). 
 
 
Figure 5.3.2D: legend on next page 
Figure 5.3.2C: ΔNC-EGFP mice have no 
anxiety phenotype in the Elevated Plus Maze 
Results of the Elevated Plus Maze performed on 
ΔNC-EGFP mice and their wild-type (WT) 
littermates. The times spent in the open and 
closed arms were determined for each genotype 
using AnyMaze software. The graph shows 
individual values and group medians. WT n=10; 
ΔNC-EGFP n=11. No difference was found 
between the ΔNC-EGFP mice and their WT 
littermates using Kolmogorov-Smirnov tests: 
closed arms p=0.950, open arms p=0.932. (Open 
arms have a normal distribution so can also be 







5.3.3 ΔNIC-EGFP mice have slightly decreased anxiety and reduced motor co-
ordination compared to their wild-type littermates 
 
Behavioural analysis of a backcrossed ΔNIC-EGFP cohort was carried out at the 
same age as the other two lines (20-21 weeks). At this age, the backcrossed scoring 
cohort had an average score of 2.50-2.75. They displayed gait abnormalities and 
partial hind-limb clasping but no activity phenotype was observed. To investigate the 
Figure 5.3.2D: ΔNC-EGFP mice have no muscle strength phenotype in the 
Hanging Wire test 
(i) Results of the Hanging Wire test performed on ΔNC-EGFP mice and their 
wild-type (WT) littermates. The time taken to bring their hind paw to a horizontal 
wire was recorded, up to a maximum score of 30 seconds. The graph shows the 
mean of three tests for each animal and the group mean and standard deviation. 
WT n=10; ΔNC-EGFP n=11. No difference was found between the ΔNC-EGFP 
mice and their WT littermates: p=0.058 (t-test). 
(ii) Correlation between Hanging wire performance and body weight. Regression 
line for all animals (genotypes combined) R2 * p=0.011. 
Figure 5.3.2E: ΔNC-EGFP mice have no motor deficit on the Accelerating 
Rotarod 
Results of the Accelerating Rotarod performed on ΔNC-EGFP mice and their 
wild-type (WT) littermates. The time taken to fall off the rotating track was 
recorded, and the mean was taken for four trials for each day. The graph shows 
mean values for each individual animal and the group medians. WT n=10; ΔN-
EGFP n=10. No difference was found between the ΔNC-EGFP mice and their 
WT littermates for any day using Kolmogorov-Smirnov tests: day 1 p=0.988, day 
2 p=0.401, day 3 p=0.759. Neither genotype showed learning, analysed using 
Friedman tests to determine variation over time: WT p=0.353, ΔN-EGFP 
p=0.549. Note: one ΔNC-EGFP animal couldn’t complete the task and was 
excluded from the experiment. 
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activity of this knock-in line further, the distance travelled and time spent immobile 
during the Open Field test were determined using a separate cohort for behavioural 
testing. The results show that these mice have no activity phenotype compared to 





Figure 5.3.3A: ΔNIC-EGFP mice have no activity phenotype in the Open 
Field Test 
(i-iv) Results of the Open Field test performed on ΔNIC-EGFP mice and their 
wild-type (WT) littermates. The data was analysed using AnyMaze software. WT 
n=10; ΔNIC-EGFP n=10. (i) Total distance travelled. Graph shows individual 
values and the group mean and standard deviation.  Not significant p=0.333 (t-
test). (ii) Distance travelled in the two 10 minute segments of the test. Graph 
shows group median and range. Not significant: segment 1 p=0.988, segment 2 
p=0.401 (KS tests). (iii) Time spent immobile (immobile episodes are >10s). 
Graph shows individual values and the group median. Not significant: p=0.164 
(KS test), or p=0.067 (t-test). (iv) Time immobile in the two 10 minute segments 
of the test. Graph shows group median and range. Not significant: segment 1: 
p=0.759, segment 2: p=0.401 (KS tests). Note: one immobile episode may be 
split between the two segments. 
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As with the other two lines described above, anxiety was tested using both the Open 
Field test and the Elevated Plus Maze. No anxiety phenotype was found in the Open 
Field test using either method of measurement: the time spent in the central region 
(Centre Time) or the Centre:Total Distance Ratio (Fig. 5.3.3B). Separation of the two 
10 minute segments of the tests did not affect this result. The ΔNIC-EGFP mice did 
show a decreased anxiety phenotype in the Elevated Plus Maze (Fig. 5.3.3C). Mice 
usually display a decreased anxiety phenotype by a reduced avoidance of the open 
arms and indeed the ΔNIC-EGFP animals tend to spend longer in the open arms than 
their wild-type littermates, although this was just below the threshold of significance 
(p=0.055, KS test or p=0.056, t-test). They did, however, spend a significantly 
reduced amount of time in the closed arms (** p=0.003, KS test or t-test). Further 
analysis shows that these mice spent significantly longer than their wild-type siblings 
in the open areas of the maze once the open central region was taken into account 
(Open arms + Centre ** p=0.009 analysed by t-test, or just below the significance 
threshold analysed by KS test p=0.055). The longer time spent in the central region 
(** p=0.008, t-test or * p=0.015, KS test) explains why the time spent in the closed 
arms but not the time spent in the open arms is significantly different. To determine 
whether the difference in time spent in the open regions was due to increased 
exploration in these regions or reduced mobility, the distance travelled was analysed. 
Firstly, the mice showed no difference in the total distance travelled (Fig. 5.3.3Cii), 
consistent with the results of the Open Field test. Analysis of the distance ratios for 
each region gives identical results to those obtained with the data on the amount of 
time spent in the regions of the maze, showing that there was no difference in their 
activity between the regions (Fig. 5.3.3Ciii). A complication in the interpretation of 
these results is that although the central region is ‘open’, it must be crossed to switch 
between all arms. This makes its inclusion in the anxiety-provoking open areas 
debatable. There is no difference in the total number of arm (closed + open) entries 
(Fig. 5.3.3Civ), indicating that the increased time and distance travelled in the central 
region was due to increased exploration of this region rather than increased switching 
between arms. Another difference between the central region and the open arms that 
complicates the interpretation of this result is that only the open arms have a sudden 
drop (i.e. a risk of falling). The related Elevated Zero Maze does not have this 
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problem, so may have given more informative results. Nevertheless, I believe there is 
sufficient evidence to conclude that the ΔNIC-EGFP mice have a mild but significant 




Figure 5.3.3B: ΔNIC-EGFP mice have no anxiety phenotype in the Open 
Field Test 
(i-iv) Results of the Open Field test performed on ΔNIC-EGFP mice and their 
wild-type (WT) littermates. The data was analysed using AnyMaze software. WT 
n=10; ΔNIC-EGFP n=10. (i) Centre time: total time spent in the central region. 
Graph shows individual values and the group mean and standard deviation.  Not 
significant p=0.402 (t-test). (ii) Time spent in the centre in the two 10 minute 
segments of the test. Graph shows group median and range. Not significant: 
segment 1 p=0.988, segment 2 p=0.988 (KS tests). (iii) Centre:Total distance 
ratio. Graph shows individual values and the group mean and standard deviation. 
Not significant: p=0.289 (t-test). (iv) Centre:Total distance ratio in the two 10 
minute segments of the test. Graph shows group mean and SD. Not significant: 





Figure 5.3.3C: ΔNIC-EGFP mice display an anxiety phenotype in the 
Elevated Plus Maze 
(i-iv) Results of the Elevated Plus Maze performed on ΔNIC-EGFP mice and their 
wild-type (WT) littermates. The data was analysed using AnyMaze software. WT 
n=10; ΔNIC-EGFP n=10. (i) Time spent in the different areas of the maze. The 
graph shows individual values and group medians. All datasets fitted a normal 
curve so can be analysed by t-tests, however KS tests were also carried out for 
better comparison to results for the other two knock-in lines. The graphs are 
therefore labelled with symbols reflecting the p values obtained in the KS tests. 
Results of statistical analysis: Closed arms ** p=0.003 (KS test) ** p=0.003 (t-
test), Open arms  n.s. 0.055 (KS test) n.s. 0.056 (t-test), Centre * p=0.015 (KS 
test) ** p=0.008 (t-test), Open arms + Centre n.s. p=0.055 (KS test) ** p=0.009 (t-
test). (ii) Total distance travelled. Graph shows individual values and the group 
mean and standard deviation.  Not significant p=0.560 (t-test). (iii) Distance 
ratios: distance travelled in each area as a proportion of the total distance each 
individual travelled. Graph shows individual values and the group mean and 
standard deviation. Statistical analysis using t-tests: Closed arms * p=0.011, 
Open arms n.s. p=0.304, Centre * p=0.026, Open arms + Centre n.s. p=0.054. 
(iv) Number of arm entries (Closed + Open). Graph shows individual values and 
the group mean and standard deviation. Not significant: p=0.303, t-test. 
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Finally, the ΔNIC-EGFP behavioural cohort underwent motor testing using the 
Hanging Wire and Accelerating Rotarod tests. As the mice display gait defects at this 
age, I expected them to have reduced motor abilities in these tests. No difference was 
observed in the Hanging Wire test (Fig. 5.3.3D; p=0.960, t-test). As seen with the 
other mouse lines, there was a lot of variation between individuals, which is common 
when this test is performed on older animals making it difficult to obtain a significant 
result. The ΔNIC-EGFP mice did, however, display a striking motor defect on the 
Accelerating Rotarod (Fig. 5.3.3E). Their reduced performance compared to their 
wild-type siblings became significant on day 3 (** p=0.003, KS test). This result was 
due to their worsening performance throughout the test (** p=0.003, Friedman test), 
not just lack of learning. As seen in the ΔNC-EGFP cohort, the wild-type littermates 
did not display learning in this experiment (p=0.601, Friedman test). The data 
presented here includes three ΔNIC–EGFP animals that failed training: i.e. they were 
unable to walk on the rod at 4 rpm for 30 seconds within a 5 minute training period. 
They managed a maximum time in the trials of 15, 23 and 33 seconds. Exclusion of 
these three animals does not affect the result of this experiment: ** p=0.010 (KS test) 




Figure 5.3.3D: ΔNIC-EGFP mice have no muscle 
strength phenotype in the Hanging Wire test 
Results of the Hanging Wire test performed on ΔNIC-
EGFP mice and their wild-type (WT) littermates. The time 
taken to bring their hind paw to a horizontal wire was 
recorded, up to a maximum score of 30 seconds. The 
graph shows the mean of three tests for each animal and 
the group mean and standard deviation. WT n=10; ΔNIC-
EGFP n=10. No difference was found between the ΔNIC-








The three novel truncated Mecp2 knock-in lines all underwent extensive phenotypic 
characterisation. Hemizygous males were used for the analysis as they provide a 
more sensitive assay for MeCP2 function in vivo. Firstly, cohorts of knock-in 
animals and their wild-type littermate controls were scored for overt RTT-like 
symptoms over the course of a year using an established system (Guy et al., 2007). 
Secondly, separate cohorts were analysed using a series of standard behavioural tests 
at 20-21 weeks of age that assess activity, anxiety, muscle strength and motor 
function. Mice expressing the least severely truncated protein, ΔN-EGFP (which is 
only missing the N-terminus), display no phenotype in any of these assays. The 
second truncation, ΔNC-EGFP (which is missing both the N- and C-termini), also 
displayed no overt RTT-like symptoms throughout the year-long scoring period, and 
had no activity or motor phenotype. They did, however, present a very mild but 
significant decreased anxiety phenotype in the Open Field test, assessed by spending 
more time in the central region. This result was not backed up by their performance 
Figure 5.3.3E: ΔNIC-EGFP mice have a motor deficit on the Accelerating 
Rotarod 
Results of the Accelerating Rotarod performed on ΔNIC-EGFP mice and their 
wild-type (WT) littermates. The time taken to fall off the rotating track was 
recorded, and the mean was taken for four trials for each day. The graph shows 
mean values for each individual animal and the group medians. WT n=10; ΔNIC-
EGFP n=10. The ΔNIC-EGFP mice have reduced ability, which becomes 
significant on day 3: day 1 n.s. p=0.164, day 2 n.s. p=0.055, day 3 ** p=0.003 
(KS tests). The WT mice did not display learning, analysed using the Friedman 
test to determine variation over time: p=0.601. The ΔNIC-EGFP show significant 
worsening performance over the course of this test, ** p=0.003 (Friedman test). 
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in the Elevated Plus Maze, where no anxiety phenotype was detected. Lastly, these 
animals have a mild but significant increased body weight phenotype, which only 
became apparent after backcrossing onto a C57BL/6J background. Mice expressing 
the third and most severely truncated protein, ΔNIC-EGFP (which consists solely of 
the MBD and the NID), displayed mild RTT-like symptoms and were lighter than 
wild-type controls but had a normal lifespan and were fertile. Phenotypic scoring 
detected gait abnormalities and hind-limb clasping in these animals. Consistent with 
gait defects, they displayed poor motor coordination on the Accelerating Rotarod. 
Conversely, no differences in muscle strength were detected in the Hanging Wire 
test. These animals displayed a decreased anxiety phenotype, which was apparent in 
the Elevated Plus Maze but not the Open Field test.  Lastly, no activity phenotype 
was detected in the Open Field test, consistent with observations during scoring. 
Overall, the N- and C-termini, which together make up 46% of the full-length 
MeCP2 protein sequence, are broadly dispensable for its function in vivo. Additional 
deletion of the Intervening region leads to reduced protein levels, weaker binding to 
the NCoR/SMRT co-repressor complex (see Chapter 4) and mild RTT-like 
symptoms. 
 
5.4.1 The use of untagged wild-type littermate controls instead of WT-EGFP mice 
 
In this study, all three novel lines were maintained separately and bred with wild-
type C57BL/6J males (using heterozygous knock-in females). This means that the 
wild-type littermates used as controls in the phenotypic characterisation carry the 
endogenous Mecp2 allele, which is not tagged with EGFP. At the early stages of this 
project, I considered breeding these lines with the pre-existing WT-EGFP mice, so 
that the resulting litters would contain EGFP-tagged truncation mutants and EGFP-
tagged WT controls. This would fit with the standard practice of using the same 
epitope tags on all mutant and wild-type proteins that are to be compared. This is 
required in most cases to provide the most stringent comparator possible when 
determining differences between wild-type and mutant proteins. In this study, 
however, the ‘bridge’ hypothesis predicts an absence of a phenotype in the novel 
knock-in mice, so the most stringent test for normal behaviour is required. The WT-
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EGFP mice are broadly normal phenotypically, validating the choice of EGFP as an 
epitope tag for this study, but they are leaner than their wild-type littermates and 
have a mild but significant defect in the Hanging Wire test. (I was aware of these 
results at the early stages of my project. They were later published in Brown, 
Selfridge et al., 2016.) The untagged wild-type mice therefore provide the more 
stringent comparator for ‘normality’. 
 
5.4.2 Both the N- and C-termini are dispensable for normal MeCP2 function in vivo 
  
As mentioned above, the results of the phenotypic characterisation of the ΔN-EGFP 
and ΔNC-EGFP mouse lines strongly suggest that both the N- and C-termini of 
MeCP2 are not required for its function in vivo. The complete absence of RTT-like 
phenotypes in the ΔN-EGFP mice is apparent as they are indistinguishable from their 
wild-type littermates in all tests. One possible exception is the fact that the wild-type 
animals displayed learning on the Accelerating Rotarod and the ΔN-EGFP 
individuals did not. While this test is frequently used to assess motor learning 
(Collins et al., 2004; Samaco et al., 2008; Goffin et al., 2012), only the wild-type 
animals in the ΔN-EGFP cohort displayed learning in this study – the wild-type 
controls in the ΔNC-EGFP and ΔNIC-EGFP cohorts did not. A possible explanation 
for this is that this test is usually carried out using younger animals. 
 
Interpretation of the results of the phenotypic characterisation of the ΔNC-EGFP 
knock-in mice is more difficult. These mice are healthy and fertile with a normal 
lifespan and display no overt RTT-like symptoms over the entirety of the year-long 
scoring period. Furthermore, no activity phenotype or motor defects were detected in 
these animals. They do, however, display slightly decreased anxiety in the Open 
Field test (but not the Elevated Plus Maze) and have a mild but significant increased 
body weight phenotype. Decreased anxiety is a common feature of mouse models of 
RTT. It is frequently assessed using the Elevated Plus Maze (Brown, Selfridge et al., 
2016; Guy, unpublished) or the similar Elevated Zero Maze (Goffin et al., 2012; 
Pitcher et al., 2015) and more rarely using the Open Field test (Samaco et al., 2008; 
Selfridge and Brown, unpublished). To my knowledge, this is the only Mecp2-
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mutant line to display an anxiety phenotype in the Open Field test but resemble wild-
type controls in Elevated Plus Maze. In contrast, two RTT models (T158M-EGFP 
and R133C-EGFP) display decreased anxiety in the Elevated Plus Maze but not the 
Open Field test (Brown, Selfridge et al., 2016 and their unpublished data), suggesting 
that the Elevated Plus Maze is a more stringent test of anxiety. 
 
The backcrossed ΔNC-EGFP mice also displayed a mild but significant increased 
body weight phenotype. Mouse models of RTT frequently have altered body weight, 
with some loss-of-function mutations causing an increase in body weight, e.g. the 
transgenic lines expressing R270X-EGFP, G273X-EGFP and R306-EGFP (Baker et 
al., 2013; Heckman et al., 2014). A decrease in body weight is more common, as 
seen in multiple Mecp2-mutant lines: T158A, T158M-EGFP, R133C-EGFP, R306C-
EGFP [knock-in], R255X, P225R and P322L (Goffin et al., 2012; Brown, Selfridge 
et al., 2016; Pitcher et al., 2015; Guy, unpublished). Body weight phenotypes in 
Mecp2-mutant mice have been shown to be affected by genetic background as nulls 
have a reduced weight phenotype on a C57BL/6 background, but become obese 
when crossed with 129 animals (Guy et al., 2001). Genetic background may also 
account for the difference in weight phenotypes reported for the two independent 
R306C-EGFP lines (Heckman et al., 2014; Brown, Selfridge et al., 2016). Consistent 
with these observations, the outbred (75% C57BL/6J) ΔNC-EGFP scoring cohort did 
not display a weight phenotype. These weight phenotypes are therefore unlikely to 
have any biological significance related to RTT pathophysiology. They do, however, 
need to be taken into account when interpreting the results of some behavioural tests. 
Of the tests used here, only the Hanging Wire test is likely to be affected by body 
weight. This is illustrated by the strong inverse correlation between body weight and 
performance in this test by the ΔNC-EGFP cohort (both ΔNC-EGFP and wild-type 
animals). Despite the slightly heavier body weight of the ΔNC-EGFP individuals, 





5.4.3 Partial loss of the NID is the likely cause of the RTT-like phenotypes displayed 
by the published 308/y mice 
 
A truncated mouse line (308/y) expressing MeCP2 residues 1-308 has been 
extensively characterised using multiple behavioural tests. These mice display 
several of the features associated with RTT, including increased anxiety, impaired 
motor function, seizures and decreased survival (90% at one year of age) 
(Shahbazian et al., 2002b; Moretti et al., 2005; McGill et al., 2006). The 
NCoR/SMRT interaction domain (NID) was mapped to residues 285-309, with 
peptides ending in residue 308 showing reduced binding (Lyst et al., 2013). If the 
‘bridge’ hypothesis is correct, the phenotype displayed by these mice is a result of 
reduced ability of MeCP2 1-308 to bind the NCoR/SMRT complex, which could be 
rescued by the addition of one or more amino acids to restore NID function. The 
ΔNC-EGFP mice produced in this study and the pre-existing ΔC (residues 1-312) 
mice (Lagger, unpublished) test this hypothesis as they both have an additional four 
amino acids (309-312) completing the NID. The lack of a discernible phenotype in 
the ΔNC-EGFP mice strongly supports this hypothesis.  
 
Characterisation of the ΔC mice also suggests that the C-terminus of MeCP2 after 
the NID is broadly dispensable, though the results are less clear. The ΔC mice 
underwent the same phenotypic characterisation as the mice produced in this study, 
after backcrossing onto the same genetic background (94% C57BL/6J). Briefly, these 
animals display no activity or anxiety phenotype in the Open Field test or the 
Elevated Plus Maze; and show normal performance in the Hanging Wire test, 
indicating normal muscle strength. They do, however, show a mild but significant 
motor learning defect on the Accelerating Rotarod, and mild breathing problems 
were recorded in the majority of animals from 20 weeks of age. Like the ΔNC-EGFP 
animals they have increased body weight, but in the ΔC cohort the two heaviest 
animals (out of a cohort of ten) died during the course of the year-long scoring 
experiment: one at 40 weeks and one at 48 weeks (Lagger and Selfridge, 
unpublished). Although both the ΔNC-EGFP and ΔC mice show a mild but 
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significant phenotype in one behavioural test (the ΔNC-EGFP mice have decreased 
anxiety in the Open Field test and the ΔC mice have reduced motor learning on the 
Accelerating Rotarod), the fact that these results are not reproduced by the other 
mouse line weakens their significance. More surprising is the reduced survival and 
mild breathing abnormalities in the ΔC line given that these mice could be 
considered biochemically more ‘normal’: the protein is not fused to an EGFP epitope 
tag and it is expressed at wild type levels in the brain (Lagger, unpublished). 
Therefore, the negligible phenotype of the ΔNC-EGFP knock-in mice may be due to 
a positive effect on protein function by either fusion with the EGFP tag or its slightly 
higher expression level. 
 
5.4.4 Additional deletion of the Intervening region results in mild RTT-like 
symptoms: should these mice be considered a model of Rett syndrome? 
 
Mice expressing ΔNIC-EGFP, the most severely truncated of the three MeCP2 
mutant proteins in this study, displayed mild RTT-like symptoms: gait abnormalities, 
hind-limb clasping, decreased anxiety (in the Elevated Plus Maze) and motor 
dysfunction (on the Accelerating Rotarod). Despite this, they are fertile and have a 
normal lifespan. Although one animal in the scoring cohort was found dead at 43 
weeks, it had only developed very mild symptoms up to that point. Its cause of death 
is therefore likely to be unrelated to the genetic mutation.  
 
To determine whether these mice should be classed as a model of RTT syndrome, I 
compared my results to characterisation of an Mecp2-mutant model expressing a 
RTT-causing mutation at the milder end of the severity spectrum, R133C. The 
R133C mutation is a common cause of a milder form of classical Rett syndrome in 
patients (Cuddapah et al., 2014), and has been shown to cause a milder phenotype in 
a series of EGFP-tagged mutant mouse models (Brown, Selfridge et al., 2016). 
R133C-EGFP mice have been characterised using the same methods after 
backcrossing onto a C57BL/6J background, facilitating direct comparison between 
these mice and the ΔNIC-EGFP mice. Hemizygous male R133C-EGFP mice display 
many of the features of RTT, including reduced survival, gait abnormalities, hind-
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limb clasping, tremors and hypoactivity. Their cumulative scores increase to an 
average of ~5 by 32 weeks when they plateau. Behavioural characterisation was 
performed at 8-10 weeks (Brown, Selfridge et al., 2016) and at 20 weeks (Brown, 
unpublished), the latter being the same age as the ΔNIC-EGFP in this study. R133C-
EGFP mice of both ages show decreased anxiety in the Elevated Plus Maze and 
reduced muscle strength in the Hanging Wire test. They do not, however, display 
altered activity or anxiety in the Open Field test or affected performance on the 
Accelerating Rotarod. Overall, the phenotype of these animals is more severe than 
that of the ΔNIC-EGFP mice as the truncated mice do not have reduced survival, 
have lower cumulative scores (Fig. S11) and do not develop tremors. 
 
Another useful comparator is a novel mouse model of RTT, expressing MeCP2 with 
the P225R mutation. Notably, this is one of the three ‘unexplained’ RTT-causing 
mutations that lie outside the MBD and NID (see section 1.6.2), and it is located in 
the Intervening region that has been deleted in the ΔNIC-EGFP mice but retained in 
the other two truncated proteins. There are an insufficient number of patients with 
this mutation to determine where it fits on the disease severity scale, but the 
phenotype displayed by the P225R knock-in mice is milder than the other mouse 
models. These animals have a median survival of 51 weeks (longer than 42 weeks for 
the R133C-EGFP mice). They do, however, display RTT-like symptoms including 
hind-limb clasping, gait abnormalities and tremors from an early age, with their 
average cumulative scores increasing to ~5-6 by 32 weeks. Behavioural 
characterisation of these mice reveals hypoactivity, decreased anxiety, and reduced 
muscle strength at 12 weeks of age (Guy and Selfridge, unpublished). Unfortunately, 
the younger age of testing limits the comparison to the ΔNIC-EGFP for these assays. 
Nevertheless, it is clear that have a more severe phenotype than the ΔNIC-EGFP 
mice presented in this study (Fig. S11). I therefore conclude that the ΔNIC-EGFP 





5.4.5 Concluding remarks 
 
In summary, the absence of RTT-like symptoms in the ΔN-EGFP and ΔNC-EGFP 
mice strongly suggests that both the N-terminal region before the MBD and the long 
C-terminus after the NID are dispensable for MeCP2 function in vivo. This result is 
striking as together these regions make up 46% of the MeCP2 protein sequence. 
Despite their length, these regions contain relatively few of the mapped MeCP2 
interaction domains and post-translational modifications (Fig. S7 and Table S2). 
These regions contain the binding sites for the heterochromatin protein HP1ɣ 
(Agarwal et al., 2007), miRNA processing complex component DGCR8 (Cheng et 
al., 2014a), and the majority of the mapped splicing factor interaction sites 
(Buschdorf and Strätling, 2004; Young et al., 2005). The ΔNC-EGFP mice could 
therefore be used to uncouple these interactions and their associated functions with 
the RTT phenotype. This is discussed further in Chapter 7. 
 
Mice expressing the shortest truncation, ΔNIC-EGFP, show mild RTT-like 
symptoms but their phenotype is much less severe than all existing mouse models 
carrying mutations that cause Classical RTT in patients. Therefore, I do not consider 
them to be a model of Rett syndrome. Their symptoms may be a result of three 
factors: lower protein levels in the brain, reduced ability to recruit the NCoR/SMRT 
co-repressor complex to chromatin in vivo, or to loss of a function that requires the 
Intervening region. Further work (discussed in Chapter 7) is needed to distinguish 
between these three factors: the first and second of which are consistent with the 







Chapter 6 – Induced activation of ΔNIC-EGFP after onset of symptoms 
reverses the Mecp2-null phenotype 
 
6.1 Introduction and aims 
 
Previous work has shown that induced activation of wild-type MeCP2 after the onset 
of symptoms in Mecp2-deficient mice leads to recovery of neurological function in 
both hemizygous males and heterozygous females (Guy et al., 2007). This result was 
a major milestone in the RTT field as it showed that Rett syndrome is caused by 
defective neurological function rather than being a neurodevelopmental disease. 
Importantly, this was a proof-of-principle experiment that showed reintroduction of 
functional MeCP2 into RTT patients had the potential to relieve symptoms of the 
disease. This led to gene therapy studies using Mecp2-mutant mice (Garg et al., 
2013; Gadalla et al., 2013; reviewed by Katz et al., 2016).  
 
In order to determine whether the Methyl-CpG Binding Domain (MBD) and 
NCoR/SMRT Interaction Domain (NID) are sufficient for MeCP2 to restore function 
to mature neurons in Mecp2-deficient mice, I repeated the genetic activation 
experiment described in Guy et al. (2007) using the ΔNIC-EGFP allele. A second 
reason for this experiment was that the packaging capacity of viral vectors used for 
gene therapy limits the choice of regulatory elements that can be included. Reducing 
the length of the Mecp2/MECP2 cDNA sequence in these vectors would potentially 
allow for better control of its expression. MeCP2 dosage is extremely important as 
too much MeCP2 results in MECP2 Duplication syndrome (van Esch et al., 2005). 
This chapter describes the results of the genetic activation experiment where the 





6.2 Generation of STOP mice and method to activate the ΔNIC-EGFP allele 
 
6.2.1 Breeding program to retain the NeoSTOP cassette and characterisation of the 
STOP mice 
 
The targeting vector used to create all three knock-in ES cell lines (Fig.  4.2.1A) was 
the same one that was used to create the null-like ‘STOP’ mice by Guy et al. (2007). 
This vector introduced a neomycin resistance gene and transcriptional stop cassette 
flanked by loxP sites (‘floxed’) into intron 2 of the Mecp2 gene. To create the lines 
that express the truncated MeCP2 alleles, the chimaeras containing the targeted ES 
cells were bred with CMV-Cre homozygous females leading to the removal of the 
cassette. In contrast, for this experiment, I wanted to produce STOP mice that do not 
express the truncated MeCP2 protein (ΔNIC-EGFP) but have the potential for this 
gene to be activated. These animals retained the floxed NeoSTOP cassette, which 
silences transcription of the ΔNIC-EGFP gene. This STOP allele is activatable upon 
recombination with Cre recombinase, which excises the floxed NeoSTOP cassette. 
To produce STOP mice, some of the ΔNIC-EGFP chimaeras were bred with wild-
type C57BL/6J females (Fig. 6.2.1A, Table 4.3.1). As before, the first hemizygous 
males were in the N=2 generation (75% C57BL/6J). These animals have very low 
levels of protein that was only just detectable by western blotting (Fig. 6.2.1Bi). This 
was more easily quantified using flow cytometry analysis of nuclei obtained from 
whole brains: 2.7% of WT-EGFP and 5.7% of ΔNIC-EGFP levels (Fig. 6.2.1Bii). 
Very similar values were obtained for neuronal (high NeuN) nuclei: 2.6% and 6.4% 
of WT-EGFP and ΔNIC-EGFP levels, respectively. A follow-up paper to the original 
genetic reversal study estimated the protein level in the STOP(WT) mice to be 
around 2.5% of wild-type levels (Robinson et al., 2012), which would be around 
1.6% of WT-EGFP levels. The higher levels observed here in the STOP(ΔNIC-
EGFP) mice is surprising given the lower levels of ΔNIC-EGFP protein in the 
knock-in mice. This result may be due to the higher sensitivity of flow cytometry 







Figure 6.2.1A: Mouse breeding programme to produce MeCP2-deficient 
mice with the potential to activate ΔNIC-EGFP 
Diagram of crosses and genotypes of offspring produced at each stage. The 
knocked-in truncated allele is denoted by *, the NeoSTOP cassette by ‘S’, 
CreERT by ‘Cretg’. Breeding pairs are indicated by black rectangles. Each 
generation is labelled by the number of times is has been backcrossed (N) and 
the resulting percentage of C57BL/6J background. 
Figure 6.2.1B: STOP mice express very low levels of ΔNIC-EGFP protein 
(Left) Western blot of crude whole brain extract derived from hemizygous male 
WT-EGFP, ΔNIC-EGFP and STOP mice (three biological replicates of each). 
MeCP2 was detected with a GFP antibody. Histone H3 was used as a loading 
control. ‘m’ =size marker, * = non-specific band. (Right) Nuclei were purified from 
the brains of WT-EGFP, ΔNIC-EGFP (see Fig. 4.4.1C) and STOP mice (three 
biological replicates of each genotype) and stained with anti-NeuN-Alexa Fluor 
647. Protein level was determined by EGFP fluorescence in all nuclei (n=50,000) 
and the neuronal (high NeuN) subpopulation (n>8,000). Graph shows mean and 
standard deviation (au = arbitrary units).Statistical analysis was performed using 




As expected, hemizygous male STOP mice developed RTT-like symptoms, 
resembling Mecp2-nulls. Mice were scored from 5 weeks of age, where symptoms 
were already apparent (Fig. 6.2.1Ci). The average score increased rapidly, similar to 
Mecp2-null animals, with symptoms resulting in premature death. The majority of 
STOP mice died between 6 and 18 weeks of age, although two individuals lived for 
32 and 45 weeks (Fig. 6.2.1Cii). The somewhat increased lifespan of the STOP 
animals compared to nulls is consistent with previous observations with the 
STOP(WT) mice (Guy et al., 2007; Robinson et al., 2012). The slight amelioration of 
the null phenotype in both STOP lines is likely to be due to the presence of low 
levels of MeCP2 protein. Although, it should be noted that the null data used for 
comparison was obtained from backcrossed mice – which is likely to contribute to 





6.2.2 Generation of mice with activatable ΔNIC-EGFP 
 
In order to achieve inducible activation of the ΔNIC-EGFP gene after the onset of 
symptoms, the CreER
T 
transgene was introduced into this line. This gene expresses 
Cre recombinase fused to a modified oestrogen receptor (ER
T
). The resulting protein 
is localised in the cytoplasm until injected Tamoxifen allows it to translocate into the 
Figure 6.2.1C: STOP mice resemble Mecp2-nulls 
Scoring (i) and survival (ii) curves for hemizygous male STOP(ΔNIC-EGFP) 
mice. STOP mice were scored from 5 weeks of age. STOP animals: scoring 
n=22, survival n=14. (Backcrossed) null scoring and survival data was obtained 
by Jacky Guy (Brown, Selfridge et al., 2016). Null animals: scoring n=12, survival 
n=24. STOP(ΔNIC-EGFP)  mice have significantly increased survival *** 
p=0.0008 (Mantel-Cox test). 
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nucleus, where it can excise the NeoSTOP cassette. This system was used by Guy et 
al. (2007), who showed that it is robust and non-leaky. Heterozygous STOP/+ 
females were bred with males that were heterozygous for the CreER
T
 transgene. This 
cross produces males of four genotypes: wild-type, wild-type CreER
T
, STOP, and 
STOP CreER
T
 (Fig. 6.2.1A). All four genotypes were included in the reversal 
experiment, in which all individuals received a series of Tamoxifen injections (see 
below). The STOP CreER
T
 individuals carry both the ΔNIC-EGFP allele with the 
floxed NeoSTOP cassette and the CreER
T
 transgene. They therefore develop 
symptoms before the successful excision of the NeoSTOP cassette upon Tamoxifen 
injection. The other three genotypes serve as controls: the wild-types (CreER
T
 
positive and negative) to check that the Tamoxifen injections do not result in toxicity 





6.2.3 Injection regime to activate the ΔNIC-EGFP allele 
 
It has previously been shown that rapid activation of Mecp2 causes toxicity (Guy et 
al., 2007). This study and the follow up study (Robinson et al., 2012) used more 
gradual injection regimes to successfully reverse symptoms in MeCP2-deficient 
mice. I used a similar regime of two weekly injections followed by five daily 
injections, each at a dose of 100 μg Tamoxifen/g weight. This procedure was started 
when the animals reached a symptom score of 2 or 3, when they were aged 12-17 
weeks of age. At this time point, they would expect to survive for another four 
weeks. The STOP(ΔNIC-EGFP) mice in this study developed symptoms more 
rapidly than the STOP(WT) animals, with eight out of nine STOP CreER
T
 
individuals reaching a score of two or more at 6 weeks of age (Table 6.2.3). Seven of 
these animals had developed a tremor and only one animal (number 5) had a lower 
score, with only gait abnormalities. Because of this somewhat earlier onset, I chose 
to begin the injection regime at this point for all STOP CreER
T
 animals and the wild-
type and STOP controls. Due to Cre toxicity (reviewed by Sharma and Zhu, 2014), 
the STOP animals that did not contain the CreER
T
 transgene had slightly lower 
scores than the CreER
T
 positive mice (Fig. 6.3.1i). This did not affect the validity of 
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the STOP animals to serve as controls in this experiment as their symptoms continue 
to progress in spite of Tamoxifen injection. If, however, the opposite had been true, 
the STOP animals would have more advanced symptoms that might reach a stage 
that is no longer reversible had the CreER
T
 allele been present. In this case, these 
animals would have required Tamoxifen injections from an earlier age (before their 
symptoms had progressed too far) to serve as proper controls. 
 
Mouse Total Activity Gait Clasping Tremor Breathing General 
condition 
1 (MGS19) 2 1 0 0 1 0 0 
2 (MGS20) 3 1 1 0 1 0 0 
3 (MGS36) 4 1 1 0 1 1 0 
4 (MGS49) 3.5 1 1.5 0 1 0 0 
5 (MGS52) 1 0 1 0 0 0 0 
6 (MGS6) 2.5 0.5 1 0 1 0 0 
7 (MGS21) 3 0.5 1.5 0 0 1 0 
8 (MGS33) 2.5 1 1 0 0.5 0 0 
9 (MGS50) 4 1 2 0 1 0 0 
Table 6.2.3: Scores of the nine STOP CreERT mice at 6 weeks of age, the day 
before the first Tamoxifen injection 
 
6.3 Successful phenotypic reversal after activation of ΔNIC-EGFP 
 
6.3.1 Reversed mice exhibited reduced symptoms and lived for the duration of the 
study 
 
As mentioned above, the STOP CreER
T
 and STOP mice had developed symptoms 
before the Tamoxifen injection regime was started. The injections halted the 
symptom progression in the STOP CreER
T
 mice, shown by the plateau in the score 
(Fig. 6.3.1i). By 12 weeks of age, their symptoms had reduced to almost the same 
levels as the wild-type controls. The scores of these animals remain around 2, similar 
to the ΔNIC-EGFP knock-in mice. All nine STOP CreER
T
 mice survived the 
duration of the experiment (28 weeks of age). The STOP mice that did not have the 
CreER
T
 transgene also developed symptoms from 4 weeks; and, as expected, these 
were not reversed by the Tamoxifen injections. Instead their symptoms progressed, 
resulting in premature death between 8 and 26 weeks of age (Fig. 6.3.1ii). The wild-
type control animals (both CreER
T
 positive and negative) displayed no RTT-like 
symptoms before the injections began, but later received low scores (mostly for 
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activity and gait) for the duration of the experiment. This relatively mild effect may 
be due to the Tamoxifen (or its oil solvent, which appeared to build up around the 
testes of some animals). Overall, this experiment shows that the severely truncated 
protein, ΔNIC-EGFP, is able to restore neuronal function in the STOP mice, 





6.3.2 Biochemical analysis shows high rates of recombination and protein 
expression in the brains of reversed mice 
 
The activation of ΔNIC-EGFP upon Tamoxifen injection can be analysed at both the 
DNA and protein level. Southern blot analysis using genomic DNA extracted from 
the brains of the reversed mice at the end of the experiment (28 weeks of age) shows 
the percentage of cells in which Cre-mediated recombination had occurred, excising 
the NeoSTOP cassette (Fig. 6.3.2A). The average recombination frequency was 
83.1% (range 73-90%). This is comparable to the original study, where the average 
recombination frequency was ~80% (Guy et al., 2007). 
Figure 6.3.1 Activation of ΔNIC-EGFP reverses RTT-like symptoms and 
prevents premature death in STOP CreERT mice 
Scoring (i) and survival (ii) curves for WT, WT CreERT, STOP and STOP CreERT 
mice, all injected with Tamoxifen (denoted by ‘+Tmx’). The time points of the 
seven Tamoxifen injections are shown by arrows on both graphs. 100% of WT, 
WT CreERT and STOP CreERT mice survived the duration of the experiment (28 





To determine if these high rates of recombination restore gene expression, the protein 
levels in these eight STOP CreER
T
 mice were analysed by western blotting (n=5) or 
flow cytometry (n=3). Western blot analysis using whole brain crude extract shows 
high levels of ΔNIC-EGFP protein in all five STOP CreER
T
 animals, which was not 
significantly different from the protein levels of the ΔNIC-EGFP mice (Fig. 6.3.2B). 
 
The protein levels in the other three reversed STOP CreER
T
 individuals were 
analysed instead by flow cytometry, using the fluorescence of the EGFP tag. Again, 
there was no significant difference between protein levels of STOP CreER
T
 mice and 
the ΔNIC-EGFP (Fig. 6.3.2C). Staining the nuclei with a NeuN antibody fused to 
Alexa Fluor 647 enabled the neuronal subpopulation to be analysed separately. 
Figure 6.3.2A High levels of recombination occurred in all the Tamoxifen-
treated STOP CreERT mice 
Southern blot using Bsu36I restriction enzyme (see Fig 4.3.2C for a map of 
restriction sites). Brain tissue from eight out nine STOP CreERT + Tmx mice was 
included in this analysis. The % of Cre-mediated recombination in each is given 
below. The STOP + Tmx mouse shows that no recombination could occur 
without the CreERT transgene. Other samples were included for reference. Note: 
the ninth STOP CreERT + Tmx mouse was perfused with paraformaldehyde to be 
used for microscopy (not yet carried out). 
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Again, the results were very similar but just over the threshold of significance: 87% 
of ΔNIC-EGFP levels, * p=0.016. These results agree with the level of Cre-mediated 












Figure 6.3.2B Cre-mediated 
recombination restored protein levels 
in STOP CreERT mice 
Western blot analysis using whole brain 
crude extract from five CreERT mice and 
one STOP mouse (all injected with 
Tamoxifen), compared to the ΔNIC-
EGFP knock-in line (n=3). The 
quantification shows the mean 
percentage protein level of the five 
CreERT individuals, relative to the ΔNIC-
EGFP controls. (Lysates were run on 
two replicate blots, values from which 
were combined in the quantification.) 
The protein level in the STOP CreERT 
mice was not significantly different from 
the ΔNIC-EGFP controls (t-test, 
p=0.437). ‘+Tmx’ denotes Tamoxifen 
injected animals. 
 
Figure 6.3.2C Cre-mediated 
recombination restored protein 
levels in the neurons of STOP 
CreERT mice 
Nuclei were purified from the brains 
of STOP CreERT mice (n=3, 
numbers 6-8) and ΔNIC-EGFP 
controls (n=3, see Fig. 4.4.1C) and 
stained with NeuN-Alexa Fluor 647. 
Protein level was determined by 
EGFP fluorescence in all nuclei 
(n=50,000) and the neuronal (high 
NeuN) subpopulation (n>8,000). 
Statistical analysis was performed 
using t-tests: all nuclei not 





Overall, the reversal of RTT-like symptoms by activation of the ΔNIC-EGFP allele 
was successful with high levels of recombination and protein expression, reflecting 




Genetic activation of ΔNIC-EGFP in MeCP2-deficient ‘STOP’ male mice after the 
onset of neurological symptoms successfully reversed the disease. High levels Cre-
mediated recombination resulting in protein levels similar to ΔNIC-EGFP mice were 
obtained in all eight Tamoxifen-injected STOP CreER
T
 animals that were analysed. 
In the future, the extent of activation of ΔNIC in specific brain regions or cell types 
could be analysed by microscopy using brain slices. The brain of the ninth STOP 
CreER
T
 animal in this cohort was perfused with paraformaldehyde to be used for 
this. Analysis of ΔNIC-EGFP protein levels in brain slices should reflect the results 
obtained by Southern blotting, western blotting and flow cytometry. The use of cell-
type specific markers for immunofluorescence will enable the determination of 
ΔNIC-EGFP levels in different cell types. 
 
The design of this experiment was almost identical to the initial study by Guy et al. 
(2007) who demonstrated successful disease reversal upon activation of the wild-
type protein. The experiment presented here differs only in two respects. Firstly, 
before the activation, the STOP(ΔNIC-EGFP) mice develop symptoms more rapidly 
than the previously described STOP(WT) mice. Both lines express low levels of 
MeCP2 protein, causing their phenotype to be slightly milder than Mecp2-nulls. The 
reduced stability and NCoR/SMRT complex binding activity of ΔNIC-EGFP 
(presented in Chapter 4) is consistent with this having a lesser effect on the STOP 
phenotype. The earlier symptom onset had no implications on the suitability of the 
STOP(ΔNIC-EGFP) mice for this experiment, it simply meant that the regime of 
Tamoxifen injections had to begin earlier to reflect their phenotypic scores: at 6 
weeks rather than 12-17 weeks. The second difference between these studies is that 
the protein introduced here, ΔNIC-EGFP, does not fully prevent RTT-like symptoms 
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in constitutively-expressing knock-in mice (see Chapter 5).  Therefore, complete 
reversal was not expected in these mice. Indeed, after Tamoxifen injections, the 
average scores of the reversed animals decreased and stabilised to ~2, similar to 
constitutively-expressing ΔNIC-EGFP mice of the same age. It is surprising, 
however, that the scores of the reversed mice in the original study by Guy et al. 
(2007) also stabilise around 2. To investigate whether reversal by ΔNIC-EGFP is as 
efficient as the wild-type protein, this experiment must be repeated with both 
genotypes intermixed and scored blind. 
 
In conclusion, introduction of ΔNIC-EGFP into MeCP2-deficient mice after 
symptom onset led to a dramatic reversal of the RTT phenotype. This experiment 
shows that the MeCP2 activities that are absent from the truncated ΔNIC-EGFP 
protein are not required to restore function to mature MeCP2-deficifient neurons. 











This study investigated whether the ability of MeCP2 to recruit the NCoR/SMRT co-
repressor complex to chromatin was sufficient for its function in vivo. This activity 
requires two domains of MeCP2: the MBD and the NID. I have produced knock-in 
mouse lines expressing truncated alleles of MeCP2 that lack the other three regions 
of the protein: the N-terminus before the MBD, the Intervening region between the 
MBD and the NID, and the C-terminus after the NID. These regions were deleted in 
a step-wise manner in increasingly short truncated proteins (Fig. 7.1). My results 
indicate that both the N- and C-terminal regions of MeCP2 (which together make up 
46% of the protein sequence) are dispensable for MeCP2 function. Additional 
deletion of the Intervening region between the MBD and the NID results in the 
presence of mild RTT-like symptoms, which may be due to reduced protein stability 
and/or reduced ability to bind the NCoR/SMRT co-repressor complex. This most 
severely truncated protein is nevertheless able to reverse the phenotype of MeCP2-






Figure 7.1: Stepwise truncations of MeCP2 protein 
(Copy of Fig. 3.1) Schematic diagram of the truncated proteins designed in this 
study, compared to the full length protein (WT-EGFP). Drawn to scale (e2 
isoforms). Linker sequences are shown as dark grey bars. Dotted lines denote 
corresponding regions between the proteins. 
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7.2 Further characterisation of the ΔN-EGFP and ΔNC-EGFP knock-in mice 
 
The three knock-in mouse lines (ΔN-EGFP, ΔNC-EGFP and ΔNIC-EGFP) produced 
in this study underwent extensive phenotypic characterisation. The methods used 
recorded the presence of overt RTT-like symptoms over the course of a year, and 
tested for activity, anxiety, muscle strength and motor coordination at 20-21 weeks 
of age (all presented in Chapter 5). While the results obtained for the ΔN-EGFP and 
ΔNC-EGFP mice strongly suggest that both the N- and C-termini may be dispensable 
for MeCP2 function in vivo, further behavioural testing may be required. It is clearly 
impossible to categorically prove the complete absence of a phenotype in these 
animals so instead I will briefly mention some tests of particular relevance. All of 
these tests have been used to detect more subtle phenotypes in Mecp2-mutant mice 
that carry milder mutations (i.e. mutations that do not cause RTT in patients). The 
well characterised mouse line expressing a C-terminally truncated allele 308/y 
(consisting of residues 1-308) displayed abnormal social interaction and nesting 
behaviour (Shahbazian et al., 2002b; Moretti et al., 2005). To better determine 
whether the addition of the extra four C-terminal amino acids (residues 309-312) 
included in the ΔNC-EGFP protein are sufficient to rescue the phenotype of the 
308/y mice, these behaviours should be tested. The C-terminal region contains a 
well-studied activity-dependent phosphorylation site (Ser421). Mice expressing the 
phospho-abolishing S421A mutant protein do not display any neurological symptoms 
except a reduced preference for novelty in the ‘3 Chamber Test’ (Cohen et al., 2011). 
Additional mutation of a nearby activity-dependent phospho-site (S424A) results in 
improved spatial memory in the Morris Water Maze and improved learning and 
memory in the context-dependent fear conditioning test (Li et al., 2011). Analysis of 
these behavioural paradigms in the ΔNC-EGFP mice will determine whether loss of 
the entire C-terminal region has less of a phenotypic effect than mutation of these 
phospho-sites. Finally, abnormal electrophysiology has been reported in all three of 
these mouse models (Shahbazian et al., 2002b; Cohen et al., 2011; Li et al., 2011) 
and also in mice expressing the A140V mutation, which causes milder intellectual 
disability in patients (Ma et al., 2014). It is therefore important to investigate this in 




As previously discussed, both increased and decreased body weight phenotypes are 
frequently reported in Mecp2-mutant mouse models. These are affected by genetic 
background so may not be of biological importance (Guy et al., 2001). Strikingly, 
mouse models of RTT consistently have reduced brain size, even if their body weight 
is increased (Baker et al., 2013; Heckman et al., 2014). Analysis of brain weights in 
the novel mice produced in this study is therefore an important part of their 
characterisation. I would not predict there to be a difference as this phenotype is not 
present in the 308/y animals (Shahbazian et al., 2002b). 
 
7.3 Investigating the cause of the mild RTT-like phenotype in the ΔNIC-EGFP 
mice 
 
Mice expressing the shortest of the three truncated proteins, ΔNIC-EGFP, exhibit 
mild RTT-like symptoms including gait abnormities, hind-limb clasping, impaired 
motor coordination and decreased anxiety. Biochemical characterisation of all three 
novel mouse lines shows that this protein differs from ΔN-EGFP and ΔNC-EGFP in 
two unexpected ways: ΔNIC-EGFP protein is present at lower level and has reduced 
binding to HDAC3 (the catalytic component of the NCoR/SMRT complex) in the 
brain. A negative phenotypic effect of one or both of these factors could be 
responsible for the neurological phenotype displayed by the ΔNIC-EGFP mice. 
Alternatively, their phenotype could be due to loss of an important function that 
requires the deleted Intervening region of MeCP2. Only the last of these three 
possibilities would contradict the ‘bridge’ hypothesis. 
 
7.3.1 Could reduced ΔNIC-EGFP protein levels be responsible for the phenotype in 
these mice? 
 
MeCP2 protein levels in the brains of the knock-in mice were analysed by western 
blotting and flow cytometry. Both techniques show that ΔNIC-EGFP levels are 
decreased compared to WT-EGFP controls, but to different extents. The higher and 
more reliable estimate (obtained by flow cytometry) estimates the ΔNIC-EGFP to be 
182 
 
48% of WT-EGFP levels in nuclei prepared from whole brains. Given the slightly 
elevated expression of the WT-EGFP protein (Brown, Selfridge et al., 2016), this 
could be as high as 76% of the endogenous untagged wild-type protein. This level is 
higher than that in the hypomorphic mice (floxed mice), which have 50% as much as 
wild-type controls (Samaco et al., 2008). As the hypomorphic mice have a milder 
phenotype than the ΔNIC-EGFP mice (Kerr et al., 2008; Cheval, Guy et al., 2012), 
reduced protein level is unlikely to be the sole cause of their mild RTT-like 
symptoms. Reduced proteins levels may, however, increase the severity of their 
phenotype. This could be investigated by overexpressing ΔNIC-EGFP from the Tau 
promoter, using the system developed by Luikenhuis et al. (2004). 
 
7.3.2 Could reduced ‘bridge’ function be responsible for the phenotype in the ΔNIC-
EGFP mice? 
 
Immunoprecipitation of these proteins from brain nuclear extracts indicated that 
binding affinity to the NCoR/SMRT complex component, HDAC3, is greatly 
reduced in the ΔNIC-EGFP truncated protein. This contrasts the earlier result 
obtained by transiently expressing these proteins in HeLa cells. Further analysis of 
NCoR/SMRT complex binding in the brain using this immunoprecipitation assay is 
required: particularly determining whether the same result is obtained for other 
members of the complex. However, difficulties in quantifying the amounts of these 
differently-sized proteins by western blotting may make quantification of their 
NCoR/SMRT binding affinities by this technique impossible. An alternative method 
of determining ‘bridge’ function is quantification of the TBL1X-mCherry 
recruitment assay (described in section 3.3.3). As shown in Fig. 3.3.3, the truncated 
proteins were able to bring TBL1X-mCherry to heterochromatin, but the percentage 
of cells in which this occurs was not calculated. Previous studies have shown this 
assay to be quantitative: wild-type MeCP2 recruits TBL1X-mCherry to 
heterochromatin in 55-70% of cells and the NID mutant, R306C, recruits TBL1X-
mCherry in 0% of cells (Lyst et al., 2013). Strikingly, recent analysis of the two 
‘unexplained’ proline mutants (P225R and P322L), showed that although they are 
both localised at pericentromeric heterochromatin when overexpressed in NIH-3T3 
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cells and can bind endogenous NCoR/SMRT complex components in HEK293 cells, 
they are only able to recruit TBL1X-mCherry in 20-30% of cells (Guy and 
Alexander-Howden, unpublished). Therefore, quantification analysis of this assay 
may uncover defects in ‘bridge’ function in the truncated proteins that I have missed. 
 
More quantitative analysis of the ability of ΔNIC-EGFP to form the other end of the 
‘bridge’, i.e. binding to methylated DNA, is also required. The method used to assess 
DNA binding in this study (localisation of MeCP2 mutant proteins to 
heterochromatic foci in mouse cells) has been used to shown defective binding of a 
large number of MBD-mutants (Table S3; e.g. Kudo et al., 2003). As several RTT-
causing MBD mutants showed normal localisation at heterochromatic foci, their 
binding abilities have been investigated further using Fluorescence Recovery After 
Photobleaching (FRAP) (Schmeideberg et al., 2009). This study showed that wild-
type MeCP2 had a residence time on heterochromatin of 15 seconds, which was 
decreased dramatically in MBD mutants. Importantly, only those mutants with 
residence times of less than ~5 seconds showed diffuse nuclear staining upon 
fixation - making FRAP more informative than localisation. FRAP analysis could 
therefore be used to further investigate the methylated DNA binding ability of ΔNIC-
EGFP. Alternative methods of analysis include a variety of in vitro techniques using 
purified proteins, which enable a dissociation constant (KD) to be calculated. The 
most commonly used technique, electrophoretic mobility shift assay (EMSA), may 
be unsuitable for this as full-length MeCP2 gets trapped in the wells of the gels so an 
N-terminal fragment (residues 1-205) is often used (Klose et al., 2005). It may be 
possible to use this technique to compare the binding of ΔNC and ΔNIC (without the 
EGFP tag), but other in vitro techniques such as Surface Plasmon Resonance (used 
by Mellén et al., 2012) may be more informative. 
 
Determining the methylated DNA binding abilities of ΔNIC-EGFP in neurons may 
be more difficult. The presence of the EGFP tag in the knock-in mice expressing the 
truncated MeCP2 proteins permits FRAP analysis using brain slices or cortical 
neurons derived from these mice. Alternatively, the knock-in ES cells produced in 
this study could be differentiated into neurons in culture and used for FRAP analysis. 
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FRAP has been used successfully to measure protein dynamics in ex vivo brain slices 
(e.g. Tønnesen et al., 2014) and cultured neurons (e.g. Caron et al., 2014). 
Unfortunately, however, preliminary studies quantifying MeCP2 dynamics at 
heterochromatic foci in cultured ES cell-derived neurons found that the foci moved 
in the Z plane (after photobleaching), where they could not be tracked – making 
measurement of recovery impossible (unpublished observations from the Bird lab). 
An alternative strategy was used by Goffin et al. (2012) to show reduced binding of 
the MBD mutant, T158A, in the brains of knock-in mice. They showed that this 
mutant protein was more readily extracted at lower NaCl concentrations than the 
wild-type protein, indicating weaker binding to DNA. As discussed in section 4.4.3, 
ΔNIC-EGFP was more readily extracted than the longer MeCP2 mutants using 
150mM NaCl and benzonase. Further analysis is required to determine its extraction 
efficiency under a variety of NaCl concentrations in the absence of benzonase. As 
percentage extraction is quantified by calculating the amount of protein extracted at 
each concentration as a fraction of the total (i.e. with 500mM NaCl and benzonase), 
its quantification would not require comparison between the differently sized 
truncation proteins,  making western blotting suitable for this assay. 
 
7.3.3 Is it possible to design a minimal MeCP2 protein with full stability and bridge 
activity 
 
In order to properly determine whether NCoR/SMRT complex recruitment activity is 
sufficient for MeCP2 function in vivo, I would need to alter the design of ΔNIC-
EGFP to restore full stability and bridge activity. Although low ΔNIC-EGFP protein 
levels despite high mRNA levels indicates that this protein is unstable, this would 
first have to be confirmed. Goffin et al. (2012) demonstrated instability of the MBD 
mutant, T158A, by treating cultured cortical neurons derived from knock-in mice 
with cycloheximide, which inhibits new protein translation. They show significantly 
reduced protein levels in T158A knock-in cells compared to wild-type controls after 
six hours of cycloheximide. Importantly, although this assay uses western blotting 
for quantification of protein levels, normalisation of protein levels at each time point 
to untreated samples makes it suitable to compare the stability of proteins of different 
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sizes. If a difference is found in this assay, it might be useful to determine how 
ΔNIC-EGFP is degraded in order to design a more stable version. A recent study 
treated T158M-expressing cell lines with inhibitors of several degradation pathways: 
calpain (with calpeptin), autophagy (with 3-methyladenine), lysosome (with 
ammonium chloride) and proteasome (with MG132 or lactacyctin). They identified 
the proteasome as the predominant pathway, with greatest elevation of T158M levels 
in MG132- and lactacystin-treated samples (Lamonica et al., 2017). This assay could 
be used to determine the pathway responsible for ΔNIC-EGFP degradation in ΔNIC-
EGFP-expressing cells, e.g. cortical neurons derived from knock-in mice. 
 
Thambirajah et al. (2009) describe two predicted PEST sequences in MeCP2, a 
common feature of intrinsically disordered proteins. These sequences are 
proline/glutamic acid/serine/threonine rich and promote degradation by the 26S 
ubiquitin proteasome system (UPS) after phosphorylation of serine residues a 
subsequent poly-ubiquitination on nearby lysines (reviewed by Ausió et al., 2014). 
The two predicted PEST sequences in MeCP2 consist of the N-terminal residues 61-
82 (PEST1) and the C-terminal residues 377-412 (PEST2). Notably, part of PEST1 
and all of PEST2 is missing from both ΔNC-EGFP and ΔNIC-EGFP. I used the 
ePESTfind predictor tool (http://emboss.bioinformatics.nl/cgi-bin/emboss/epestfind) 
to look for predicted PEST sequences in these truncated proteins. Although this tool 
found the two predicted PEST sequences in the full-length sequences, no PEST 
sequences were found in either of the truncated proteins. Therefore, this is unlikely to 
be the pathway responsible for ΔNIC-EGFP degradation. 
 
Given that the levels of both ΔN-EGFP and ΔNC-EGFP proteins are similar to WT-
EGFP in the brains of knock-in mice, it is most likely that replacement of the 
Intervening domain with the exogenous linker and SV40 NLS is responsible for 
protein instability. Structural information of this region in both the wild-type and 
truncated proteins could uncover any mis-folding in ΔNIC-EGFP. Novel mass 
spectrometry-based methods that analyse crosslinked peptides can be used to 
determine intramolecular interactions in MeCP2, which had previously been 
impossible as it is so highly disordered. Surprisingly, recent analysis has identified 
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multiple crosslinks in part of the Intervening region: residues 212-237 (Connelly and 
Belsom, unpublished). This sequence is highly conserved in evolution (Fig. S2) and 
contains the ‘unexplained’ RTT-causing mutation, P225R, that causes instability 
(Guy, unpublished). Structural analysis of ΔNIC-EGFP (ideally compared to ΔNC-
EGFP) is needed to determine how deletion of this region affects its structure. 
 
It is also important that an alternative minimal MeCP2 protein has full bridge 
activity. I have already discussed methods of determining whether this is reduced in 
ΔNIC-EGFP (see section 7.3.2). If reduced activity is detected in one or more of 
these assays, they could be used to determine whether full activity is restored in 
alternative designs. Some of these assays (e.g. FRAP and SPR) require transiently-
expressed or purified MeCP2 protein so could easily be used to test multiple designs. 
Other assays require the Mecp2 alleles to be stably expressed – which is more labour 
intensive. Although I have discussed assays that use brain tissue from knock-in mice, 
it is likely that ES cell-derived neurons could also be used.  
 
It is yet to be determined whether ΔNC-EGFP has mildly decreased NCoR/SMRT 
complex binding activity in vivo – as suggested by the slight reduction in HDAC3 
that was co-immunoprecipitated from ΔNC-EGFP brains (compared to WT-EGFP 
and ΔN-EGFP samples). Further investigation of the bridge activity of ΔNC-EGFP 
protein (using the assays described in section 7.3.2) is needed to determine whether 
deletion of the Intervening region is solely responsible for reduced activity in ΔNIC-
EGFP. If ΔNC-EGFP has reduced activity, it may be necessary to alter which 
residues in the N- and C-terminal regions are removed. Alternative epitope tags can 
also be used. If, however, ΔNC-EGFP does not have reduced activity, only the 
intervening linker sequence would need to be changed. The NID used in this study 
was extended at the N-terminal end to include a predicted α-helix (Fig. S4; see 
Chapter 3). This was almost certainly unnecessary as recent analysis of 
NCoR/SMRT complex binding by MeCP2 has reduced the minimal NID sequence to 
298-309 (Kruusvee et al., 2017). New designs could therefore use a shorter NID 
sequence. One possible reason for decreased bridge activity in ΔNIC-EGFP is steric 
hindrance between the MBD and the NID as a result of bringing them closer 
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together. This could be overcome by replacing the Intervening region with a flexible 
linker sequence of similar length.  While such a design would no longer infer such a 
great advantage for Gene Therapy due to its increased sequence length (see section 
7.5.1), its use would still robustly test the bridge hypothesis as potentially 
dispensable native MeCP2 sequences have been removed. 
 
7.4 Uncoupling the RTT phenotype from other proposed functions of MeCP2 
 
Given the absence of RTT-like symptoms in ΔN-EGFP and ΔNC-EGFP hemizygous 
male mice, these lines could be used as a vital tool to uncouple some of the proposed 
interactions and their associated molecular phenotypes from disease. Although the 
shorter of the two truncations (ΔNC-EGFP) is missing half of the full-length amino 
acid sequence, only a few of the mapped binding sites are deleted. The N-terminus 
contains the full binding site for HP1ɣ (Agarwal et al., 2007) making the loss of this 
interaction likely in these truncation proteins. Deletion of the N-terminal region may 
also affect binding to FOXG1 (Dastidar et al., 2012). This region contains five 
identified post-translational modifications, of which only one (pSer13) has been 
studied (Yasui et al., 2014). Deletion of the C-terminus is highly likely to abolish 
binding to the splicing factors, FBP11 and HYPC (Buschdorf and Strätling, 2004), 
the miRNA processing component, DGCR8 (Cheng et al., 2014a), and the kinase, 
CDKL5 (Mari et al., 2005), as all four interactions have been shown to be lost by 
removal of C-terminal fragments. Additionally, the C-terminally truncated protein 
consisting of residues 1-308 was shown to only interact very weakly with a third 
splicing factor, YB-1 (Young et al., 2005). Further analysis is required to determine 
whether the addition of the extra four amino acids present in ΔNC-EGFP are 
sufficient to restore full YB-1 binding. The C-terminal region contains six identified 
post-translational modifications, of which only two (pSer421 and pSer424) have 
been characterised in vivo (Tao et al., 2009; Cohen et al., 2011; Li et al., 2011). Their 
phenotypes are discussed above in section 7.2. Lastly, the extreme C-terminus has 
been proposed to be required for intramolecular interactions that are regulated by 




7.4.1 Confirming the loss of these interaction partners in the N- and C-terminally 
truncated proteins 
 
Three functions stand out that could be affected by the deletion of both termini: 
complete loss of the ability to regulate miRNA processing (via DGCR8), and partial 
loss of alternative splicing regulation (via FBP11, HYPC and YB-1) and chromatin 
condensation (via HP1ɣ). To investigate whether the truncated proteins can perform 
these functions, I would first confirm their inability to bind the relevant MeCP2 
interaction partners using immunoprecipitation experiments. These could be 
performed with brain nuclear extracts (using WT-EGFP brains as a positive control) 
to determine binding abilities in neurons; and using transient overexpression in HeLa 
cells, enabling additional truncations to be used as controls (for example, sequences 
matching the ones used in the original mapping of these interactions). 
 
7.4.2 Uncoupling miRNA processing dysfunction from the RTT phenotype 
 
If binding to the miRNA processing complex is lost in ΔNC-EGFP but not ΔN-
EGFP, as predicted by its mapping to the C-terminus (Cheng et al., 2014a), miRNA 
processing defects would be predicted in the ΔNC-EGFP mice but not the ΔN-EGFP 
mice. Genome-wide miRNA processing defects could be analysed by RNA-
sequencing of the non-coding RNA fraction and then comparing both these lines to 
the previous data obtained using null mice (Cheng et al., 2014a; Tsujimura et al., 
2015). This experiment could uncouple miRNA processing defects (if they are 
present in ΔNC-EGFP mice) with RTT-like symptoms. A smaller scale experiment 
could focus on miR-199a, a miRNA reported to be processed by MeCP2 that 
regulates cell size via the AKT/mTOR pathway (Tsujimura et al., 2015). Levels of 
primary, precursor and mature miR-199a RNAs could be analysed by quantitative 
PCR to determine whether it is normally transcribed (primary transcript) but 
inefficiently processed (precursor and mature RNAs) in brains of the ΔNC-EGFP 





7.4.3 Uncoupling alternative splicing dysfunction from the RTT phenotype 
 
Deletion of the C-terminus is likely to abolish binding to three of splicing factors that 
interact with full-length MeCP2: FBP11, HYPC and YB-1 (Buschdorf and Strätling, 
2004; Young et al., 2005). As described above, loss of these interactions would first 
have to be confirmed. The 308/y mice could also be used as a comparator as this 
protein has been shown to have greatly reduced binding to YB-1 (Young et al., 2005) 
and is missing the other two interaction domains. mRNA-sequencing analysis could 
be used to determine whether the splicing defects observed in the null (Li et al., 
2016) and 308/y (Young et al., 2005) mice are also present in the ΔNC-EGFP mice 
but not the ΔN-EGFP mice. This experiment could uncouple splicing defects (if they 
are present in ΔNC-EGFP mice) with RTT-like symptoms. 
 
7.4.4 Uncoupling loss of HP1ɣ binding from the RTT phenotype 
 
The least well-studied of these three functions is the role of the heterochromatin 
protein, HP1ɣ, when complexed to MeCP2. This interaction has been shown to 
require the deleted N-terminal region (Agarwal et al., 2007) so is likely to be 
abolished in ΔN-EGFP.  If so, the myoblast system used by Brero et al (2005) could 
be used to determine whether ΔN-EGFP has reduced chromatin condensation activity 
compared to the WT-EGFP protein. This is measured by a reduced number of 
chromocentres due to their clustering. Loss of HP1ɣ binding by MeCP2 may result in 
lower levels of HP1ɣ localisation, and as a result reduced H3K9 trimethylation, at 
heterochromatin (Agarwal et al., 2007). This method may identify differences in 
chromatin remodelling activity between these proteins but it would tell us very little 
about how chromatin structure is affected in the brain by the loss of HP1ɣ binding. 
Although the novel 3D imaging technique (ChromATin) developed by Linhoff et al. 
(2015) detected increased chromatin density in Mecp2-null neurons in female 
Mecp2+/- brains, it is yet to be determined whether it can detect potentially subtler 
differences in neurons expressing mutant MeCP2 proteins that cause milder 
phenotypes, e.g. those that retain MBD function. It may be that this technique is not 
sensitive enough to detect a change in chromatin condensation in ΔN-EGFP mice, 
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which is predicted to be subtle given that all other domains in MeCP2 that have been 
attributed to chromatin remodelling activity are retained in this protein. 
 
7.4.5 Uncoupling loss of intramolecular interactions from the RTT phenotype 
 
It has long been considered that MeCP2 is highly unstructured (Ghosh et al., 2011). 
This belief is now being challenged with increased evidence of intramolecular 
interactions (Cheng et al., 2014a; Connelly and Belsom, unpublished). Additionally, 
changes in MeCP2 conformation upon S80 dephosphorylation have be proposed to 
regulate its activity, with intramolecular binding rendering it less active (Cheng et al., 
2014a). It is therefore likely that loss of these interactions due to deletion of required 
regions of MeCP2 results in a constitutively active state. Cheng et al. (2014a) 
demonstrate the intramolecular interaction using two independent methods. Firstly, 
they showed direct interaction between N- and C-terminal fragments of MeCP2 by 
co-immunoprecipitation. As the division between these fragments is residue 305/306, 
this method is unsuitable for determining whether intramolecular binding is lost in 
proteins truncated after residue 312 (the C-terminal fragment would only consist of 
residues 306-312). The second strategy they used could, however, prove to be 
informative. They used FRET (Fluorescent Resonance Energy Transfer) between 
CFP (cyan fluorescent protein) fused to the N-terminus and YFP (yellow fluorescent 
protein) fused to the C-terminus to detect interactions between the two ends of 
transiently-expressed proteins in cultured cells. Expression in mouse cortical neurons 
enabled them to determine the effects of Ser80 dephosphorylation upon stimulation 
with KCl. They show that stimulation leads to an increase in intramolecular binding 
(FRET efficiency). This technique could be used to determine whether similar 
conformational changes occur upon neuronal stimulation in the truncated proteins. 
Their C-terminal EGFP tag could be utilised as part of the fluorescent protein pair in 
this analysis, combined with an N-terminal mCherry tag (Albertazzi et al., 2009). 
Loss of the activity-dependent intramolecular interaction in ΔNC-EGFP protein 




7.4.6 Preservation of transcriptional regulation in the phenotypically normal ΔN-
EGFP and ΔNC-EGFP mice? 
 
As well as uncoupling potentially less important roles, it is important to demonstrate 
correct gene repression via NCoR/SMRT complex recruitment in ΔN-EGFP and 
ΔNC-EGFP mice. The regions of MeCP2 protein retained in both truncations include 
all of the mapped sites for transcriptional repressors, which all lie within the 
historically defined Transcriptional Repression Domain (TRD). As the binding sites 
of the two transcriptional activators (CREB1 and MYCN) have not been mapped, it 
is impossible to predict whether the truncated proteins retain these interactions. If 
either, all the interactions with transcriptional repressors and activators are retained, 
or NCoR/SMRT recruitment is sufficient for proper MeCP2-mediated transcriptional 
regulation, then it could be predicted that gene expression patterns are unaltered in 
ΔN-EGFP and ΔNC-EGFP mice. RNA-sequencing analysis using tissue samples 
from these mouse lines would determine whether this is the case. Analysis of this 
data should pay particular attention to the regulation of long genes and genes that 
have potential phenotypic consequences.  
 
A possible caveat to the interpretation of this experiment would be if defective 
miRNA processing or alternative splicing had downstream effects on mRNA 
transcript levels. Altered levels of mature miRNAs could affect the transcript levels 
of their target genes and mis-spliced transcripts could have altered stability. In this 
case, analysis of nascent transcription could be performed. Given the proposed role 
of MeCP2 in the regulation of transcriptional elongation in gene bodies (Kinde et al., 
2016; Cholewa-Waclaw and Shah, unpublished), analysis of transcriptional 
elongation is likely to be most informative. Either Global nuclear Run On-
sequencing (GRO-seq) or Native Elongating Transcript sequencing (NET-seq) could 
be used for this. GRO-seq involves the purification of nuclei, from which lysates are 
used for in vitro transcription with BrdUTP. The resulting nascent transcripts are 
purified with an antibody that recognises BrdUTP and then sequenced (Core et al., 
2008). NET-seq is a newer technique that analyses nascent transcripts that have been 
transcribed in vivo. The chromatin fraction is obtained from nuclei and treated with 
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MNase before immunoprecipitation of elongating RNA polymerase II 
(phosphorylated at Ser2 in the C-terminal domain) using a phospho-specific 
antibody. The associated RNAs are then sequenced (Nojima et al., 2015). So far, 
only GRO-seq has been used for the analysis of nascent transcription in tissues 
(mouse liver by Fang et al., 2014). Analysis of nascent RNA transcription in Mecp2-
mutant mouse models may be of particular value to the field as these techniques also 
detect spurious unstable transcripts, which are  missed in standard RNA-seq 
experiments due to their rapid degradation. Skene et al. (2010) observed that loss of 
MeCP2 results in elevated transcription from repeated regions (analysed by qPCR) 
that can be detected in nuclear RNA but not total RNA preparations. It is possible 
that there are more global defects in spurious or abortive transcription that have so 
far been overlooked. A final complication is differentiating between a MeCP2-
mediated global effect of transcription via recruitment of transcriptional 
repressors/activators or by altering global chromatin structure via recruitment of 
chromatin remodelling enzymes. HP1ɣ is the only protein involved in chromatin 
remodelling whose interaction is thought to be lost in the truncated proteins, ΔN-
EGFP and ΔNC-EGFP.As HP1ɣ is found mainly in constitutive heterochromatin 
rather than gene-rich regions, loss of HP1ɣ-binding is likely to have minimal effects 
of transcription. 
 
7.5 Therapeutic advantages of truncating MeCP2 
 
7.5.1 The use of the truncated Mecp2 alleles in Gene Therapy 
 
While the primary reason for investigating the functionality of truncated MeCP2 
proteins in this study was to test the bridge hypothesis, the restricted packaging 
capacity of viral vectors used for Gene Therapy meant that reducing the essential 
coding sequence length could be a therapeutic benefit. To be useful for Gene 
Therapy, truncated MeCP2 has to be sufficient not only to prevent the onset of 
neurological symptoms (as seen in the knock-in mice that constitutively express 
these proteins), but it is also able to reverse these symptoms. I therefore used the 
Cre/loxP system designed by Guy et al. (2007) to induce activation of the shortest 
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truncated allele, ΔNIC-EGFP, in symptomatic MeCP2-deficient male mice, resulting 
in successful symptom reversal and prevention of premature death. This result 
suggests that recruitment of the NCoR/SMRT complex to chromatin is the key 
function of MeCP2 required for restoring function to mature MeCP2-deficient 
neurons. It is highly likely that similar results would be obtained using the other two 
less severe truncations: ΔN-EGFP and ΔNC-EGFP. 
 
A recent Gene Therapy study using Mecp2-null male mice by our collaborators at the 
University of Glasgow (Stuart Cobb’s lab) optimised conditions to improve 
transduction efficiency and symptom reversal. These are the best results to date, 
delaying premature death by ~26 weeks (Table 1.3.7; Gadalla et al., 2017). One of 
the key parameters in this study was the use of self-complementary AAV vectors, 
which have half the packaging capacity than other vectors (e.g. single stranded AAV 
vectors) – 2.2 kb of exogenous DNA. As the full-length MECP2 cDNA sequence is 
1.5 kb long, only 700 bp remained for regulatory elements. They developed a vector 
(Fig. 7.5.1) that included a 426 bp fragment of the mouse Mecp2 promoter and 
selected regions of the 3’UTR (including conserved miRNA recognition sites). In 
order to explore the therapeutic potential of the truncated MeCP2 proteins, they must 
first be tested using the same optimised conditions developed by Gadalla et al. 
(2017). For this, the large C-terminal EGFP tag must be removed and replaced with a 
C-terminal Myc tag, consistent with the wild-type vector. Therefore, this experiment 
would determine the functionality of these proteins without EGFP. If viral delivery 
of these alleles can successfully prevent neurological symptoms in the Mecp2-null 
mice, further experiments can be performed using alternative regulatory elements 
that may better control dosage and improve symptomatic rescue. These regulatory 
elements can utilities the extra packaging capacity that results from shortening the 
coding sequence (Fig. 7.5.1). 
 
A major concern for Gene Therapy is toxicity from overexpression: resulting in 
neurological dysfunction in the brain or liver toxicity if viral vectors preferentially 
infect the liver. The study by Gadalla et al. (2017) found that there is an extremely 
narrow dosage window between inefficient rescue and overexpression-induced 
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toxicity. Importantly, the permanence of Gene Therapy treatment means that too high 
dosages of virally-delivery DNA cannot be removed. Excitingly, the recent 
development of post-translational regulatory mechanisms could mean that MeCP2 
dosage could be controlled at the protein level. Two examples of these mechanisms 
are the SMASh tag and the Destabilisation Domain (DD) of FKBP12, both of which 
can be fused to the protein of interest at either terminus, allowing induction of 
degradation (SMASh tag) or stabilisation (DD-FKBP12) by drugs that work in a 
dose-dependent manner (reviewed by Hannah and Zhou, 2015; Auffenberg et al., 
2016). These systems would therefore allow the levels of MeCP2 protein to be 
modulated by increasing or decreasing the dose of these drugs. Another possible 
concern for Gene Therapy is that rapid introduction of MeCP2 was found to be toxic 
even in asymptomatic animals (Guy et al., 2007). All Gene Therapy studies have 
used a single viral injection, as the immune response makes repeated treatment 
impossible (Ciesielska et al., 2013). Contrary to the findings by Guy et al. (2007), 
three separate Gene Therapy studies reported symptomatic rescue in animals treated 
at 4-6 weeks of age (Gadalla et al., 2013; Garg et al., 2013; Matagne et al., 2017). A 
possible explanation for this discrepancy is the low transduction efficiency in the 
brains of these mice (2-25%) compared to the high recombination rate using the 
Cre/loxP system (~80%). It is therefore important to keep this observation in mind 
when optimising transduction efficiencies of Gene Therapy vectors. The use of 
regulatory tags may provide a mechanism for avoiding toxicity caused by to rapid 
reintroduction: by slowly increasing the stability of protein produced from virally-
delivered genes. These post-translational regulatory mechanisms are of particular 
relevance my findings as the SMASh and DD-FKBP12 tags are ~300 bp and ~110 bp 
long, respectively, so would only fit in scAAV vectors in the coding sequence length 
is reduced.  
 
The full stability of ΔNC-EGFP and absence of a discernible phenotype in the 
knock-in mice suggests that ΔNC would be a better choice than ΔNIC to use in Gene 
Therapy experiments. Although slightly longer than ΔNIC, it removal of the N- and 
C-terminal regions would create an extra ~700 bp of space for regulatory sequences. 
Unexpectedly, preliminary experiments in the Cobb lab using their optimised 
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conditions have found that ΔNIC provided better phenotypic rescue than ΔNC 
(Gadalla, Hector and Cobb, unpublished). This was particularly surprising as 
removal of the EGFP tag is likely to further reduced stability of ΔNIC. One possible 
explanation is that its decreased stability and/or activity reduces the risk of toxic 
overexpression. While MeCP2 protein dosage is widely regarded as crucial for 
neuronal function (reviewed by Chao and Zoghbi, 2012), it is important to note that 
having normal levels of MeCP2 is only 50% of cells (as in the case for RTT patients) 
causes much more severe symptoms in (female) mouse models than (male) 
hypomorphic mice that have ~50% of normal protein levels in all cells (Guy et al., 
2001; Chen et al., 2001; Samaco et al., 2008; Kerr et al., 2008). Due to the lack of 
control when DNA is introduced by viral delivery, it may be that using a less 
stable/active protein for Gene Therapy results in a larger percentage of cells that lie 
within an optimal window (e.g. between 0.5 and 1.5-fold native MeCP2 activity). 
This is likely to be particularly important when treating female patients due to 
mosaicism. Thorough analysis of protein transduction efficiencies and the resulting 
MeCP2 expression levels in different cell types is therefore of vital importance when 




Figure 7.5.1: Gene Therapy vectors containing truncated MECP2 alleles 
Schematic of the vector developed by Gadalla et al. (2017) containing the human 
MECP2 cDNA sequence with a C-terminal Myc tag, a 426 bp fragment of the 
mouse Mecp2 promoter and selected elements from the Mecp2 3’UTR. The full-
length cDNA sequence can be replaced by humanised versions of the ΔNC and 
ΔNIC alleles (replacing the EGFP tag with the Myc tag after the GSSGSSG linker 
sequence). This creates space for additional regulatory elements within the 2.2 




7.5.2 The use of the truncated Mecp2 alleles in Protein Replacement Therapy 
 
Unlike for Gene Therapy, reducing the sequence length of MeCP2 has no direct 
advantages for Protein Replacement Therapy. These truncated proteins may, 
however, have altered properties that make them more suitable. The main obstacle to 
overcome in Protein Replacement Therapy trials is crossing the blood brain barrier 
(BBB) and entering neuronal cells. Further work is needed to test the transduction 
efficiency of these proteins with different tags (e.g. the TAT sequence). Altering the 
design of these proteins (e.g. by removing the EGFP tag or the extreme N-terminal 
sequences) may also improve transduction. 
 
7.6 Concluding remarks 
 
The mice produced in this study provide a valuable tool for determining whether the 
multiple roles attributed to MeCP2 are relevant for Rett syndrome pathophysiology. 
Analysis of their molecular phenotypes is likely to facilitate uncoupling of several 
protein interactions and their associated roles from the disease symptoms exhibited 
by Mecp2-null and other loss-of-function mice. Molecular analysis of these mice 
alongside those expressing the NID mutant, R306C-EGFP (Brown, Selfridge et al., 
2016), would be particularly useful for furthering our understanding of the 
importance of NCoR/SMRT complex recruitment. This would allow differentiation 
between the molecular consequences of only disrupting NCoR/SMRT complex 
binding and retaining this interaction but abolishing progressively more of the other 
functions of MeCP2. The use of novel technologies to investigate nascent 
transcription in the brains of mice expressing truncated/mutant MeCP2 is a priority 
in furthering our understanding of the role of MeCP2 in regulating transcriptional 
elongation. 
 
Identification of the key function of MeCP2 could be of therapeutic benefit. The 
most obvious advantage is the use of shortened alleles in Gene Therapy, allowing for 
larger regulatory elements within the limited capacity of scAAV viral vectors. The 
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truncated proteins may also be beneficial for Protein Replacement Therapy, if their 
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Figure S1: Protein sequence alignment of the MBD domains 
Protein sequence alignment of the MBDs in all four members of the MBD protein 
family (human and mouse) using ClustalWS, shaded according to BLOSUM62 
score. The position of the intron in all genes encoding these proteins is indicated 
by the arrow above. Conservation is shown below. Residue numbers correspond 
to that of human/ mouse MeCP2 (e2 isoforms). The aligned region shown spans 
the length of the extended MBD of MeCP2 used in the truncated protein, ΔNIC-












Figure S2: Alignment of MeCP2 protein sequences 
Alignment of MeCP2 protein sequences using mammalian e1 isoforms and the 
sole isoform in Xenopus and zebrafish. The different N-terminus of the 
mammalian e2 isoform is also shown (top left). Sequences were aligned using 
ClustalWS and shaded according to BLOSUM62 score. Annotated with (from 
top): RTT-missense mutations (red); activity-dependent phosphorylation sites 
(orange); minimal Methyl-CpG binding domain (MBD) 78-162 (Nan et al., 1993); 
and NCoR/SMRT interaction domain, 285-309 (Lyst et al., 2013). Residue 
numbers correspond to human isoform e2. The alternative e1 extreme N-
terminus is numbered according to the human protein (grey and italic). The 
alignment is separated into the regions defined in this study (see Chapter 3). 
 
Figure S3: Mutations in MeCP2 expressed by knock-in/transgenic mice 
Schematic diagram of MeCP2 protein (e2) annotated with missense (above) and 
truncating (below) mutations expressed by knock-in/transgenic mouse models. 
RTT-causing mutations are shown in red, milder mutations are shown in blue and 
phospho-abolishing mutations are shown in orange. These mouse models are 
discussed in section 1.4 and 1.5. MeCP2 is annotated with several domains: the 
Methyl-CpG binding domain (MBD, residues 78-162); AT-hook 1 (H1, residues 
184-195); AT-hook 2 (H2, residues 265-272); the Transcriptional repression 
domain (TRD, residues 207-310); and the NCoR/SMRT Interaction Domain (NID, 








































RTT ExAC Conserved? 
Lys12
6
 ac     N (♀) Zebrafish E 
Ser13
6,9
 phos       Zebrafish D 
Lys22
11
 ac removed by SIRT1     Mouse R 
Ser68
5
 phos       Xenopus A, Zebrafish V 
Ser70
5
 phos       Xenopus E, Zebrafish A 
Ser80
1,2,3,5
 phos HIPK2 kinase     yes 
Lys82
6
 ac     R (♀) yes 
Ser86
8
 phos       yes 
Lys119
6
 ac       yes 
Tyr120
12
 phos       Xenopus F, Zebrafish F 
Lys130
6
 ac       yes 
Lys135
6
  ac removed by SIRT1 E   yes 
Thr148(/Ser149)
2
 phos       yes 
(Thr148/)Ser149
2,6
 phos       Zebrafish I 
Thr160
4
 phos     S (♀) yes 
Ser164
2,13
 phos       yes 
Ser166
413
 phos       yes 
Lys171
11
 ac removed by SIRT1   Q (♀) Zebrafish R 
Ser178
13
 phos     C (♀) Xenopus A, Zebrafish M 
Lys200
11
 ac removed by SIRT1     Xenopus P, Zebrafish - 
Lys223
10
 SUMO       yes 
Ser229
1,2,6
 phos     L Xenopus -, Zebrafish P 
Lys233
6
 ac       Xenopus T 
Lys249
6
 ac       Zebrafish R 
Lys256
6
 ac removed by SIRT1     yes 
Lys271
6
 ac removed by SIRT1     yes 
Ser274
4,6,8
 phos       Zebrafish A 
Lys289
11
 ac removed by SIRT1     yes 
Lys305(/307)
6
 ub   R, T   yes 
(Lys305/)307
6
 ub       yes 
Thr308
8
 phos       yes 
Lys321
6
 ac       Zebrafish E 
Ser399[401]
2,6
 phos     H/A Xenopus G, Zebrafish G 
Lys412[Lys414]
14
 SUMO       yes 
Ser421[423]
1,2,8
 phos CamKII kinase   P Xenopus -, Zebrafish E 
Ser424[Ser426]
2,5
 phos       Zebrafish T 
Lys447[Lys449]
7
 ac added by p300; 
removed by SIRT1 
    yes 
 Table S2: Post-translational modifications in MeCP2. Includes all the published 
post-translational modifications (PTMs) and the responsible enzymes identified in 
neurons or brain tissue. Activity dependent modifications are highlighted in grey. 
Ser80 is dephosphorylated upon neuronal activity (highlighted in red). Columns 4 
and 5 list RTT-causing mutations and neutral variants at these sites, respectively. 
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Column 6 lists different amino acids at these sites in MeCP2 homologs in 
chimpanzee, mouse, rat, xenopus and zebrafish. Amino acids standardly used as 
PTM- abolishing mutations are shown in red, and as mimetic mutations in green. 
Phosphorylation sites preserved by mutation to another phosphorylatable amino 
acid (S/T/Y) are shown in blue.  
References: (1) Zhou et al., 2006; (2) Tao et al., 2009; (3) Bracaglia et al., 2009; (4) Tweedie-Cullen et 
al., 2009; (5) Huttlin et al., 2010; (6) Gonzales et al., 2012; (7) Zocchi and Sassone-Corsi, 2012; (8) 
Ebert et al., 2013; (9) Yasui et al., 2014; (10) Cheng et al., 2014b; (11) Pandely et al., 2015; (12) Bergo 





Mutation Localisation to PHC? Binding in EMSA/SPR? 
L100V Intermediate
3,5,6
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S134F  Very weak (mCpG and hmC)
7
 






















D156A   
F157L   



















G161V   
Table S3: Missense mutations in the MBD of MeCP2 that cause Classical Rett 
syndrome often disrupt binding to methylated DNA 
The DNA-binding abilities of MBD mutants have been investigated using several 
methods: localisation to pericentromeric heterochromatin (PCH) in mouse cells; and 
binding methylated-DNA probes in in vitro binding assays (Electrophoretic mobility 
shift assay, EMSA; Surface Plasmon Resonance, SPR).  
References: 1. Ballestar et al., 2000; 2. Free et al., 2001; 3. Kudo et al., 2003; 4. Ho et al., 2008; 5. 
Schmiedeberg et al., 2009; 6. Agarwal et al., 2011; 7. Mellén et al., 2012; 8. Goffin et al., 2012; 9. 





PHD Secondary Structure prediction of mouse MeCP2 (isoform e2): Oct 2013 
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PHD Secondary Structure prediction of mouse MeCP2 (isoform e2): Oct 2016 
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Figure S4: Secondary structure prediction of mouse MeCP2 e2 isoform 
PHD software (https://npsa-prabi.ibcp.fr/NPSA/npsa_phd.html) was used to 
predict the secondary structure around the NID (residues 272-312, highlighted in 
pink) for the design of the truncated proteins. Predicted alpha helices are 
denotes by the letter ‘H’ and beta strands by the letter ‘E’, with capitalisation 
reflecting higher confidence. Although, the predicted secondary structure has 
changed since I designed these proteins in October 2013, the predicted alpha 
helix at the N-terminal end of the NID (residues 274-287, highlighted in grey) is 
still present. The NID used in this study was extended at the N-terminus to retain 




Alignment of the truncated MeCP2 proteins 
Key: extreme N terminus MBD linkers SV40 NLS NID EGFP 
 
WT-EGFP/1-748   MAAAAATAAAAAAPSGGGGGGEEERLEEKSEDQDLQGLRDKPLKFKKAKKDKKEDKEGKH 
ΔN-EGFP/1-689   MAAAAATAAAAAAPSGGGGGGEEERLEEK------------------------------- 
ΔNC-EGFP/1-516  MAAAAATAAAAAAPSGGGGGGEEERLEEK------------------------------- 
ΔNIC-EGFP/1-432 MAAAAATAAAAAAPSGGGGGGEEERLEEK------------------------------- 
 
WT-EGFP/1-748   EPLQPSAHHSAEPAEAGKAETSESSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEG 
ΔN-EGFP/1-689   ----------------------------PAVPEASASPKQRRSIIRDRGPMYDDPTLPEG 
ΔNC-EGFP/1-516  ----------------------------PAVPEASASPKQRRSIIRDRGPMYDDPTLPEG 
ΔNIC-EGFP/1-432 ----------------------------PAVPEASASPKQRRSIIRDRGPMYDDPTLPEG 
 
WT-EGFP/1-748   WTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRG 
ΔN-EGFP/1-689   WTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRG 
ΔNC-EGFP/1-516  WTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRG 
ΔNIC-EGFP/1-432 WTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRG 
 
WT-EGFP/1-748   SPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTGRPKAAASEGVQVKRVLEKSPGKLVVK 
ΔN-EGFP/1-689   SPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTGRPKAAASEGVQVKRVLEKSPGKLVVK 
ΔNC-EGFP/1-516  SPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTGRPKAAASEGVQVKRVLEKSPGKLVVK 
ΔNIC-EGFP/1-432 SPSRREQKPP-------------------------------------------------- 
 
WT-EGFP/1-748   MPFQASPGGKGEGGGATTSAQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEA 
ΔN-EGFP/1-689   MPFQASPGGKGEGGGATTSAQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEA 
ΔNC-EGFP/1-516  MPFQASPGGKGEGGGATTSAQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEA 
ΔNIC-EGFP/1-432 ----------------------------------GSSGSSGPKKKRKVPGSVVAAAAAEA 
 
WT-EGFP/1-748   KKKAVKESSIRSVHETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPG 
ΔN-EGFP/1-689   KKKAVKESSIRSVHETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPG 
ΔNC-EGFP/1-516  KKKAVKESSIRSVHETVLPIKKRKTRETV------------------------------- 
ΔNIC-EGFP/1-432 KKKAVKESSIRSVHETVLPIKKRKTRETVG------------------------------ 
 
WT-EGFP/1-748   RKSKESSPKGRSSSASSPPKKEHHHHHHHSESTKAPMPLLPSPPPPEPESSEDPISPPEP 
ΔN-EGFP/1-689   RKSKESSPKGRSSSASSPPKKEHHHHHHHSESTKAPMPLLPSPPPPEPESSEDPISPPEP 
ΔNC-EGFP/1-516  ------------------------------------------------------------ 
ΔNIC-EGFP/1-432 ------------------------------------------------------------ 
 
WT-EGFP/1-748   QDLSSSICKEEKMPRGGSLESDGCPKEPAKTQPMVATTTTVAEKYKHRGEGERKDIVSSS 
ΔN-EGFP/1-689   QDLSSSICKEEKMPRGGSLESDGCPKEPAKTQPMVATTTTVAEKYKHRGEGERKDIVSSS 
ΔNC-EGFP/1-516  ------------------------------------------------------------ 
ΔNIC-EGFP/1-432 ------------------------------------------------------------ 
 
WT-EGFP/1-748   MPRPNREEPVDSRTPVTERVSCKDPPVATMVSKGEELFTGVVPILVELDGDVNGHKFSVS 
ΔN-EGFP/1-689   MPRPNREEPVDSRTPVTERVSCKDPPVATMVSKGEELFTGVVPILVELDGDVNGHKFSVS 
ΔNC-EGFP/1-516  ----------------------GSSGSSGMVSKGEELFTGVVPILVELDGDVNGHKFSVS 
ΔNIC-EGFP/1-432 ----------------------GSSGSSGMVSKGEELFTGVVPILVELDGDVNGHKFSVS 
 
WT-EGFP/1-748   GEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPE 
ΔN-EGFP/1-689   GEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPE 
ΔNC-EGFP/1-516  GEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPE 
ΔNIC-EGFP/1-432 GEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPE 
 
WT-EGFP/1-748   GYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNV 
ΔN-EGFP/1-689   GYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNV 
ΔNC-EGFP/1-516  GYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNV 
ΔNIC-EGFP/1-432 GYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNV 
 
WT-EGFP/1-748   YIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKD 
ΔN-EGFP/1-689   YIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKD 
ΔNC-EGFP/1-516  YIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKD 
ΔNIC-EGFP/1-432 YIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKD 
 
WT-EGFP/1-748   PNEKRDHMVLLEFVTAAGITLGMDELYK 
ΔN-EGFP/1-689   PNEKRDHMVLLEFVTAAGITLGMDELYK 
ΔNC-EGFP/1-516  PNEKRDHMVLLEFVTAAGITLGMDELYK 
ΔNIC-EGFP/1-432 PNEKRDHMVLLEFVTAAGITLGMDELYK 
 




cDNA sequences of the truncated MeCP2 alleles 


























































Figure S6: cDNA sequences of truncated MeCP2 alleles (e1 isoforms) –











































Figure S6: cDNA sequences of truncated MeCP2 alleles (e1 isoforms) –






Protein (e1) % of FL MeCP2 protein sequence Predicted size (kDa) 
WT-EGFP 100% 81 
ΔN-EGFP 88% 75 
ΔNC-EGFP 54% 56 
ΔNIC-EGFP 34% 47 
Table S4: Basic information about MeCP2 truncated proteins 





Figure S7: Binding sites of MeCP2 interaction partners retained in the 
truncated proteins  
As Fig. 1.5, but with MBD and NID domains extended to the regions defined in 
this study (extensions shown in a darker shade). MBD residues 72-173 and NID 
residues 173-312. Shaded grey areas show the deleted regions. Proteins whose 








Figure S8A: Preliminary Southern blot screen of ΔN-EGFP and ΔNIC-EGFP 
clones 
The upper portion shows the ΔN-EGFP and ΔNIC-EGFP targeting strategies with 
maps of the restriction sites of the enzyme used in Southern analysis, BsrGI. An 
internal probe, recognising the 3’ homology arm was used, drawn as a black line. 
The clones taken forward for further analysis are highlighted (blue for ΔN-EGFP, 







Figure S8B: Southern blotting shows two successfully targeted ΔN-EGFP 
clones 
Screening of potential positive clones by Southern blotting. The left hand portion 
shows WT and ΔN-EGFP sequences with maps of the restriction sites of the 
enzyme used in Southern analysis, BamHI. The untagged ΔN allele is produced 
by internal recombination. The untagged ΔN clone 1A2 (produced during ΔNC-
EGFP targeting) was included as a control in this analysis. An internal probe, 
recognising the 3’ homology arm was used, drawn as a black line. The positive 
clones, 4E1 and 4G9, are highlighted in blue. 
Figure S8C: Southern blotting shows five successfully targeted ΔNIC-EGFP 
clones 
Screening of potential positive clones by Southern blotting. The top portion 
shows WT and ΔNIC-EGFP genomic DNA sequences with maps of the 
restriction sites of the enzyme used in Southern analysis, Bsu36I. An internal 
probe, recognising the 3’ homology arm was used, drawn as a black line. The 






Figure S9: Making nuclear extracts with knock-in mouse brains for 
immunoprecipitation analysis 
Following the MeCP2 truncation proteins through the steps of the nuclear 
extraction protocol. Nuclear extracts (inputs) are used for immunoprecipitation, 
the pellet at this stage is discarded. After incubation with GFP-TRAP beads, the 
remaining MeCP2 in the unbound supernatant was determined. Analysis by 
western blotting using a GFP antibody to detect MeCP2 truncation proteins. * 
denotes the presence of IgG from small amounts of blood in these samples, 














































































































































































































































































































































































































































































































































































































































































































































































































































Figure S11: ΔNIC-EGFP phenotype is less severe than the mildest RTT 
models, R133C-EGFP and P225R 
Scoring of backcrossed hemizygous male ΔNIC-EGFP mice (this study) 
compared to R133C-EGFP mice (Brown, Selfridge et al., 2016) and P225R mice 
(Guy, unpublished). Graphs show mean values. All cohorts were scored from 4-
52 weeks of age. ΔNIC-EGFP n=10, R133C-EGFP n=10 and P225R n=19. 
